

SUBJECT INDEX

- A_{1c}, pramlintide effects on BW and, in controlled NIDDM, 1638-1642
- AA (arachidonic acid), antidiabetic effects of zinc and, in STZ-DM, 7-12
- Ab(s) (antibody), *see* Autoantibodies
- ABCA1 gene, R219K polymorphism of serum HDL-C and TG, related to age, AT, and race, 930-934
- Abdominal adipocytes
before and after differentiation into, 987-992
SC, effects of 17 β -estradiol and ICI:compound 182,780 on HSL and LPL expression in, 383-388
- Abdominal adipose tissue (AT)
distribution of, in PM women, racial and ethnic differences in, 186-191
effects of aging or, on insulin action, 850-857
effects of GH, fitness, insulin and, on lipids and Lps in older subjects, 73-80
in lean and obese NIDDM Thai women, 1444-1447
and PP triglyceridemia, 1381
pre- and post-20-week exercise, 37-39
see also Abdominal adipocytes
- Abdominal preadipocytes, apoptosis of, before and after differentiation into adipocytes, 987-992
- ACAC (acetoacetate), ingested glucose effects on, 96, 97
- ACE, *see* Angiotensin-converting enzyme DD genotype; Angiotensin-converting enzyme inhibitors
- Acetaldehyde, effects of acute exposure to alcohol on levels of, 392-394
- Acetoacetate (ACAC), ingested glucose effects on, 96, 97
- N-Acetylcysteine (NAC), effects of, on GSH redox state-gluconeogenesis relation in renal cortical tubules, 742-743
- Acquired immunodeficiency syndrome (AIDS), 1- μ g and 250- μ g ACTH stimulation tests of adrenal function in, 647-651
- Acromegaly, remission of, assessed with OGTT, 181-185
- ACS (acute coronary syndrome) in NIDDM, invasive versus noninvasive management of, S1:9
- ACTH (adrenocorticotrophic hormone), *see* Corticotropin; Corticotropin stimulation tests
- Acute alcohol exposure, effects of, on brain protein synthesis, 389-396
- Acute atopic dermatitis exacerbation, urinary pentosidine in children with, oxidative stress and, 1601-1605
- Acute coronary syndrome (ACS) in NIDDM, invasive versus noninvasive management of, S1:9
- Acute endurance exercise, effects of, on skeletal muscle uncoupling protein-3 gene expression in untrained subjects, 152-158
- Acyl coenzyme (CoA) esters, activation of cardiac and beta-cell K_{ATP} channels by, in side-chain length-specific manner, 1313-1319
- Acyl coenzyme (CoA) hydrolases/thioesterases, hepatic induction of mitochondrial and cytosolic, in DM and fasting, 1527-1529
- Acylation-stimulating precursor (ASP) proteins in AT of obese subjects, 1360-1366
- Acyltransferase, lecithin:cholesterol, total and regional AT associated with activities of CETP and, in Hispanic and Anglo PM women, 282-289
- AD (Alzheimer's disease), dysphagia and aspiration pneumonitis with, S2:36-38
- Adaptation
age-dependent liver thyroid, in DM, serum and hepatic IGF-1 expression and, 1117-1125
to insulin resistance, hyperinsulinemia as, 840
- Adenine dinucleotide phosphate oxidase, nicotinamide, effects of, on insulin-stimulated glucose disposal, 709
- Adenosine monophosphate, *see* cAMP
- Adenosine triphosphate, *see* ATP
- Adherence to exercise regimen by young obese adults, glucose and insulin responses and, 1177
- Adipopectin
adipocyte-derived plasma concentrations of, associated with MS and small-dense LDL particles, 1612-1614
in NIDDM, TZD effects on, 756
- Adipocytes
abdominal, *see* Abdominal adipocytes
ceramide effects on insulin-induced PKC ζ translocation in, 19-24
concentrations of plasma adipopectin derived from, associated with MS and small-dense LDL particles, 1612-1614
leptin release in, in obesity, G_i-coupled receptor agonists, glucocorticoids, insulin, and pertussis toxin regulating, 60-68
in NIDDM, *see* Adipocytes in NIDDM
plasma adipopectin concentrations derived from, associated with MS and small-dense LDL particles, 1612-1614
PTPase in, insulin-mediated glucose uptake, insulin-induced oxidative inhibition and, 705-712
- Adipocytes in NIDDM
insulin-resistant, effects of hyperglycemia reversal on, 239-245
TZD effects on size of, 756
- Adipogenic potential of CLX-9021, 1012-1018
- Adipopectin gene mutation in lean and obese subjects, 881-884
- Adipopectin mRNA (messenger ribonucleic acid) in AT, 958-963
- Adipose tissue (AT)
adipopectin expression and, 958-963
chronic effects of DHEA on metabolism of, 264-272
distribution of, *see* Postmenopausal women, race and ethnicity of, and AT distribution; Regional adipose tissue; Subcutaneous adipose tissue; Visceral adipose tissue
exercise and, *see* Adipose tissue, exercise effects on
fenofibrate effects on plasma cholesterol and resistin expression in, 351-355
gluconeogenesis and, 1513
gynoid, lymphatic function in women with swelling syndrome and, 805-809
in hereditary HTG, captopril effects on, 1406-1412
in men, plasma ghrelin, insulin resistance, smoking and, 1460-1463
in metabolic syndrome, 726, 727
in NIDDM, TZD effects on, 754
in older women, IGF-1 effects on glucose kinetics or insulin sensitivity in, 1184
oxidation of, *see* Oxidation, AT
plasticity as SNS response to fasting, 1621-1626
in PM women, *see* Adipose tissue in PM women, race and ethnicity and
and PP triglyceridemia, 1381, 1384
PPAR γ 2 Pro12Ala polymorphism effects on, 779

NOTE. Page references to Supplement 1 (August 2003) and Supplement 2 (October 2003) are preceded by S1 and S2, respectively.

Adipose tissue (AT) (*Continued*)

- relation of sex hormones to insulin, risk for myocardial infarction and, in men, 784-790
- restricted salt intake effects on age-related changes in, 1072-1077
- and risk factor for CHD, 1532
- and risk for NIDDM, 1213
- R219K polymorphism of serum TG and AT ABCA1 gene related to age and, racial difference in, 930-934
- see also* Fat mass; Obesity and entries beginning with element: Adip-

Adipose tissue (AT), exercise effects on

- endothelial lipase genotype and, 1507
- in insulin-resistant exercising men, PPAR γ Pro12Ala polymorphism and association with oxidized LDL and cardioplipin autoantibodies, 210
- in men with CAD, 1414, 1415
- in obesity, G $_i$ -coupled receptor agonists, glucocorticoids, insulin, and pertussis toxin regulating leptin release in, 60-68
- pre- and post-20-week exercise program and pleiotropic genetic effects between SHBG concentrations and AT, 35-41
- running and/or cycling effects on AT oxidation, 747-752

Adipose tissue (AT) in PM women, race and ethnicity and distribution of, *see* Postmenopausal women, race and ethnicity of, and AT distribution

- total, associated with CETP and LCAT activities in Hispanic and Anglo PM women, 282-289

ADMA (asymmetric dimethylarginine) in NIDDM, glycemic control and GFR associated with, 303-307

ADRB3, *see* β_3 -Adrenergic receptor Trp64Arg polymorphismAdrenal function in AIDS, 1- μ g and 250- μ g ACTH stimulation tests of, 647-651Adrenaline, *see* Epinephrine α (alpha)-Adrenergic blockers, effects of, during exercise

- on catecholamine response to exercise at high altitude (4,300 meters), 1471-1477
- on glucose kinetics regulation during intense exercise, 1615-1620

 β (beta)-Adrenergic blockers

- effects of, on insulin secretion after renal transplantation in older subjects, 573-578
- effects of, on regulation of glucose kinetics during intense exercise, 1615-1620

 β_3 (beta $_3$)-Adrenergic receptor (ADRB3) Trp64Arg polymorphism

- ALDH2 and, associated with liver dysfunction and metabolic syndrome, 1096-1101
- effects of, on LDL particle size, 356-361

Adrenocortical responses to submaximal exercise by PM women, race and, 1643-1647

Adrenocorticotrophic hormone, *see* Corticotropin; Corticotropin stimulation tests

Adrenomedullin (AM), plasma, in PHP, 159-162

Adult plasma insulin, effects of malnutrition in first year of life on, 1005-1011

Adulthood, risk of insulin resistance syndrome in offspring of NIDDM parents from childhood to young, 443-453

ADVANCE prevention of CV disease with NIDDM, S1:24-28

- due to hyperglycemia, S1:24-25
- due to hypertension, S1:25

Advanced atherosclerotic lesions, doxazosin effects on progression of, in hypercholesterolemia, 1240-1245

Advanced glycation end (AGE) product(s)

- aortic smooth muscle cell growth stimulated by, 1558-1563
- monocyte adhesion to ECs induced by, in NIDDM with CV disease, gliclazide effects on, S1:14-16

Advanced glycation end (AGE) product(s) (*Continued*)

- urinary excretion of, in children with acute exacerbation of atopic dermatitis, 1601-1605

Aerobic power, *see* $\dot{V}O_2$ max in exerciseAfrican Americans, *see* Race and ethnicity

Age

- of acromegalic subjects, 182
- and ADRB3 Trp64Arg polymorphism effects on LDL particle size, 357, 358
- of boys, and effects of testosterone and GH on protein metabolism and body composition, 965
- of breast cancer patients, 1607
- of chronic pancreatitis subjects, 580
- CRP relation to, 1543, 1544
- and CV disease risk, *see* Age, and risk for CV disease
- of diabetic nephropathy subjects, 1259
- of DM subjects, *see* Age of DM subjects
- effects of malnutrition during first year of life on adult plasma insulin and glucose tolerance, 1005-1011; *see also* Age of glucose-tolerant subjects
- of ESRD subjects, and HD-induced changes in Lps, 117
- estrogen and medroxyprogesterone acetate effects on, 1331
- and exercise, *see* Age, exercise effects and
- FAs and, *see* Age, FAs and
- first-degree relatives of NIDDM subjects, *see* Age of first-degree relatives of NIDDM subjects
- gluconeogenesis and, 1513
- of glucose-intolerant and diabetic subjects, mannose levels and, 1021
- of glycemic subjects, alcohol intake and, 131
- and grape seed extract effects on LDL oxidation, 1252
- of hair-losing women, 928
- and HCT effects on tHcy in HTN, 262
- of HIV-infected subjects with lipodystrophy, 622, 1346, 1347
- of hyperalphalipoproteinemic subjects, plasma CRPs and, 433
- of hyperlipidemic subjects, 1192, 1193
- of hypoalphalipoproteinemic subjects, *see* Age of hypoalphalipoproteinemic subjects
- of hypopituitarism subjects, 51
- of insulin-resistant and/or MS subjects, *see* Age of insulin-resistant subjects
- of lysine-intolerant subjects, 936
- and Mg-creatine supplementation effects on body water, 1137
- of NIDDM subjects, *see* Age of NIDDM subjects
- of nondiabetic subjects, *see* Age of nondiabetic subjects
- of obese subjects, *see* Age of obese subjects
- of PHP subjects, 160
- and plasma galanin response to HUT in recurrent VVS, 316
- of PM women, *see* Age of PM women
- and PP leukocyte increase, 200
- and PP triglyceridemia, 1381
- and PPAR γ_2 Pro12Ala polymorphism effects on insulin clearance, 779
- of pre-eclamptic subjects, neutrophil intracellular pH and Na $^+$ /H $^+$ exchanger activity and, 88
- and pregnancy loss, 1628
- and relation of sex hormones to AT, insulin, and risk for MI in men, 785, 787
- of renal transplant recipients, 574
- and risk for CHD, 1532
- and risk for NIDDM, 888, 1213
- R219K polymorphism of serum TG and HDL-C ABCA1 gene related to AT, race and, 930-934

Age (*Continued*)

- and swelling syndrome and gynoid adiposity effects on lymphatic function, 806, 807
- and Taq1B polymorphism with Lp variations, 1565, 1567, 1568
- see also* Adulthood; Middle-age men; Older subjects; Young subjects
- Age, exercise effects and
 - acute endurance exercise effects on skeletal muscle UCP-3 mRNA, 154
 - and adrenocortical responses to exercise in PM women, 1644
 - on HDL-C, 1507
 - plasma prebeta-1 HDLs and, 439
 - prior exercise effects on PP lipemia, 419-421
 - on serum level of IGF-1, of IGFBP-1 and -3, 822
 - on SHBG concentrations, 37
- Age, FAs and
 - trans* FA intake effects on LDL size and, 695
 - and FFA metabolism regulation by NPY gene Leu7Pro polymorphism, 644
- Age, and risk for CV disease, 1296
 - carotid IMT association with LDL receptor mutation and, 1434-1436
 - plasma cortisol and, 525
- Age of DM subjects
 - and atherogenic role of lysophosphatidylcholine in LDLs, 311
 - with ESRD, HD-induced changes in Lps and, 117
 - of GDM subjects, sHcy and, 721
 - liver thyroid status adaptation dependent on, in DM, serum and hepatic IGF-1 expression and, 1117-1125
 - see also* Age of IDDM subjects; Age of NIDDM subjects
- Age of first-degree relatives of NIDDM subjects
 - with NIDDM, 1069, 1580
 - and TNFR concentrations and, 1069
- Age of glucose-tolerant subjects
 - of glucose-tolerant first-degree relatives of African-American NIDDM subjects, 567
 - mannose levels and, 1021
- Age of hypoalphalipoproteinemic subjects
 - plasma CRPs and, 433
 - of primary hypoalphalipoproteinemic subjects, vascular damage and, 329, 330
- Age of IDDM subjects
 - with CAN, 816, 817
 - of obese IDDM subjects, intracellular platelet Mg and, 469
- Age of insulin-resistant NIDDM Japanese subjects, non-obese
 - PAI-1-associated insulin resistance and, 227
 - platelet count and, 1247
- Age of insulin-resistant NIDDM subjects
 - with IGT, beta-cell function and insulin sensitivity and, 477
 - muscle glycogen synthase polymorphism and, 896, 897
- Age of insulin-resistant subjects
 - adipocyte insulin resistance, 240
 - FFA-induced peripheral tissue resistance, 234
 - hypertriglyceridemic, with normal glucose tolerance, 617, 618
 - with liver dysfunction, 1097
 - NA-induced insulin resistance, 701
 - see also* Age of insulin-resistant NIDDM subjects; Age of insulin-resistant subjects with PCOS
- Age of insulin-resistant subjects with PCOS
 - obese subjects, 714, 909, 910
 - SHBG and, 726, 727
- Age of NIDDM men
 - and effect of glycemic control on LDL particle size in NIDDM, 1577

Age of NIDDM men (*Continued*)

- insulin-resistant, PPAR γ Pro12Ala polymorphism association with oxidized LDL and cardiolipin autoantibodies in, 215
- with uncomplicated well-controlled NIDDM and preclinical diabetic cardiomyopathy, 1058
- Age of NIDDM subjects
 - with adipocyte insulin resistance, 240
 - and ADMA association with GFR, 304
 - with CAN, 816, 817
 - with carotid atherosclerosis, beraprost sodium effects on VCMA-1 expression in HUVECs and circulating VCAM-1 and, 195
 - of Chinese subjects, 1449, 1450
 - of early-onset NIDDM subjects, LPL *HindIII* gene polymorphism-lipid level association and, 339, 340
 - and food intake effects on 24-hour profile of circulating glycated insulin, 632
 - on glibenclamide-metformin therapy, 864
 - of hypoadipoectinemic Japanese subjects, 1275
 - with nephropathy and macroangiopathy, 1518-1521
 - of NIDDM first-degree first-degree relatives of NIDDM subjects, 1069, 1580
 - with obesity, fasting and daylong TGs and, 1045
 - and phospholipid-dependent procoagulation activity, 103
 - PP lipemia after fat ingestion and, 1039
 - and pramlintide effects on A_{1c} and BW, 1639
 - with retinopathy, 606
 - as risk for atherosclerosis in Japanese NIDDM subjects, 1303, 1304
 - and rosiglitazone effects on serum Lp(a), 732
 - on TGZ therapy, *see* Age of NIDDM subjects, TGZ effects and
 - see also* Age of insulin-resistant NIDDM subjects; Age of NIDDM men
- Age of NIDDM subjects, TGZ effects and
 - on endothelial function, 175, 177
 - metformin and TGZ effects on regulation of skeletal muscle morphology, 541
- Age of nondiabetic subjects
 - with ESRD, and HD-induced changes in Lps, 117
 - with obesity, plasma SSAO, CV disease risk and, 690-691
- Age of obese men
 - and effects of weight loss on PP lipemia and LDL receptor binding, 138
 - PPAR γ Pro12Ala polymorphism association with oxidized LDL and cardiolipin autoantibodies and, 215
- Age of obese subjects
 - with central obesity, 1001
 - and FFA-induced peripheral tissue insulin resistance, 234
 - with HIV and lipodystrophy 714, 909, 910
 - hypercholesterolemic, and disturbed monocyte cholesterol synthesis, 2
 - morbidly obese subjects, 1552
 - with and without NIDDM, 1045
 - nondiabetic, plasma SSAO and CV disease risk and, 690, 691
 - with normal cholesterol, 380
 - of obese NIDDM children, intracellular platelet Mg and, 469
 - see also* Age of obese men; Age of obese women
- Age of obese women
 - and high-fat and high-CHO diet on cardiac autonomic nervous system activity, 1428
 - of morbidly obese women, SM FA oxidation in, 736
 - of PM women, effects of weight loss and, 601
- Age of PM women
 - CETP and LCAT activities and, 284, 285, 287

- Age of PM women (*Continued*)
 estrogen receptor α gene and collagen IA1 gene effects on relation of 25(OH)D and PTH to BMD, 1131
 with metabolic syndrome, risk for CV disease and, 364, 368, 369
 obese, effects of weight loss and, 601
 and subcutaneous and visceral AT distribution, 187
- AGE products, *see* Advanced glycation end product(s)
- Aging
 Alzheimer's disease in, dysphagia and aspiration pneumonitis with, S2:36-38
 effects of, on vascular system, S2:31-35
 effects of restricted salt intake and, 1072-1077
 effects of stress and, on hippocampal structure and function, S2:17-21
 frailty in, sarcopenia and visceral protein depletion and, S2:22-26
 genes of, S2:5-8
 introduction to, S2:4
 overview of, S2:3-4
 resilience in, mediators of allostasis and allostatic load and, S2:10-16
 treatment and, *see* Treatment of the elderly
see also Older subjects
- AIDS (acquired immunodeficiency syndrome), 1- μ g and 250- μ g ACTH stimulation tests of adrenal function in, 647-651
- ALA (α -lipoic acid), effects of CLA interaction with, on insulin action in obesity, 1167-1174
- Alanine (Ala)
 blood, glycogen phosphorylase inhibitor effects on, 1423
 gluconeogenesis and, in preterm infants, 945-949
 glutamine effects on metabolism of, in hepatic tissue, 1064
 plasma, in HIV infection with lipodystrophy, 1346
- Alanine₂ (Ala₂)-substituted analogs, effects of GIP N-terminal, on cAMP production, glucose degradation, insulin secretion, and hyperglycemia, 679-687
- Albumin, *see* Albuminuria in DM; Proteinuria; Urinary excretion, albumin
- Albuminuria in DM
 with CAN, 816, 817
 in NIDDM with CV disease, multifactorial intervention and, S1:20
see also Microalbuminuria in NIDDM
- Alcohol intake (and alcoholism)
 acute, effects of, on brain protein synthesis, 389-396
 effects of, on Ca²⁺-regulatory muscle proteins, 1102-1112
 effects of light, on paraoxonase by upregulation liver mRNA, 1287-1294
 fasting and daylong TGs and, 1046
 gestational, effects of, on glucose tolerance in offspring, 454-462
 glycemia and, in American Indians, 129-135
 and hypocholesterolemia, 1281
 in MS with liver dysfunction, 1098
 and L-NAME and L-NNA effects on skeletal muscle and jejunal protein synthesis, 397-401
 by non-obese subjects with PAI-1-associated insulin resistance, 227
 and Taq1B polymorphism with Lp variations, 1565, 1568
 WinSAAM simulation of metabolism of, 1155-1156
- Alcoholic myopathy, 1102-1112
- Aldehyde dehydrogenase (ALDH2), ADRB3 Trp64Arg polymorphism and, associated with liver dysfunction and metabolic syndrome, 1096-1101
- Aldosterone
 and 17 α -hydroxylase/17,20 lyase deficiency, 489
 plasma, *see* Plasma aldosterone
- Aldosteronism, primary, K supplementation effects on natriuretic response to central volume expansion in, 1597-1600
- Alkaline phosphatase (ALP)
 bone-specific, and BMD in chronic pancreatitis, 579-581, 584
 in PHP, 160
- Allo-tetrahydrocortisol, rosiglitazone effects on urinary excretion of, 231
- Allostasis (and allostatic load), mediators of, and resilience in aging, S2:10-16
- Almonds with viscous fiber, soy protein, and phytosterols for hypercholesterolemia, 1478-1483
- ALP, *see* Alkaline phosphatase
- Alpha-adrenergic blockers, *see* α -Adrenergic blockers, effects of, during exercise
- Alpha (α) cells, portal vein insulin decrease and responses of, to non-insulin-induced hypoglycemia, 1418-1425
- 17Alpha (α)-hydroxylase/17,20 lyase deficiency, heterozygous mutation of *CYP17* gene and, 488-492
- Alpha (α)-ketoglutarate (KG), ornithine, NO and glutamine involvement in insulin secretion induced by, 344-350
- Alpha (α)-lipoic acid (ALA), effects of CLA interaction with, on insulin action in obesity, 1167-1174
- Alpha-lipoprotein, *see* High-density lipoprotein(s)
- Alzheimer's disease (AD), dysphagia and aspiration pneumonitis with, S2:36-38
- AM (adrenomedullin), plasma, in PHP, 159-162
- American Indians (Native Americans), alcohol intake and glycemia in, 129-135
- Amine oxidase, plasma semicarbazide-sensitive, as CV disease risk in nondiabetic obese subjects, 688-692
- Amino acids, 810-820
 acute effects of glutamine on metabolism of, in hepatic tissue, 1062
 influence of, on CAN in DM, 815-820
 proteasome activity inhibited by, 810-814
see also specific amino acids
- 2-Aminoethane sulfonic acid (taurine) transport, glucose concentration inhibiting transport of, in cardiomyocytes, 827-833
- Aminothiols, plasma, effects of supplementation with FcTO on, 775
- AN (anorexia nervosa), metabolic and endocrine abnormalities after recovery from, 296-302
- Anaplerosis in insulin secretion, study of, with pancreatic islet mitochondria metabolites, 993-998
- Anatomy of CAD in NIDDM, S1:6
- Androstenedione in PCOS, 909
- Androsterone, rosiglitazone effects on urinary excretion of, 231
- Angiotensin-converting enzyme (ACE) DD genotype, circulating E-selectin and, and CV damage in central obesity, 999-1004
- Angiotensin-converting enzyme (ACE) inhibitors
 effects of, on insulin secretion after renal transplantation in older subjects, 573-578
see also specific angiotensin-converting enzyme inhibitors
- Angiotensin II, effects of, on vasopressin V₂ mRNA in IMCD, 290-295
- Anglo subjects, *see* Race and ethnicity
- Anorexia nervosa (AN), metabolic and endocrine abnormalities after recovery from, 296-302
- Anthropometric indices
 CRP relation to, ethnic and gender differences in, 1542-1546
 risk for CV disease by ethnic background and, 1295-1301
see also specific anthropometric indices
- Anti-aging strategies to preserve hippocampal function, S2:19-20

- Antibodies, *see* Autoantibodies
- Antidiabetic effects
 of AA and zinc in STZ-DM, 7-12
 see also specific antidiabetic therapies
- Antihyperglycemic effects, *see* Glycemic control
- Antihypertensive drugs, *see* Hypotensive effects
- Aortic endothelial cells (ECs)
 β -estradiol and IGF-1 effects on eNOS activity in, 482-487
 human, glycated HDL regulation of ROS and reactive nitrogen species in, 42-49
- Aortic smooth muscle cells (SMCs)
 AGE products stimulating growth of, 1558-1563
 human, glizalide effects on MCP-1 protein in, in NIDDM with CV disease, S1:16
- Apo(s), *see specific apolipoproteins*
- Apolipoprotein A (apo A)
 in adults malnourished during first year of their life, 1006
 in postmenopausal women, estrogen and medroxyprogesterone acetate effects on, 1332, 1333
- Apolipoprotein A-I (apo A-I)
 CRPs, *see* Apolipoprotein A-I, CRPs and
 in diabetic and nondiabetic ESRD subjects, HD-induced changes in, 118
 exercise and, *see* Apolipoprotein A-I, exercise effects on
 in hypercholesterolemia, effects of diet composed of almonds, viscous fiber, soy protein, and phytosterols on, 1479
 Lp-containing, race and risk for CHD and, 1530-1536
 in NIDDM, *see* Apolipoprotein A-I in NIDDM
 in older subjects, effects of GH, abdominal VAT, fitness, and insulin on, 76-78
 swelling syndrome and gynoid adiposity effects on, 806, 807
 and Taq1B polymorphism with Lp variations, 1565, 1567
- Apolipoprotein A-I (apo A-I), CRPs and
 plasma CRPs in hyperalphalipoproteinemia and
 hypoalphalipoproteinemia and, 433
 in young men and, 1114
- Apolipoprotein A-I (apo A-I), exercise effects on
 apo A-I clearance, 954
 on plasma apo A-I, 439
- Apolipoprotein A-I (apo A-I) in NIDDM
 and effects of glycemic control on LDL particle size, 1577
 in obesity with and without NIDDM, 1045
- Apolipoprotein A-I:A-II (apo A-I:apo A-II), Lp-containing, race and risk for CHD and, 1530-1536
- Apolipoprotein A-II (apo A-II), and Taq1B polymorphism with Lp variations, 1565, 1567
- Apolipoprotein A-IV (apo A-IV), postprandial distribution of, between apo B- and non-apo B-containing Lps in obese women, 1537-1541
- Apolipoprotein B (apo B)
 in adults malnourished in first year of their life, 1006
 CRPs in young men and, 1114
 in diabetic and nondiabetic ESRD subjects, HD-induced changes in, 118
 in hyperalphalipoproteinemia and hypoalphalipoproteinemia, plasma CRPs and, 433
 in hypercholesterolemia, effects of almonds, viscous fiber, soy protein, and phytosterols on, 1479
 in NIDDM, and effects of glycemic control on LDL particle size, 1577
 in obesity with and without, fasting and daylong TGs and, 1045
 in older subjects, effects of GH, abdominal VAT, fitness, and insulin on, 76-78
 ovariectomy effects on insulin resistance in, 659-661
- Apolipoprotein B (apo B) (*Continued*)
 PP apo A-IV distribution between non-apo B and apo B-containing Lps in obese women, 1537-1541
 PP leukocyte increase and, 200
 PP triglyceridemia and, 1381, 1384
 swelling syndrome and gynoid adiposity effects on, 806, 807
 and Taq1B polymorphism with Lp variations, 1565, 1567
- Apolipoprotein B-48 (apo B-48)
 atorvastatin effects on LDL receptor activity and metabolism of, in normolipidemia with CAD, 1279-1286
 in obese men, effects of weight loss on, 138
- Apolipoprotein B-100 (apo B-100)
 long- and short-term GHR effects on Lp composition and kinetics of, in hypopituitarism, 50-59
 in NIDDM with hypoadinopectinemia, 1281
- Apolipoprotein C (apo C), and Taq1B polymorphism with Lp variations, 1565, 1567
- Apolipoprotein C-III (apo C-III), effects of deficiency in, on hypertriglyceridemia development in STZ-DM, 1354-1359
- Apolipoprotein E (apo E), and Taq1B polymorphism with Lp variations, 1565, 1567
- Apolipoprotein E (apo E) deficiency, effects of FM-VP4 on plasma cholesterol and atherosclerotic lesion formation in, 425-431
- Apolipoprotein E (apo E) genotype, dietary fat intake interaction with, in older subjects, 279-281
- Apolipoprotein E (apo E) polymorphism, effects of, on plasma lipid response to high-CHO diet and high-MUFA diet, 1454-1459
- Apoptosis
 of abdominal preadipocytes before and after differentiation into adipocytes, 987-992
 RA- and 4HPR-induced growth arrest and, of orbital fibroblasts in GO, 1387-1392
 shift to stem cell compartment and colonocyte, due to raw potato starch effects on butyrate formation in colon, 1400-1405
- Aquaporin-2 (AQP-2) mRNA (messenger ribonucleic acid) in IMCD, angiotensin II effects on, 290-295
- Arachidonic acid (AA), antidiabetic effects of zinc and, in STZ-DM, 7-12
- Arg, *see* Arginine
- Arg²⁶⁴Cys polymorphism, aromatase, effects of interaction between VDR polymorphism and, on BMD of PM African-American women, 521-523
- Arginine (Arg)
 gluconeogenesis and plasma citrulline response to, 1512-1516
 glutamine effects on metabolism of, in hepatic tissue, 1064
 metabolism of extrahepatic, after burn injury, 1232-1239
 see also Arg²⁶⁴Cys polymorphism; Asymmetric dimethylarginine; N(G)-Nitro-L-arginine; L- ω -Nitro-L-arginine methyl ester; Trp64Arg polymorphism and entries beginning with terms: Arginine-vasopressin
- Arginine-vasopressin (AVP; vasopressin) V₂ mRNA (messenger ribonucleic acid), angiotensin II effects on, in IMCD, 290-295
- Arginine-vasopressin (AVP; vasopressin) V₂ receptor, renal, bosentan effects on, 1141-1146
- Aromatase, effects of interaction between of VDR and Arg²⁶⁴Cys polymorphism of, on BMD of PM African-American women, 521-523
- Ascorbic acid (vitamin C), metabolomic mapping of, with F-ASA and ¹⁹F-NMR spectroscopy in DM, 760-770
- Asian/Pacific Islander women, PM, with metabolic syndrome, CV disease risk in, 362-371
- ASP (acylation-stimulating precursor) proteins in AT of obese subjects, 1360-1366

- Aspartate (Asp), glutamine effects on metabolism of, in hepatic tissue, 1064
- Aspiration pneumonia with dysphagia in Alzheimer's disease, S2: 36-38
- Aspirin for CV disease in NIDDM, S1:22
- Asymmetric dimethylarginine (ADMA) in NIDDM, glycemic control and GFR associated with, 303-307
- Asymptomatic atherosclerosis in Japanese NIDDM subjects without diabetic microvascular complications, risk for, 1302-1306
- AT, *see* Adipose tissue
- Atherogenic role of lysophosphatidylcholine in LDLs, PLA₂ effects on, in DM, 308-314
- Atherosclerosis
risk for asymptomatic, in Japanese NIDDM subjects without diabetic microvascular complications, 1302-1306
see also Atherosclerosis in NIDDM; Atherosclerotic lesions
- Atherosclerosis in NIDDM
with CV disease, gliclazide effects on, S1:13-18
doxazosin effects on progression of advanced atherosclerotic lesions in hypercholesterolemia, 1240-1245
see also Carotid atherosclerosis in NIDDM
- Atherosclerotic lesions
advanced, doxazosin effects on progression of, in hypercholesterolemia, 1240-1245
effects of FM-VP4 on plasma cholesterol and formation of, in apo E deficiency, 425-431
- Athletes, *see* Exercise
- Atopic dermatitis, urinary pentosidine in children with acute exacerbation of, oxidative stress and, 1601-1605
- Atorvastatin
effects of, on apo B-48 metabolism and LDL receptor activity in normolipidemia with CAD, 1279-1286
effects of, on sucrose-induced PP hypertriglyceridemia in olive oil-fed subjects, 609-617
- ATP (adenosine triphosphate)
effects of insulin and, on MAPK in liver cells, Ca²⁺ and, 590-598
extracellular, GSH redox state-gluconeogenesis relation in renal cortical tubules and, 742
see also K_{ATP} channels, beta-cell, in NIDDM with CV disease
- At-rest subjects (sedentary subjects), serum IGF-1, IGFBP-1, and IGFBP-3 level in, glucose disposal and, 821-826
- Autoantibodies
to cardiolipin and oxidized LDLs, PPAR γ Pro12Ala polymorphism associated with, in nondiabetic and NIDDM subjects, 213-217
relationship of ICA512/IA-2 and GAD as IDDM markers, to residual beta-cell function and glycemic control in young IDDM subjects, 25-29
- Autonomic nervous system, *see* Sympathetic nervous system
- AVP, *see entries beginning with terms:* Arginine-vasopressin
- Baldness (hair loss) in women, DHT and testosterone production rate in, 927-929
- Banding, minimally invasive gastric, for morbid obesity, metabolic and psychosocial effects of, 1551-1557
- BAP (bone-specific alkaline phosphatase), and BMD in chronic pancreatitis, 579-581, 584
- Barley, long-term effects of high intake of, on glucose tolerance and lipid metabolism, 1206-1210
- BC3H-1 myocytes, captopril effects on insulin action in, 273-278
- Bcl-2 protein, levels of, during RA and 4HPR therapy of GO, 1391
- BDNF (brain-derived neurotrophic factor), effects of, on obesity with hepatic insulin resistance, 203-208
- Beraprost sodium, effects of, on VCMA-1 expression in HUVECs and circulating VCAM-1 in NIDDM with carotid atherosclerosis, 192-198
- Beta-adrenergic blockers, *see* β -Adrenergic blockers
- Beta₃-adrenergic receptor, *see* β_3 -Adrenergic receptor Trp64Arg polymorphism
- Beta (β)-carotene, plasma and LDL-C, in heavy smokers, grape seed extract effects on, 1255
- Beta (β) cell(s) (islets of Langerhans)
effects of calpain inhibitor-exposed, on mitochondrial fuel metabolism and exocytosis of insulin, 528-534
effects of gestational alcoholism on offspring's, 456-458
effects of lipodystrophy on, in HIV infection, 1343-1353
in young IDDM subjects, relationship of autoantibodies to ICA512/IA-2 and GAD as IDDM markers, to glycemic control in, and residual function of, 25-29
see also Beta cell(s) in NIDDM
- Beta (β) cell(s) (islets of Langerhans) in NIDDM
with CV disease, *see* Beta cell(s) in NIDDM with CV disease
insulin sensitivity and function of, in NIDDM Japanese subjects with impaired glucose tolerance, 476-481
- Beta (β) cell(s) (islets of Langerhans) in NIDDM with CV disease
gliclazide MR effects on, S1:30-32
K_{ATP} channels of, *see* K_{ATP} channels, beta cell, in NIDDM with CV disease
- Beta (β)-estradiol (E₂), effects of IGF-1 and, on eNOS activity in aortic endothelial cells, 482-487
- 17Beta (β)-estradiol (E₂), effects of ICI:compound 182,780 on LPL and HSL expression in SC abdominal adipocytes, 383-388
- Beta (β)-hydroxybutyrate (β -OHB), concentrations of, after recovery from anorexia nervosa, 297
- Beta (β)-hydroxy-cortisol, rosiglitazone effects on urinary excretion of, 231
- Beta-lipoproteins, *see* Low-density lipoprotein(s)
- Biliopancreatic diversion (BPD), effects of, on body composition and EE, 552-558
- Biological systems
simulation of, with WinSAAM, 1155-1156
see also specific biological systems
- Black Americans, *see* Race and ethnicity
- Blood adipopectin, hypoadipopectinemia in insulin-resistant NIDDM Japanese subjects, visceral AT in, 1274-1278
- Blood alanine (Al), glycogen phosphorylase inhibitor effects on, 1423
- Blood cholesterol, *see* Hypercholesterolemia
- Blood glucose
adipocyte-derived plasma adipopectin and, 1613
alcohol intake and, 129-135
in hepatic insulin resistance with obesity, BDNF effects on, 205
in obesity, adipopectin gene mutations and, 882
plasma ghrelin and, 1461
PP, in DM with CAN, 816
pre-pregnancy protein-restricted diet effects on, 16
see also Fasting blood glucose; Glycemia
- Blood glycerol, glycogen phosphorylase inhibitor effects on, 1423
- Blood glycogen, effects of restricted diet on, 325
- Blood homocysteine, *see* Hyperhomocysteinemia
- Blood insulin, *see* Insulinemia
- Blood lactate, glycogen phosphorylase inhibitor effects on, 1423
- Blood lipids, *see* Blood lipids, diet effects on; Dyslipoproteinemia; Hyperlipidemia; Normolipidemia; Postprandial lipemia; Triglyceridemia
- Blood lipids, diet effects on
margarine-enriched phytosterol effects, in young men, 1373-1378

- Blood lipids, diet effects on (*Continued*)
 phytosterol, viscous fibers, soy protein, and almond diet effects, 1480
- Blood pressure (BP)
 and ADRB3 Trp64Arg polymorphism effects on LDL particle size, 357, 358
 in adults malnourished in first year of their life, 1006, 1009
 aging and, 853, 856
 and CRPs in young men, 1114
 and CV disease, *see* Blood pressure, CV disease and diet effects on, *see* Blood pressure, diet effects on
 in DM, *see* Blood pressure in DM
 exercise effects on, *see* Blood pressure, exercise effects on
trans FA intake, LDL size and, 695
 fasting and daylong TGs and, 1046
 in first-degree relatives of NIDDM subjects, TNF- α -863A allele frequency and TNF- α receptor 2 concentration and, 1069
 of heavy smokers, grape seed extract effects on, 1252
 in 17 α -hydroxylase/17,20 lyase deficiency, 489
 of hyperlipidemic subjects, 1192, 1193
 in insulin resistance and/or MS, *see* Blood pressure in insulin-resistant subjects
 in non-obese subjects, *see* Blood pressure in non-obese subjects
 in obesity, *see* Blood pressure in obesity
 in PHP, 160
 and plasma galanin response to HUT in recurrent VVS, 316, 318
 plasma ghrelin and, 1461
 in PM women, *see* Blood pressure in PM women
 in pre-eclampsia, 88
 in primary aldosteronism, 1598, 1599
 in primary hypoalphalipoproteinemia, vascular damage and, 329, 330
see also Hypertension
- Blood pressure (BP), CV disease and, 1296
 carotid IMT with LDL receptor mutation and, 1434-1436
 plasma cortisol and, 525, 526
- Blood pressure (BP), diet effects on
 almond, viscous fiber, soy protein, and phytosterol diet effects, 1479
 high-fat and/or high-CHO diet effects in non-obese and obese women, 1428
 high-sucrose diet and TGZ effects, 980
 of malnourishment in first year of life, 1006, 1009
 margarine-enriched phytosterol effects in young men, 1374
- Blood pressure (BP), exercise effects on
 with or without α - and β -adrenergic blockade, 1617
 in DM with insulin withdrawal, 794
 PPAR γ Pro12Ala polymorphism and, in men, 210
- Blood pressure (BP) in DM
 with CAN, 816, 817
 in GDM, sHcy and, 721
 with insulin withdrawal, effect of exercise on, 794
see also Blood pressure in NIDDM
- Blood pressure (BP) in insulin-resistant subjects
 in MS with liver dysfunction, 1097, 1098
 normal, in HUG-associated insulin resistance, 794
 PPAR γ Pro12Ala polymorphism and, in men, 210
- Blood pressure (BP) in Japanese NIDDM subjects
 with impaired glucose tolerance, 477
 in lean subjects with porphyromonas gingivalis and carotid atherosclerosis, 143
- Blood pressure (BP) in NIDDM
 and ADMA association with GFR and glycemic control, 304
 in Chinese subjects, 1449-1451
- Blood pressure (BP) in NIDDM (*Continued*)
 in early-onset NIDDM, LPL *HindIII* gene polymorphism-lipid level association and, 339, 340
 with hypoadipopectinemia, 1280
 with insulin resistance, 716, 896, 897
 in Japanese subjects, *see* Blood pressure in Japanese NIDDM subjects
 in men with uncomplicated well-controlled NIDDM and preclinical diabetic cardiomyopathy, 1058
 with nephropathy and macroangiopathy, 1518-1521
 in NIDDM first-degree relatives of NIDDM subjects, 1580
 with and without obesity, fasting and daylong TGs and, 1046
 and troglitazone effects on endothelial function, 175, 177
- Blood pressure (BP) in non-obese subjects
 high-fat and/or high-CHO diet effects on, 1428
 with NIDDM, fasting and daylong TGs and, 1046
- Blood pressure (BP) in obesity
 adiponectin gene mutations and, 882
 in central obesity, 1000, 1001
 high-fat or high-CHO diet effects on, 1428
 with insulin resistance and PCOS, 716
 in morbid obesity, 1552-1554
 with NIDDM, fasting and daylong TGs and, 1046
see also Blood pressure in obesity, weight loss effects on
- Blood pressure (BP) in obesity, weight loss effects on
 massive weight loss effects, 901, 903
 in obese men, 138
 in obese PM women, 602, 603
- Blood pressure (BP) in PM women
 with metabolic syndrome, as CV disease risk, 364, 366-369
 obese, effects of weight loss on, 602, 603
- Blood triglycerides, *see* Triglyceridemia
- BMD, *see* Bone mineral density
- BMI, *see* Body mass and body mass index
- Body composition
 of boys, synergistic effects of testosterone and GH on protein metabolism and, 964-969
see also Body composition, exercise effects on; Fat mass; Lean body mass
- Body composition, exercise effects on
 one-year exercise effects in men with CAD, 1413-1417
 in young obese adults, 1177
- Body fat, *see* Adipose tissue
- Body mass and body mass index (BMI)
 of acromegalic subjects, 182
 adipocyte-derived plasma adiponectin and, 1613
 adipocyte PTPase, insulin-mediated glucose uptake, insulin-induced inhibition of oxidation and, 707-708
 and ADRB3 Trp64Arg polymorphism effects on LDL particle size, 357, 358
 and atherogenic role of lysophosphatidylcholine in LDLs, 311
 of boys, and effects of testosterone and GH on protein metabolism and body composition, 965
 CRP relation to, 1114, 1543, 1544
 of diabetic nephropathy subjects, 1259
 diet and, *see* Body mass and body mass index, diet effects on
 of DM subjects, *see* Body mass and body mass index of DM subjects
 estrogen and medroxyprogesterone acetate effects on, 1331
 exercise effects and, *see* Body mass and body mass index, exercise effects and
 FAs and, *see* Body mass and body mass index, FAs and GHR effects on, 53
 gluconeogenesis and, 1513

- Body mass and body mass index (BMI) (*Continued*)
 and grape seed extract effects on LDL oxidation, 1252
 of hair-losing women, 928
 of HIV infection subjects with lipodystrophy, 622, 1346, 1347, 1351
 of hyperlipidemic subjects, 1192, 1193
 of metabolic syndrome subjects, 726, 727; *see also* Body mass and body mass index of insulin-resistant subjects
 of nondiabetic ESRD subjects, HD-induced changes in Lps and, 117
 of non-obese subjects, *see* Body mass and body mass index of non-obese subjects
 of obese subjects, *see* Body mass and body mass index in obesity
 of older subjects, *see* Body mass and body mass index of older subjects
 plasma ghrelin and, 1461
 of PM women, *see* Body mass and body mass index of PM women
 and PP leukocyte increase, 200
 and PP triglyceridemia, 1381, 1384
 PPAR γ_2 Pro12Ala polymorphism effects on, 779
 and pregnancy loss, 1628
 of primary hypoalipolipoproteinemic subjects, 329, 330
 of renal transplant recipients, 574
 risk for CV disease and, *see* Body mass and body mass index, as risk for CV disease
 and risk factor for CHD, 1532
 and R219K polymorphism of ABCA1 gene, 931, 932
 and sex hormone relation to AT, insulin, and risk for MI in men, 785
 swelling syndrome, gynoid adiposity and, 806, 807
 and Taq1B polymorphism with Lp variations, 1565, 1567, 1568
- Body mass and body mass index (BMI), diet effects on, 632
 of alcohol intake, 131
 fat ingestion, 1039
 malnourishment in first year life and, 1006-1008
 margarine-enriched phytosterol diet in young men, 1374
 restricted diet, 970-977
see also Body mass and body mass index, FAs and
- Body mass and body mass index (BMI), exercise effects and acute endurance exercise effects on BMI, 154
 of exercising PM women, adrenocortical responses to exercise and, 1644
 on plasma prebeta-1 HDLs, 439
 on SHBG concentrations, 37-39
 in young obese adults, glucose and insulin responses and, 1177
see also Body mass and body mass index, exercise effects on, in men
- Body mass and body mass index (BMI), exercise effects on, in men with CAD, 1414, 1415
 in free-living obese men, energy intake restriction and 16-week exercise effects on, 107-115
 on PPAR γ Pro12Ala polymorphism, 210
- Body mass and body mass index (BMI), FAs and
trans FA intake and, 695, 696
see also Body mass and body mass index, FFAs and
- Body mass and body mass index (BMI), FFAs and
 and FFA-induced peripheral tissue insulin resistance, 234
 and FFA metabolism regulation by NPY gene Leu7Pro polymorphism, 644
- Body mass and body mass index (BMI), as risk for CV disease, 1296
 carotid IMT association with LDL receptor mutation and, 1434-1436
- Body mass and body mass index (BMI), as risk for CV disease, 1296 (*Continued*)
 in nondiabetic subjects, 690-691
 plasma cortisol and, 525, 526
 race and, 1296
- Body mass and body mass index (BMI) of DM subjects
 and atherogenic role of lysophosphatidylcholine in LDLs, 311
 with CAN, 816, 817
 with ESRD, HD-induced changes in Lps and, 117
 of GDM subjects, sHcy and, 721
 of IDDM children, intracellular platelet Mg and, 469
see also Body mass and body mass index of NIDDM subjects
- Body mass and body mass index (BMI) of first-degree relatives of NIDDM subjects
 glucose-tolerant relatives, 567
 TNFR2 concentration and, 1069
- Body mass and body mass index (BMI) of insulin-resistant subjects
 with adipocyte insulin resistance, 240
 in FFA-induced peripheral tissue insulin resistance, 234
 with hypertriglyceridemia and normal glucose tolerance, 617, 618
 of insulin-resistant Japanese subjects with IGT, 477
 insulin-resistant obese PCOS women, 714, 716
 with liver dysfunction, 1097, 1098
 of NA-induced insulin-resistant subjects, 701
 in NIDDM men, effects of glycemic control on LDL particle size and, 1577
 of non-obese subjects with PAI-1-associated insulin resistance, 227, 228
- Body mass and body mass index (BMI) of Japanese NIDDM subjects
 with IGT, beta-cell function and insulin sensitivity in, 477
 non-obese subjects with porphyromonas gingivalis and carotid atherosclerosis, 143
- Body mass and body mass index (BMI) of NIDDM subjects
 with adipocyte insulin resistance, 240
 ADMA association with GFR and glycemic control and, 304
 with carotid atherosclerosis, beraprost sodium effects and, 195
 Chinese subjects, 1449, 1450
 with early-onset NIDDM, LPL *HindIII* gene polymorphism-lipid level association and, 339, 340
 glibenclamide-metformin therapy and, 864
 with hypoadinopectinemia, 1280
 with insulin resistance, 896, 897
 in Japanese subjects, *see* Body mass and body mass index of Japanese NIDDM subjects
 with nephropathy and macroangiopathy, 1518-1521
 of NIDDM first-degree relatives of NIDDM subjects, 1580
 of NIDDM men, and effects of glycemic control on LDL particle size, 1577
 in obesity, *see* Body mass and body mass index in obesity
 and phospholipid-dependent procoagulation activity, 103
 and pramlintide effects on A $_{1c}$ and BW, 1639
 with retinopathy, 606
 TZDs effects on, *see* Body mass and body mass index of NIDDM subjects, TZD effects on
see also Body mass and body mass index of first-degree relatives of NIDDM subjects
- Body mass and body mass index (BMI) of NIDDM subjects, TGZ and
 skeletal muscle morphology regulation with metformin and TGZ, 541
 TGZ effects on endothelial function and, 175
- Body mass and body mass index (BMI) of NIDDM subjects, TZD effects on, 754

- Body mass and body mass index (BMI) of NIDDM subjects, TZD effects on, 754 (*Continued*)
 rosiglitazone effects on serum Lp(a), 732
see also Body mass and body mass index of NIDDM subjects, TGZ and
- Body mass and body mass index (BMI) of non-obese subjects
 as CV disease risk in nondiabetic subjects, 690-691
 high-fat and high-CHO diet on cardiac autonomic nervous system in non-obese women, 1428
 Japanese subjects with porphyromonas gingivalis and carotid atherosclerosis, 143
 with PAI-1-associated insulin resistance, 227, 228
- Body mass and body mass index (BMI) of obese men
 of free-living obese men, energy restriction intake and 16-week exercise effects on body composition and, 107-115
 weight loss effects on, 138
- Body mass and body mass index (BMI) of obese women
 high-fat and high-CHO diet on cardiac autonomic nervous system and, 1428
 insulin-resistant obese PCOS women, 714, 716
 morbidly obese women, SM FA oxidation in, 736
 PM women, effects of weight loss on, 601
 PP apo A-IV distribution between apo B- and non-apo B-containing Lps and, 1538-1540
- Body mass and body mass index (BMI) in obesity
 adiponectin gene mutations and, 882
 BPD effects on, 552-558
 with central obesity, 1001
 effects of massive weight loss on, 901
 fasting and daylong TGs and, 1046
 and FFA-induced peripheral tissue insulin resistance, 234
 hypercholesterolemic, disturbed cholesterol synthesis effects on monocytes and, 4
 of morbidly obese subjects, 1552-1554
 nondiabetic, plasma SSAO and CV risk and, 690, 691
 with normal cholesterol, 380
 of obese IDDM and/or NIDDM children, intracellular platelet Mg and, 469
see also Body mass and body mass index of obese men; Body mass and body mass index of obese women
- Body mass and body mass index (BMI) of older subjects
 and GH, abdominal VAT, fitness, and insulin effects on, 76
 insulin action and, 853
- Body mass and body mass index (BMI) of PM women
 CETP and LCAT activities and, 286
 with metabolic syndrome, 364, 366-369
 obese, effects of weight loss on, 601
 racial differences in, 187
- Body water, Mg-creatine supplementation effects on, 1136-1140
- Body weight (BW)
 adipocyte-derived plasma adinopectin and, 1613
 and bosentan effects on renal AVP V₂, 1142
 cycling effects on serum level of IGF-1, IGFBP-1 and -3, 822
 diet effects on, *see* Body weight, diet effects on
 of DM subjects, *see* Body weight of DM subjects
 doxazosin effects on, in HTN, 1149
 estrogen and medroxyprogesterone acetate effects on, 1331
 exercise and, *see* Body weight, and exercise effects
 gluconeogenesis and, 1513
 and glutamine effects on protein and amino acid metabolism in hepatic tissue, 1063, 1064
 in gynoid adiposity with swelling syndrome subjects, 806, 807
 of insulin-resistant subjects with liver dysfunction, 1097
 of lysine intolerance subjects, 936
- Body weight (BW) (*Continued*)
 and Mg-creatine supplementation effects on body water, 1137
 of older subjects, *see* Body weight of older subjects
 of older women, IGF-1 effects on glucose kinetics or insulin sensitivity in, 1184
 of PCOS subjects, *see* Body weight of PCOS subjects
 of primary aldosteronism subjects, 1598
 relation of sex hormones to AT, insulin, and risk for MI and, 785
 and risk for NIDDM, 888, 1213
 total, GHR effects on, 53
 of young subjects, smokeless nicotine effects on, 68
see also Non-obese subjects; Obesity
- Body weight (BW), diet effects on
 high-CHO and/or high-MUFA diet, 1457
 high-sucrose diet effects on, 980
 malnourishment in first year of life, 1006-1008
- Body weight (BW), and exercise effects
 acute endurance exercise effects on, 154
 endothelial lipase genotype and, 1507
 in men with CAD, 1414, 1415
 on plasma prebeta-1 HDLs, 439
 on postprandial lipemia and LDL receptor binding in men, 138
- Body weight (BW) of DM subjects
 age-dependent liver thyroid status adaptation and, 1118
 with CAN, 816, 817
 of STZ-DM subjects, and effects of apo C-III deficiency on hypertriglyceridemia development, 1355
see also Body weight of NIDDM subjects
- Body weight (BW) of NIDDM subjects
 with controlled NIDDM, pramlintide effects on A_{1c} and, 1638-1642
 EPA effects on, 31
 with hypoadinopectinemia, 1280
 and PPAR γ Pro12Ala polymorphism association with oxidized LDL and cardiolipin autoantibodies, 215
 and troglitazone effects on endothelial function, 177
 TZD effects on, 754
- Body weight (BW) of older subjects
 effects of GH, abdominal VAT, fitness, and insulin on, 76
 insulin action and, 853
- Body weight (BW) of PCOS subjects
 with insulin resistance, 714
 with MS, metformin and diet effects on, 910, 911
- Bone mass, *see* Bone mineral density
- Bone mineral density (BMD)
 and chronic pancreatitis, 579-585
 in PM women, *see* Bone mineral density in PM women
 restricted diet effects on, 970-977, 1265-1273
- Bone mineral density (BMD) in PM women
 effects of estrogen receptor and collagen IA1 genes on PTH and 25 hydroxyvitamin D with, 1129-1135
 effects of interaction between VDR polymorphism and aromatase Arg²⁶⁴ polymorphism on, racial differences in, 521-523
 in obese PM women, effects of weight loss on, 601
- Bone-specific alkaline phosphatase (BAP), and BMD in chronic pancreatitis, 579-581, 584
- Bosentan, effects of, on renal arginine-vasopressin V₂ receptor, 1141-1146
- Boys, synergistic effects of testosterone and GH on protein metabolism and body composition of, 964-969
- BP, *see* Blood pressure
- BPD (biliarypancreatic diversion), effects of, on body composition and EE, 552-558

Brain

- aging and central function of, in allostasis, S2:13-14
- of offspring, effects of pre-pregnancy protein-restricted diet on weight of, 15
- see also* Brain-derived neurotrophic factor; Brain proteins
- Brain-derived neurotrophic factor (BDNF), effects of, in obesity with hepatic insulin resistance, 203-208
- Brain proteins, effects of acute alcohol on synthesis of, 389-396
- Breast cancer, insulin signaling via Shc in, 1606-1611
- Breath test, 2-keto[1-¹³C]isocaproate, mitochondrial response of obese women to calorie-restricted diet measured with, 463-467
- 2-Bromopalmitate in study of GSIS potentiation by palmitate, 1367-1371
- BSO (L-buthioninesulfoximine), effects of, on GSH redox state-gluconeogenesis relation in renal cortical tubules, 742-743
- Burn injury, metabolism of extrahepatic arginine after, burn injury, 1232-1239
- L-Buthioninesulfoximine (BSO), effects of, on GSH redox state-gluconeogenesis relation in renal cortical tubules, 742-743
- Butyrate, raw potato starch effects on formation of, colonocyte apoptosis and shift to stem cell compartment due to, 1400-1405
- BW, *see* Body weight

C, *see* Cholesterol

Ca (calcium)

- and effects of insulin and ATP on MAPK in liver cells, 590-598
- in PHP, 160
- see also* Ca²⁺-regulatory muscle proteins; Intra-arterial Ca stimulation test
- Ca (calcium) stimulation test, intra-arterial, insulinoma detection with, 1320-1329
- Ca²⁺ (calcium₂)-regulatory muscle proteins, alcohol effects of, 1102-1112
- CAD, *see* Coronary artery disease
- Caenorhabditis* models of aging genetics, S2:5-6
- Caipo (*imopea batatas*), mode of action of, in NIDDM, 875-880
- Calcitriol [1,25(OH)₂D₃], BMD and, in chronic pancreatitis, 579-584
- Calcium, *see* Ca
- Calorie-restricted diet, 2-keto[1-¹³C]isocaproate breath test assessing mitochondrial response of obese women to, 463-467
- Calpain inhibitors, effects of beta cells exposed to, on mitochondrial fuel metabolism and insulin exocytosis, 528-534
- cAMP (cyclic adenosine monophosphate)
 - effects of, on AVP V₂ expression in IMCD, 293
 - effects of N-terminal Ala₂-substituted analogs of GIP on production of, 679-687
 - in GO, RA and 4HPR effects on, 1381
 - lactate formation and, in adipocytes and AT from obese subjects, 62
- CAN, *see* Cardiac autonomic neuropathy in DM
- Captopril effects
 - on Hcy in hypertension, 261-263
 - on insulin action in BC3H1 myocytes, 273-278
 - on insulin-stimulated glycogen synthesis in skeletal muscle but not on FA synthesis in AT in hereditary hypertriglyceridemia, 1406-1412
- Carbohydrate(s) (CHO)
 - in *trans* FA diet, 695, 696
 - fasting, *see* Fasting carbohydrates
 - glycogen level and ingested glucose effects on net storage of, 94-101
 - intake of, *see* Carbohydrate(s), intake of

Carbohydrate(s) (CHO) (*Continued*)

- testosterone and GH effects on metabolism of, in boys, 966, 967
- see also* Oxidation, CHO and specific carbohydrates
- Carbohydrate(s) (CHO), intake of
 - daylong TGs and, 1046
 - by exercising young obese adults, 1179
 - with high-fiber diet, 1207
 - with margarine-enriched phytosterols, 1375
 - see also* High-carbohydrate diet
- Carboxykinase, mRNA of phosphoenol pyruvate, in hepatic insulin resistance with obesity, 205
- N^ω-(Carboxymethyl)-lysine (CML), serum level of, in NIDDM, 163-167
- Carboxy-terminal propeptide of type I collagen (CICP), and BMD in chronic pancreatitis, 579-581
- Cardiac adenosine triphosphate-sensitive potassium channels (K_{ATP} channels), acyl CoA esters activating, in side-chain length-specific manner, 1313-1319
- Cardiac autonomic nervous system
 - effects of high-fat and/or high-CHO diet on activity of, in non-obese and obese women, compared, 1426-1432
 - see also* Cardiac autonomic neuropathy in DM
- Cardiac autonomic neuropathy (CAN) in DM
 - influence of obesity, duration of DM, and microangiopathic complications on, 815-820
 - relation of LVDD and, to preclinical diabetic cardiomyopathy in men with uncomplicated well-controlled NIDDM, 1056-1061
- Cardiac output (CO), effects of exercise on, in DM with insulin withdrawal, 794
- Cardiolipin autoantibodies, PPAR γ Pro12Ala polymorphism associated with oxidized LDL autoantibodies and, in nondiabetics and in NIDDM, 213-217
- Cardiomyocytes, high glucose concentration inhibiting taurine transport in, 827-833
- Cardiomyopathy, preclinical diabetic, in men with uncomplicated well-controlled NIDDM, relation of CAN and LVDD to, 1056-1061
- Cardiovascular (CV) disease
 - aging and, S2:8
 - see also* Cardiovascular disease, risk for; Cardiovascular system
- Cardiovascular (CV) disease, risk for
 - carotid IMT associated with LDL receptor mutation independently of, 1433-1438
 - by ethnic background and anthropometric indices, 1295-1301
 - insulin and, *see* Insulin, risk for CV disease and
 - Lp content in apo A-I and apo A-I:apo A-II and risk for CHD, 1530-1536
 - plasma cortisol and, 524-527
 - plasma SSAO as, in nondiabetic obese subjects, 688-692
 - see also* Cardiovascular disease, risk for, in obese women;
- Non-insulin-dependent diabetes mellitus, risk for CV disease in; Risk for CAD
- Cardiovascular (CV) disease, risk for, in obese women
 - effects of supplementation with FcTO containing MCTs, n-3 PUFAs, and phytosterols on, 771-777
 - with PCOS, effects of insulin resistance and obesity on, 713-719
 - in PM women with MS, racial differences in, 362-371
- Cardiovascular (CV) system
 - ACE DD genotype, circulating E-selectin, and damage to, in central obesity, 999-1004
 - in aging, *see* Cardiovascular system in aging
 - see also* Heart; Vascular system *entries beginning with terms:* Myocardial, Ventricular *element: Card- specific organs and conditions*

- Cardiovascular (CV) system in aging
 effects of aging on vascular system, S2:31-35
 glucocorticoids and, S2:10-11
- Carnitine, palmitoyl-, oxidation of, in morbidly obese women, 736
- β (beta)-Carotene, plasma, in heavy smokers, grape seed extract effects on, 1255
- Carotid artery, *see* Carotid atherosclerosis in NIDDM; Intima-media thickness, carotid artery
- Carotid atherosclerosis in NIDDM
 beraprost sodium effects on VCAM-1 expression in HUVECs and on circulating VCAM-1 in, 192-198
 with porphyromonas gingivalis in non-obese NIDDM Japanese subjects, 142-145
- Carotid endarterectomy (CEA), IH following, in insulin resistance, 834-839
- Casein-based diet, effects of short-term hydrolyzed, on IDDM development, 333-337
- Catecholamines
 α -adrenergic blocker effects on response of, to exercise at high altitude (4,300 meters), 1471-1477
 leptin effects on response of, to insulin-induced hypoglycemia, 1484-1490
 as mediators of allostasis, aging and, S2:11-12
see also Epinephrine; Norepinephrine; Plasma catecholamines
- CE (cholesterol ester), GHR effects on, in hypopituitarism, 56
- CEA (carotid endarterectomy), IH following, in insulin resistance, 834-839
- Cell differentiation
 adipocyte, apoptosis of abdominal preadipocytes before and after, 987-992
 of insulinoma cells, 1320-1329
- Cellular fibronectin (cFn) in EC injury, transient hyperhomocysteinemia and changes in, 501-507
- Cellular models of aging genetics, S2:6
- Cellulose fiber in short-term hydrolyzed casein-based diet, 334
- Central nervous system
 in aging, role of glucocorticoids in, S2:11
see also Brain
- Central obesity, ACE DD genotype, circulating E-selectin, and CV damage in, 999-1004
- Central volume expansion
 in primary aldosteronism, K supplementation effects on natriuretic response to, 1597-1600
 in salt-sensitive hypertension, plasma FA response to, 508-513
- Ceramide, effects of, on insulin-induced PKC ζ translocation in adipocytes, 19-24
- Cessation of smoking, effects of, in CV disease with NIDDM, S1:22
- CETP, *see* Cholesteryl ester transfer protein
- C-514 polymorphism of hepatic lipase gene, effects on interaction between S447X polymorphism of LPL gene and, on serum TGs in young adults, 1337-1342
- cFn (cellular fibronectin) in EC injury, transient hyperhomocysteinemia and changes in, 501-507
- CHD (coronary heart disease), race and Lp content in apo A-I and apo A-I:apo A-II as risk factor for, 1530-1536
- Childhood
 risk of insulin resistance syndrome in offspring from childhood to young adulthood in offspring of NIDDM parents, 443-453
see also Children
- Children
 with acute atopic dermatitis exacerbation, pentosidine and oxidative stress in, 1601-1605
 obese IDDM and NIDDM, intracellular Mg of platelets in, 468-471
- Children (*Continued*)
see also Childhood; Offspring; Parents
- Chinese subjects, NIDDM, 27-bp repeat polymorphism in intron 4 of ECNOS gene in, serum uric acid level and, 1448-1453
- CHO(s), *see* Carbohydrate(s)
- Cholesterol (C)
 in diabetic and nondiabetic ESRD subjects, HD-induced changes in, 118
 dietary, LDL size and intake of, 695, 696
 effects of supplementation with, on linoleic acid-induced EC activation, 493-500
 exercise effects on reverse transport of, 950-957
 in first-degree relatives of NIDDM subjects, 1069
 free, GHR effects on, in hypopituitarism, 56
 in men at risk for developing NIDDM, 888
 in MS with PCOS, metformin and diet effects on, 910, 911
 in obesity without NIDDM, 1045
 in older subjects, effects of GH, abdominal VAT, fitness, and insulin on, 76-78
 plasma, *see* Plasma cholesterol
 and PP leukocyte increase, 200
 and PP triglyceridemia, 1381, 1384
 pre-pregnancy restricted-protein diet effects on, 16
 and relation of sex hormones to AT, insulin, and risk for MI in men, 785
 and risk factor for CHD, 1532-1534
 serum, *see* Serum cholesterol
see also Cholesterol acyltransferase; Cholesterol ester; Cholesterol in NIDDM; Cholesterol in obesity; High-density lipoprotein-cholesterol; Hypercholesterolemia; Intermediate-density lipoprotein-cholesterol; Low-density lipoprotein-cholesterol; Total cholesterol
- Cholesterol (C) in NIDDM
 with insulin resistance, 896, 897
 with obesity, fasting and daylong TGs and, 1046
- Cholesterol (C) in obesity
 and adiponectin gene mutations, 882
 fasting and daylong TGs and, 1046
 with insulin resistance, estrogen and, 660
 in nondiabetic subjects, plasma SSAO, CV disease risk and, 690, 691
 normal, serum DHEAS, serum leptin and, 379-381
 in obese women, PP apo A-IV distribution between apo B- and non-apo B-containing Lps and, 1538, 1539
- Cholesterol acyltransferase, lecithin:, total and regional AT associated with activities of CETP and, in PM women, race and ethnicity and, 282-289
- Cholesterol ester (CE), GHR effects on, in hypopituitarism, 56
- Cholesteryl ester transfer protein (CETP)
 Taq1B polymorphism with Lp variations in Japanese subjects, 1564-1570
 total and regional AT associated with activities of LCAT and, in PM women, race and ethnicity and, 282-289
- Chronic effects of DHEA on AT metabolism, 264-272
- Chronic glipizide gastrointestinal therapeutic system (GITS), metabolic effects of, on serum glucose, insulin secretion, insulin sensitivity, and hepatic insulin extraction in glucose-tolerant first-degree relatives of African-American NIDDM subjects, 565-572
- Chronic pancreatitis, BMD and, 579-585
- Chylomicrons, effects of different types and amounts of FAs on retinoid secretion in, after high-dose preformed vitamin A supplementation, 514-519

- CICP (carboxy-terminal propeptide of type I collagen), and BMD in chronic pancreatitis, 579-581
- Circulating E-selectin, ACE DD genotype, and CV damage in central obesity, 999-1004
- Circulating free fatty acids (FFAs), relation of NA-induced insulin resistance to AT oxidation and, but not to SM lipid content, 699-704
- Circulating glycated insulin in NIDDM, food intake effects on 24-hour profile of, 631-635
- Circulating mannose, physiological changes in levels of, in normal glucose tolerance, glucose intolerance, and DM, 1019-1027
- Circulating vascular cell adhesion molecule-1 (VCAM-1) in NIDDM with carotid atherosclerosis, beraprost sodium effects on VCAM-1 expression in HUVECs and, 192-198
- Citrate synthase (CS), effects of restricted diet on, 325
- Citrulline, plasma, gluconeogenesis and response of, to arginine, 1512-1516
- CLA (conjugated linoleic acid), effects of α -lipoic acid interaction with, on insulin action in obesity, 1167-1174
- Clinical aspects of aging effects on vascular system, S2:33-34
- Clinical efficacy of gliclazide MR for CV disease in NIDDM, S1:29-30
- Clinical implications of sulfonylureas for CV disease in NIDDM, S1:4
- CLX-9021 (PPAR γ agonist), antihyperglycemic activity and low adipogenic potential of, 1012-1018
- CML [N^ω-(carboxymethyl)-lysine], serum level of, in NIDDM, 163-167
- CMV (cytomegalovirus) infection, as determinant of insulin secretion after renal transplantation in older subjects, 573-578
- CO (cardiac output) in DM with insulin withdrawal, effect of exercise on, 794
- CoA, *see* Coenzyme A
- Coagulation systems, relation of frailty in the elderly to activation of, S2:22-23
- Cobalamin in HTN, HCT effects on, 262
- Coenzyme A (CoA)
 palmitoyl-, oxidation of, in morbidly obese women, 736
 see also Acyl coenzyme A esters; Acyl coenzyme hydrolases/thioesterases; Coenzyme Q10
- Coenzyme Q10 (CoQ10), and infertility in varicocele, 402-406
- Cognitive function in insulin-mediated hypoglycemia, counterregulatory responses to, after massive weight loss by severely obese subjects, 900-907
- Collagen, carboxy-terminal propeptide of type I, and BMD in chronic pancreatitis, 580
- Collagen IA1 gene, effects of estrogen receptor α gene and, on relation of PTH and 25(OH)D to BMD in PM women, 1129-1135
- Collecting duct, inner medullary, angiotensin II effects on AVP V₂ mRNA in, 290-295
- Colon, colonocyte apoptosis and shift to stem cell compartment due to effects of butyrate formation in, 1400-1405
- Colonocytes, shift to stem cell compartment and apoptosis of, due to raw potato starch effects on butyrate formation in colon, 1400-1405
- Computations, WinSAAM, 1154-1155
- Conjugated linoleic acid (CLA), effects of α -lipoic acid interaction with, on insulin action in obesity, 1167-1174
- Connecting peptides, *see* C-peptides
- Continuous insulin delivery, effects of pulsatile and, on insulin action, compared, 1050-1055
- CoQ10 (coenzyme Q10), and infertility in varicocele, 402-406
- Corn oil in short-term hydrolyzed casein-based diet, 334
- Cornstarch
 long-term effects of high intake of, on glucose tolerance and lipid metabolism, 1206-1210
 in short-term hydrolyzed casein-based diet, 334
- Coronary artery disease (CAD)
 atorvastatin effects on apo B-48 metabolism and LDL receptor activity in normolipidemia with, 1279-1286
 exercise effects on, *see* Coronary artery disease, exercise effects on
 risk for, *see* Risk for CAD
 see also Coronary artery disease in NIDDM
- Coronary artery disease (CAD), exercise effects on, 950-951
 on impaired fasting glucose, 409-410
 in men, 1413-1417
- Coronary artery disease (CAD) in NIDDM, S1:6-9
 anatomy and outcome of, S1:6
 detection of, S1:6-7
 therapy of, *see* Coronary artery disease in NIDDM, therapy of
- Coronary artery disease in NIDDM, therapy of, S1:7-10
 of documented CAD, S1:7-9
 secondary prevention of, S1:7-8
 sulfonylureas for, S1:9-10; *see also* Gliclazide in NIDDM with CV disease
- Coronary heart disease (CHD), race and Lp content in apo A-I and apo A-I:apo A-II as risk factor for, 1530-1536
- Cortical tubules, renal, gluconeogenesis-redox state relation in, 739-746
- Corticotropin (adrenocorticotrophic hormone; ACTH), and 17 α -hydroxylase/17,20 lyase deficiency, 489
- 1- and 250- μ g Corticotropin (adrenocorticotrophic hormone; ACTH) stimulation tests of adrenal function in AIDS, 647-651
- Cortisol (hydrocortisone)
 effects of, on glucose output by kidney in DM, 474
 effects of intense exercise on, with and without α - and β -adrenergic blockers, 1619
 and 17 α -hydroxylase/17,20 lyase deficiency, 489
 plasma, *see* Plasma cortisol
 response of, to insulin-induced hypoglycemia after massive weight loss by severely obese subjects, 900-907
 rosiglitazone effects on production of, in men, 230-232
- Costa Rican population, *trans* FA intake and LDL size in, 693-698
- Counterregulatory hormones
 response of, to insulin-induced hypoglycemia after massive weight loss by severely obese subjects, 900-907
 see also Dopamine; Glucagon; Norepinephrine; Pancreatic polypeptide
- C-peptides (CPs; connecting peptides)
 effects of HRT on, in PM subjects, 1088
 fasting, *see* Fasting C-peptides
 in glucose-tolerant first-degree relatives of African-American NIDDM subjects, 567, 568
 massive weight loss effects on, 903
 in men at risk for developing NIDDM, 888, 889
 in NIDDM, *see* C-peptides in NIDDM
 in nondiabetic obese subjects, plasma SSAO and CV disease risk and, 690, 691
 plasma, *see* Plasma C-peptides
 PPAR γ ₂ Pro12Ala polymorphism effects on, 781
 and risk for NIDDM, 1213
 serum, in hypoadinopectinemic Japanese subjects, 1275
- C-peptides (CPs; connecting peptides) in NIDDM
 with diabetic nephropathy, 606
 in hypoadinopectinemic Japanese NIDDM subjects, 1275

- C-peptides (CPs; connecting peptides) in NIDDM (*Continued*)
 plasma, in hypoalphalipoproteinemia and hyperalphalipoproteinemia, 432-436
- C-reactive proteins (CRPs)
 in NIDDM with diabetic retinopathy, 606
 plasma, in hypoalphalipoproteinemia and hyperalphalipoproteinemia, 432-436
 relation of ethnic and gender differences, 1542-1546
 in young men, associated with serum leptin, QTc interval, and HDL-C, 1113-1116
- Creatine-magnesium (Mg) supplementation, effects of, on body water, 1136-1140
- Creatinine
 in DM, *see* Creatinine in NIDDM; Serum creatinine in DM
 in HTN, *see* Creatinine in HTN
 in MS with liver dysfunction, 1097
 in non-obese subjects with PAI-1-associated insulin resistance, 227
- Creatinine in HTN
 HCT effects on, 262
 in salt-sensitive HTN, 509
- Creatinine in NIDDM
 in Chinese NIDDM subjects, 1449-1451
 with nephropathy and macroangiopathy, 1518-1521
 in NIDDM first-degree relatives of NIDDM subjects, 1580
 and phospholipid-dependent procoagulation activity, 103
 with retinopathy, 606
 serum, with carotid atherosclerosis, beraprost sodium effects on, 195
- CRP, *see* C-reactive proteins
- CS (citrate synthase), and effects of restricted diet on sarcolemmal lactate transport, 325
- CS-045, *see* Troglitazone
- CV system, *see* Cardiovascular system
- Cyclic adenosine monophosphate, *see* cAMP
- Cycling
 effects of, on serum level of IGF-1, IGFBP-1 and -3, glucose disposal and, 821-826
 effects of running and/or, on AT oxidation, 747-752
- CYP17 gene, heterozygous mutation of, and 17 α -hydroxylase/17,20 lyase deficiency, 488-492
- CYP19 gene polymorphism, effects of interaction between VDR polymorphism and, on BMD of postmenopausal African-American women, 521-523
- CYP2D6 mutation, tramadol pharmacokinetics and, 1439-1443
- CYP7B1 (oxysterol 7 α -hydroxylase), regulation of, 636-642
- Cystatin C
 diabetic nephropathy diagnosis with, 1258-1264
 in HTN, HCT effects on, 262
- Cysteine (Cys), effects of supplementation with FeTO on, in obese women, 775
- Cysteinyl, effects of supplementation with FeTO on, in obese women, 775
- Cysteinylglycine (L- γ -glutamyl-L-cysteinylglycine), *see* Glutathione
- Cytokines
 as mediators of allostasis, aging and, S2:12-13
see also specific cytokines
- Cytomegalovirus (CMV) infection, as determinant of insulin secretion after renal transplantation in older subjects, 573-578
- Cytosolic acyltransferase coenzyme A (CoA)
 hydrolases/thioesterases, hepatic induction of, in DM and fasting, 1527-1529
- Darglitazone, effects of, on insulin secretion, 1395-1396
- Daylong triglycerides (TGs), fasting and, in obesity with and without NIDDM, 1043-1049
- DBP (diastolic blood pressure), *see* Blood pressure
- DD genotype, ACE, circulating E-selectin, and CV damage in central obesity, 999-1004
- Decarboxylase, autoantibodies to ICA512/IA-2 and glutamic, as IDDM markers, and their relationship to residual beta-cell function and glycemic control in young IDDM subjects, 25-29
- Dehydroepiandrosterone (DHEA)
 chronic effects of, on AT metabolism, 264-272
 as mediator of allostasis, aging and, S2:11
 in MS with PCOS, 909
- Dehydroepiandrosterone sulfate (DHEAS)
 and 17 α -hydroxylase/17,20 lyase deficiency, 489
 serum, in obesity with normal cholesterol, 379-381
- Dehydrogenase, lactate, effects of restricted diet on, 325
- Dehydrogenase 2, aldehyde, ADRB3 Trp64Arg polymorphism and, associated with liver dysfunction and metabolic syndrome, 1096-1101
- 6-Deoxy-6-fluoro-ascorbic acid (F-ASA), metabolomic mapping of vitamin C with ¹⁹F-NMR spectroscopy and, in DM, 760-770
- [³H]-2-Deoxy-D-glucose (DOG)
 adipocyte, ceramide effects on, 19-24
 high-sucrose diet and TGZ effects on SM uptake of, 982
- Deoxyribonucleic acid (DNA)-binding activity in NF- κ B for ELAM-1, ICAM-1, and VCAM-1 in NIDDM with CV disease, S1:16
- Dermatitis, urinary pentosidine in children with acute exacerbation of atopic, oxidative stress and, 1601-1605
- Detection of CAD in NIDDM, S1:6-7
- Dexamethasone for 17 α -hydroxylase/17,20 lyase deficiency, 489
- DHEA, *see* Dehydroepiandrosterone
- DHEAS, *see* Dehydroepiandrosterone sulfate
- DHT, *see* Dihydrotestosterone
- Diabetes mellitus (DM)
 age-dependent liver thyroid status adaptation and serum and hepatic IGF-1 expression in, 1117-1125
 effects of, on lipid profile, 919
 effects of obesity, microangiopathic complications, and duration of, on CAN in, 815-820
 with ESRD, HD-induced changes in Lps in, 116-121
 family history of, *see* Family history of DM
 gestational, serum homocysteine in, 720-723
 induction of mitochondrial and cytosolic acyl CoA hydrolases/thioesterases by liver in, 1527-1529
 insulin withdrawal in, and prevention of ischemic heart failure with exercise in, 791-797
 metabolomic mapping of vitamin C with F-ASA and ¹⁹F-NMR spectroscopy in, 760-770
 physiological changes in circulating mannose levels in, 1019-1027
 PLA₂ effects on atherogenic role of lysophosphatidylcholine in LDLs in, 308-314
 renal output of glucose in, 472-475
see also Cardiac autonomic neuropathy in DM; Diabetic cardiomyopathy; Diabetic retinopathy, NIDDM; Insulin-dependent diabetes mellitus; Non-insulin-dependent diabetes mellitus; Streptozotocin-induced diabetes mellitus
- Diabetic cardiomyopathy, preclinical, in men with well-controlled uncomplicated NIDDM, relation of CAN and LVDD to, 1056-1061
- Diabetic macroangiopathy and nephropathy in NIDDM, plasma Hcy and plasma TM in, 1517-1522

- Diabetic microvascular complications, asymptomatic atherosclerosis
in Japanese NIDDM subjects without, risk for, 1302-1306
- Diabetic nephropathy
cystatin C diagnosis of, 1258-1264
and macroangiopathy in NIDDM, plasma Hcy and plasma TM in,
1517-1522
see also Diabetic retinopathy, NIDDM
- Diabetic retinopathy, NIDDM
carotid atherosclerosis with, 195
serum IL-18 and serum TNF- α in, 605-608
- Diastolic blood pressure, *see* Blood pressure
- Diet
metformin and, in management of MS with PCOS, 908-915
see also Dietary restriction; Energy intake; Food intake in
NIDDM; Malnutrition; Nutritional status; Supplementation
entries beginning with terms: Dietary, Postprandial *specific*
types of diets and food substances
- Dietary carbohydrates, *see* Carbohydrate(s)
- Dietary cholesterol (C)
effects of, on LDL size, 695, 696
in high-CHO and high-MUFA diet, 1455
in margarine-enriched phytosterols, 1375
- Dietary fat
effects of, on GS activity and mRNA, 535-539
in high-fiber diet, 1207
ingested glucose and oxidation of, 96-98
interaction between apo E genotype and intake of, in older
subjects, 279-281
in margarine-enriched phytosterols, 1375
in NIDDM, *see* Dietary fat in NIDDM
see also Fatty acids; Oil
- Dietary fat in NIDDM
and healthy subjects described with incremental area under
response curve, 1034-1037
with hypocholesterolemia, 1280
- Dietary fiber
cellulose, in short-term hydrolyzed casein-based diet, 334
long-term effects of high, on glucose tolerance and lipid
metabolism, 1206-1210
in margarine-enriched phytosterols, 1375
viscous, combined with soy protein, almonds, and phytosterols for
hypercholesterolemia, 1478-1483
- Dietary glucose, *see* Oral glucose
- Dietary iron (Fe), hepatic hepcidin mRNA regulation by, 1229-1231
- Dietary management of CV disease in NIDDM, S1:22-23
- Dietary protein
of exercising young obese adults, 1179
in *trans* FA diet, 695, 696
in high-CHO and high-MUFA diet, 1455
in margarine-enriched phytosterol diet, 1375
in NIDDM with hypocholesterolemia, 1280
oxidation of, NS glucose intake, 96, 98
restricted, effects of pre-pregnancy restricted, on vital organs of
offspring, 13-18
in short-term hydrolyzed casein-based diet, 334
- Dietary restriction
effects of, on BMD, 970-977, 1265-1273
effects of, on lactate sarcolemmal transport, 322-327
effects of restricted salt intake on age-related changes in AT and
liver lipogenesis, 1072-1077
energy-, effects of 16-week exercise and, on body composition
and BMI, 107-115
obese women on calorie-, 2-keto[1- ^{13}C]isocaproate breath test
assessment of mitochondrial response to, 463-467
- Dietary restriction (*Continued*)
pre-pregnancy protein-, effects of, on offspring's vital organs, 13-
18
- Dihydrotestosterone (DHT)
production rate, in female hair loss, 927-929
rosiglitazone effects on production of, in men, 230-232
- F-2,3 Diketogulonic acid (F-DKG), and metabolomic mapping of
vitamin C in DM, 762
- Dimethylarginine, asymmetric, in NIDDM, glycemic control and
GFR associated with, 302-307
- Dimethylbiguanide, *see* Metformin
- Dipeptyl peptidase IV (DPPIV) inhibition in NIDDM, enteroinsular
axis and, 81-86
- Disodium ascorbyl phytostanyl phosphate (FM-VP4), effects of, on
plasma cholesterol and atherosclerotic lesion formation in apo
E deficiency, 425-431
- Diuretics, effects of, on insulin secretion after renal transplantation
in older subjects, 573-578
- Diversion, effects of pancreaticobiliary, on body composition and
EE, 552-558
- DM, *see* Diabetes mellitus
- DNA (deoxyribonucleic acid)-binding activity in NF- κ B for ELAM-
1, ICAM-1, and VCAM-1 in NIDDM with CV disease, S1:
16
- Documented coronary artery disease (CAD) in NIDDM, therapy of,
S1:7-9
- DOG, *see* [^3H]-2-Deoxy-D-glucose
- Dopamine
effects of high glucose concentrations on release of, by
pheochromocytoma-12 cells, 922-926
response of, to insulin-induced hypoglycemia after massive weight
loss by severely obese subjects, 900-907
- Dose
and effects of FM-VP4 on plasma cholesterol and atherosclerotic
lesion formation in apo E deficiency, 425-431
and effects of milrinone on gluconeogenesis, lipolysis, and insulin
secretion, 1497
thyroxine, primary hypothyroidism during pregnancy and, 122-128
see also entries beginning with terms: High-dose, Low-dose
- Doxazosin
effects of, on advanced atherosclerotic lesions in
hypercholesterolemia, 1240-1245
effects of, on endothelial function and insulin action in HTN,
1147-1152
- DPPIV (dipeptyl peptidase IV), inhibition of, in NIDDM,
enteroinsular axis and, 81-86
- Drosophila* models of aging genetics, S2:5-6
- Drug dissolution, pharmacokinetics of, in the elderly, S2:27
- Drug distribution, pharmacokinetics of, in the elderly, S2:27-28
- Drug-drug interactions in the elderly, S2:30
- Drug elimination, pharmacokinetics of, in the elderly, S2:28
- Drug metabolism, changes in, in the elderly, S2:27
- Drug therapy in the elderly, S2:27-30
drug-drug interactions and, S2:30
pharmacodynamics of, S2:28-30
pharmacokinetics of, S2:27-28
see also specific drugs
- Dyslipidemia
in MS with liver dysfunction and, 1097, 1098
in NIDDM with CV disease, multifactorial intervention effects on,
S1:22
see also Hyperalphalipoproteinemia; Hypercholesterolemia;
Hypertriglyceridemia; Hypoalphalipoproteinemia

- Dyslipoproteinemia
 in NIDDM, with carotid atherosclerosis, beraprost sodium effects and, 195
see also Hyperalphalipoproteinemia; Hypoalphalipoproteinemia
- Dysphagia (swallowing disorders) in Alzheimer's disease, aspiration pneumonia with, S2:36-38
- Early-onset non-insulin-dependent diabetes mellitus (NIDDM)
 lipid levels in, associated with LPL *HindIII* gene polymorphism, 338-343
 troglitazone effects on endothelial function in, 173-180
- Early vascular damage in primary hypoalphalipoproteinemia, 328-332
- EC(s) (endothelial cells), *see* Endothelial cells
- ECNOS (endothelial constitutive nitric oxide synthase) gene, serum uric acid levels and 27-bp repeat polymorphism of intron 4 of, in Chinese NIDDM subjects, 1448-1453
- EE, *see* Energy expenditure
- ELAM-1 (endothelial leukocyte adhesion molecule-1), DNA-binding activity for NF- κ B for, in NIDDM with CV disease, S1:16
- Elastase, fecal, and BMD in chronic pancreatitis, 579-582
- Elderly subjects, *see* Older subjects
- Endarterectomy, carotid, IH following, in insulin resistance, 834-839
- Endocrine abnormalities after recovery from anorexia nervosa, 296-302
- Endocrine changes in aging, and frailty of the elderly, S2:23
- Endothelial cells (ECs), 493-507
 aortic, *see* Aortic endothelial cells
 cholesterol supplementation effects on linoleic acid-induced activation of, 493-500
 eNOS in, *see* Endothelial nitric oxide synthase in ECs
 human umbilical, *see* Human umbilical endothelial cells
 injury to, in transient hyperhomocysteinemia, changes in markers of, 501-507
 in NIDDM with CV disease, gliclazide effects on AGE product-induced monocyte adhesion to, S1:13-18
 retinal, high glucose effects on IGF-1-MAPK activation in, 547-551
- Endothelial constitutive nitric oxide synthase (ECNOS) gene, 27-bp repeat polymorphism of intron 4 of, serum uric acid levels and, in Chinese NIDDM subjects, 1448-1453
- Endothelial function
 in HTN, doxazosin effects on, 1147-1152
 in hyperlipidemia, HDL-C effects on, 1191-1195
see also Endothelial function in NIDDM
- Endothelial function in NIDDM, 168-180
 with CV disease, S1:32-33
 in early and late NIDDM, troglitazone effects on, 173-180
- Endothelial growth factor mRNA (messenger ribonucleic acid), vascular, in heart of STZ-DM subjects, 675-678
- Endothelial leukocyte adhesion molecule-1 (ELAM-1), DNA-binding activity for NF- κ B in, in NIDDM with CV disease, S1:16
- Endothelial lipase genotype, exercise-dependent HDL-C response to, 1505-1511
- Endothelial nitric oxide synthase (eNOS) in ECs
 in aortic ECs, effects of β -estradiol and IGF-1 on activity of, 482-487
 cholesterol effects on activation of, 496
- Endothelin (ET), plasma, and bosentan effects on renal AVP V₂, 1142
- Endothelin-1 (ET-1), effects of insulin resistance on level of, 845-849
- End-stage renal disease (ESRD)
 HD-induced changes in Lps in diabetic and nondiabetic subjects with, 116-121
- End-stage renal disease (ESRD) (*Continued*)
 hyperhomocysteinemic, MTHFR genotype effects on vitamin B₁₂ effects on Hcy and MMA in, plasma glycine level and, 168-172
- Endurance exercise
 effects of acute, on skeletal muscle uncoupling protein-3 gene expression in untrained subjects, 152-158
see also Cycling; Running
- Energy expenditure (EE)
 by boys, testosterone and GH effects on, 966-967
 BPD effects on, 552-558
 resting, *see* Resting energy expenditure
 total, carbohydrate oxidation and, in HIV lipodystrophy syndrome, 620-625
- Energy intake
 by exercising young obese adults, 1178
 fasting and daylong TGs in obesity with and without NIDDM and, 1046
 with margarine-enriched phytosterols, 1375
 by obese men, effects of, weight loss effects on, 138
see also Diet; Fuel metabolism
- eNOS, *see* Endothelial nitric oxide synthase in ECs
- Enteroinular axis, and DPPIV inhibition in NIDDM, 81-86
- EPA (ethyl icosapentate), effects of, on skeletal muscle lipid accumulation and insulin resistance in NIDDM, 30-34
- Epigenetics of aging, genetics and, S2:6-7
- Epinephrine (adrenaline)
 effects of, on renal glucose output in DM, 474, 475
 leptin effects on response of, to insulin-induced hypoglycemia, 1484-1490
 in obesity, *see* Epinephrine in obesity
 plasma, *see* Plasma epinephrine
- Epinephrine (adrenaline) in obesity
 in hepatic insulin resistance with obesity, BDNF effects on, 205
 response of, to insulin-induced hypoglycemia after massive weight loss by severely obese subjects, 900-907
- Erythrocytes, *see* Red blood cells
- ESRD, *see* End-stage renal disease
- Estradiol
 α -adrenergic blocker effects on, in high-altitude exercise, 1473
 in PM women, estrogen receptor α gene and collagen IA1 gene effects on, 1131, 1132
 relation of, to AT, insulin, and risk for MI in men, 785, 786
- β (beta)-Estradiol, effects of IGF-1 and, on eNOS activity in aortic endothelial cells, 482-487
- 17 β (beta)-Estradiol, effects of ICI:compound 182,780 and, on LPL and HSL expression in SC abdominal adipocytes, 383-388
- Estrogen
 and gender differences in insulin resistance with obesity, 659-661
 with MPA, *see* Estrogen with MPA in PM women
 in older subjects, effects of GH, abdominal VAT, fitness, and insulin on, 76
- Estrogen with MPA in PM women
 effects of, on TG-rich Lps and HDLs, 1330-1336
 effects of tibolone and, with and without MPA on body composition and fasting CHOs, 1085-1091
- Estrogen receptor α gene, effects of collagen IA1 gene and, on relation of PTH and 25 hydroxyvitamin D to BMD in PM women, 1129-1135
- Estrone, relation of, to AT, insulin, and risk for MI in men, 785, 786
- ET (endothelin), plasma, bosentan effects on renal AVP V₂ receptor and, 1142
- ET-1 (endothelin-1), effects of insulin resistance on level of, 845-849

- Ethanol, *see* Alcohol intake
- Ethnicity, *see* Race and ethnicity
- Ethyl icosapentate (EPA), effects of, on lipid accumulation in skeletal muscle and insulin resistance in NIDDM, 30-34
- Etiocolanolone, rosiglitazone effects on urinary excretion of, 231
- Etiology
of swallowing disorders in the elderly, S2:36-37
see also specific conditions
- Evidence-based multifactorial intervention in NIDDM with CV disease, S1:19-22
- Exchangeable magnesium (Mg) pool masses in HTN, 626-630
- Exercise
 α -adrenergic blocker effects during, *see* α -Adrenergic blockers, effects of, during exercise
AT and, *see* Adipose tissue, exercise effects on
effects of, on body composition, *see* Body composition, exercise effects on
effects of, on HDL-C, *see* High-density lipoprotein-cholesterol, exercise effects on
effects of, on plasma prebeta-1 HDLs, 437-442
effects of, on RCT, 950-957
endurance, *see* Endurance exercise
insulin withdrawal in DM and prevention of ischemic heart failure with, 791-797
intense, β -adrenergic blocker effects on regulation of glucose kinetics during, 1615-1620
in obesity, *see* Obesity, exercise effects on
prior, effects of, on PP lipemia, 418-424
and Taq1B polymorphism with Lp variations, 1565, 1567, 1568
see also Men, exercise effects on; Women, exercising
- Exercise in NIDDM
with CV disease, S1:22-23
effects of enhanced protein kinase C ζ activity and IR tyrosine phosphorylation due to, on NIDDM, 1028-1033
skeletal muscle release of IL-6 and TNF- α in NIDDM during, 939-944
- Exocytosis, insulin, effects of calpain inhibitor-exposed beta cells on mitochondrial fuel metabolism and, 528-534
- Exogenous glucose, *see* Oral glucose
- Experimental protocols, simulation of, with WinSAAM, 1155-1156
- Extracellular adenosine triphosphate (ATP), gluconeogenesis-GSH redox state in renal cortical tubules and, 742
- Extrahepatic arginine (Arg), metabolism of, after burn injury, 1232-1239
- FA(s), *see* Fatty acids
- Factor V Leiden mutation, G1691A, recurrent pregnancy loss associated with PCOS, PAI activity and, 1627-1632
- Family, *see* Children; Family history of DM; First-degree relatives of NIDDM subjects
- Family history of DM
and insulin secretion after renal transplantation in older subjects, 573-578
PPAR γ_2 Pro12Ala polymorphism effects on insulin clearance and, 779
- F-ASA (6-deoxy-6-fluoro-ascorbic acid), metabolomic mapping of vitamin C with ^{19}F -NMR spectroscopy and, in DM, 760-770
- Fasting
liver induction of mitochondrial and cytosolic acyl CoA hydrolases/thioesterases in, 1527-1529
plasticity as SNS response to, in AT, 1621-1626
- Fasting apolipoprotein B-48 (apo B-48) in NIDDM with hypoadinopectinemia, 1281
- Fasting blood glucose (FBG)
in DM with CAN, 816; *see also* Fasting blood glucose in NIDDM
low-dose glyburide effects on, 410
swelling syndrome and gynoid adiposity effects on, 806, 807
- Fasting blood glucose (FBG) in NIDDM
ADMA association with GFR, glycemic control and, 304
and hyperglycemia reversal effects on adipocyte insulin resistance, 240
- Fasting carbohydrates (CHOs)
CHO intake and, 1046
effects of tibolone and estrogen with and without MPA on body composition and, 1085-1091
- Fasting C-peptides (CPs; connecting peptides)
in NIDDM with nephropathy and macroangiopathy, 1519
in nondiabetic obese subjects, plasma SSAO, CV disease risk and, 690, 691
plasma, in HIV infection with lipodystrophy, 1346
in young IDDM subjects, 27
- Fasting free fatty acids (FFAs; nonesterified fatty acids)
in hereditary HTG, 1408
and PPAR γ_2 Pro12Ala polymorphism effects on insulin clearance, 780
- Fasting glucose
and ADRB3 Trp64Arg polymorphism effects on LDL particle size, 357, 358
CRPs in young men and, 1114
FAs and, *see* Fasting glucose, FAs and
gluconeogenesis and, 1513
IGF-1 effects on, in older women, 1185
impaired, low-dose glyburide effects on, 407-412
in NIDDM, *see* Fasting glucose in NIDDM
PP triglyceridemia and, 1381, 1384
and risk for NIDDM, 1213
see also Fasting blood glucose; Fasting plasma glucose
- Fasting glucose, FAs and
trans FA intake effects on, 695
and FFA metabolism regulation by Leu7Pro polymorphism of NPY gene, 644
- Fasting glucose in Japanese NIDDM subjects
with impaired glucose tolerance, 477
in non-obese subjects, *see* Fasting glucose in non-obese Japanese NIDDM subjects
- Fasting glucose in NIDDM
with hypoadinopectinemia, 1280
with insulin resistance, 896, 897
in preclinical diabetic cardiomyopathic men with uncomplicated well-controlled NIDDM, 1058
rosiglitazone effects on, 732
see also Fasting glucose in Japanese NIDDM subjects
- Fasting glucose in non-obese Japanese NIDDM subjects
platelet count and, 1247
with porphyromonas gingivalis and carotid atherosclerosis, 1243
- Fasting glycemia in first-degree relatives of NIDDM subjects, 1069
- Fasting glycerol in hereditary HTG, 1408
- Fasting insulin
and ADRB3 Trp64Arg polymorphism effects on LDL particle size, 357, 358
CRPs in young men and, 1114
in exercising men, PPAR γ Pro12Ala polymorphism and, 210
and FFA metabolism regulation by NPY gene Leu7Pro polymorphism, 644
gluconeogenesis and, 1513
IGF-1 effects on, in older women, 1185
in NIDDM, *see* Fasting insulin in NIDDM

- Fasting insulin (*Continued*)
 PP triglyceridemia and, 1381, 1384
 and risk factor for CHD, 1532
 and risk for NIDDM, 1213
see also Fasting plasma insulin; Fasting serum insulin
- Fasting insulin in Japanese NIDDM subjects
 with impaired glucose tolerance, 477
 non-obese Japanese NIDDM subjects, platelet count and, 1247
- Fasting insulin in NIDDM
 and glibenclamide-metformin therapy, 864
 with insulin resistance, 896, 897
 in NIDDM Japanese subjects, *see* Fasting insulin in Japanese NIDDM subjects
- Fasting lactate in hereditary HTG, 1408
- Fasting plasma cholesterol (C), total, in obese PM women, effects of weight loss on, 602
- Fasting plasma C-peptides (CPs) of HIV infection with lipodystrophy, 1346
- Fasting plasma free fatty acids (FFAs; nonesterified acids) in insulin resistance
 in adipocyte insulin resistance, 240
 in FFA-induced peripheral insulin resistance, 235
- Fasting plasma glucose (FPG)
 in DM, *see* Fasting plasma glucose in NIDDM
 doxazosin effects on, in HTN, 1149
 in exercising men, PPAR γ Pro12Ala polymorphism and, 210
 in HIV infection with lipodystrophy, 1346, 1351
 in insulin resistance, *see* Fasting plasma glucose in insulin resistance
 long-term effects of high-fiber diet on, 1207, 1208
 in obesity, *see* Fasting plasma glucose in obesity
- Fasting plasma glucose (FPG) in DM
 and atherogenic role of lysophosphatidylcholine in LDLs, 311
 in obese IDDM children, intracellular platelet Mg and, 469
see also Fasting plasma glucose in NIDDM
- Fasting plasma glucose (FPG) in insulin resistance
 in FFA-induced peripheral tissue insulin resistance, 234
 with hypertriglyceridemia, 617, 618
 in MS with liver dysfunction, 1097, 1098
 in NA-induced insulin resistance, 701
 in PAI-1-associated insulin resistance in non-obese subjects, 227, 228
- Fasting plasma glucose (FPG) in NIDDM
 with carotid atherosclerosis, beraprost sodium effects and, 195
 food intake effects on 24-hour profile of, 632
 and glibenclamide-metformin therapy, 864
 in Japanese NIDDM subjects, as risk for atherosclerosis and, 1303, 1304
 with nephropathy and macroangiopathy, 1518-1521
 PPAR γ Pro12Ala polymorphism association with oxidized LDL and cardiolipin autoantibodies and, 215
 with retinopathy, 606
 TGZ and, *see* Fasting plasma glucose in NIDDM, TGZ and
- Fasting plasma glucose (FPG) in NIDDM, TGZ and muscle morphology regulation with metformin and TGZ, 541
 TGZ effects on endothelial function, 175, 177
- Fasting plasma glucose (FPG) in obesity
 in morbid obesity, 1552-1554
 in obese IDDM children, intracellular platelet Mg and, 469
- Fasting plasma high-density lipoprotein-cholesterol (HDL-C), total, in obese PM women, effects of weight loss on, 602
- Fasting plasma insulin
 adult, effects of malnutrition in first year of life on, 1005-1011
 in FFA-induced peripheral tissue insulin resistance, 234
- Fasting plasma insulin (*Continued*)
 in HIV infection with lipodystrophy, 1346, 1351
see also Fasting plasma insulin in NIDDM
- Fasting plasma insulin in NIDDM
 and PPAR γ Pro12Ala polymorphism association with oxidized LDL and cardiolipin autoantibodies, 215
 and skeletal muscle morphology regulation with metformin and TGZ, 541
- Fasting plasma lipids in obese PM women, effects of weight loss on, 602
- Fasting plasma low-density lipoprotein-cholesterol (LDL-C), total, in obese PM women, weight loss effects on, 602
- Fasting plasma triglycerides (TGs) in obesity
 with and without NIDDM, daylong and, 1046
 in PM women, effects of weight loss on, 602
- Fasting serum glucose, PPAR γ_2 Pro12Ala polymorphism effects on, 780
- Fasting serum insulin
 in NIDDM, hyperglycemia reversal effects on, 240
 PPAR γ_2 Pro12Ala polymorphism effects on, 780
- Fasting triglycerides (TGs)
 in NIDDM, and PP lipemia after fat ingestion, 1040
 in obesity with and without NIDDM, 1043-1049
- Fat, *see* Adipose tissue; Dietary fat *entries beginning with terms:*
 Fat, Fatty and element: Lip-
- Fat-free mass, *see* Lean body mass
- Fat mass (FM)
 in HIV lipodystrophy subjects, 622
 swelling syndrome, gynoid adiposity and, 806, 807
 and TNF- α -863 allele and TNFR2 concentration in first-degree relatives of NIDDM subjects, 1069
see also Fat mass in obese subjects; Lean body mass
- Fat mass (FM) in obese subjects
 BPD effects on, 552-558
 in free-living obese men, energy intake restriction and 16-week exercise program effects on, 107-115
 in obese women, *see* Fat mass in obese women
- Fat mass (FM) in obese women
 calorie-restricted diet effects on, 464
 in obese PM women, effects of weight loss on, 601
- Fatty acids (FAs), 508-514
 captopril effects on synthesis of, in AT in hereditary hypertriglyceridemia, 1406-1412
 effects of different types and intake of, on retinoid secretion in chylomicrons after high-dose preformed vitamin A supplementation, 514-519; *see also: trans* Fatty acids; Free fatty acids; Monounsaturated fatty acids; Polyunsaturated fatty acids; Saturated fatty acids
 in NIDDM, TZD effects on metabolism and, 753-759
 oxidation of, *see* Oxidation, FA
 plasma, *see* Plasma fatty acids
 and skeletal muscle oxidation in morbidly obese black and white women, 735-738
- trans* Fatty acids (FAs)
 intake of, and LDL size, 693-698
 in margarine-enriched phytosterols, 1374
- FBG, *see* Fasting blood glucose
- FC (free cholesterol), GHR effects on, in hypopituitarism, 56
- FcTO (functional oil) containing MCTs, phytosterols, and n-3 PUFAs, effects of supplementation with, on cardiovascular risk in obese women, 771-777
- F-DHA (fluoro-dehydroascorbic acid), and metabolomic mapping of vitamin C in DM, 760-770

- F-DKG (F-2,3 diketogulonic acid), and metabolomic mapping of vitamin C in DM, 762
- Fe (iron), dietary, hepatic hepcidin mRNA regulation by, 1229-1231
- Fecal elastase, and BMD in chronic pancreatitis, 579-582
- Females, *see* Sex; Women
- Femoral arteries, IMT of, in primary hypoalphalipoproteinemia, 328-332
- Femoral bone mineral density (BMD), effects of dietary restriction on, 1265-1273
- Fenofibrate, effects of, on plasma cholesterol and resistin expression in AT, 351-355
- FFAs, *see* Free fatty acids
- FFM (fat-free mass), *see* Lean body mass
- Fiber, *see* Dietary fiber
- Fibrinogen
- alcohol intake effects on, 131
 - effects of margarine-enriched phytosterols on blood lipids, platelet function and, in young men, 1373-1378
 - in PM women with metabolic syndrome, 364, 366-369
- Fibroblasts, orbital, in GO, RA- and 4HPR-induced growth arrest and apoptosis of, 1387-1392
- Fibronectin (Fn), cellular, in EC injury, transient hyperhomocysteinemia and changes in, 501-507
- First-degree relatives of NIDDM subjects
- glucose-tolerant, of African-American NIDDM subjects, metabolic effects of chronic glipizide GITS on insulin secretion, insulin sensitivity, serum glucose, and hepatic insulin extraction in, 565-572
 - with NIDDM, insulin secretory response to gastric inhibitory polypeptides, 1579-1585
 - TNF α -863A allele and TNF- α receptor 2 concentration in, 1068-1071
- First year of life, effects of malnutrition during, on adult plasma insulin and glucose tolerance, 1005-1011
- Fitness
- effects of GH, abdominal VAT, insulin and, on lipids and Lps in older subjects, 73-80
 - see also* $\dot{V}O_2$ max in exercise
- FIZZ3, *see* Resistin
- Fluid volume in aging, role of glucocorticoids in, S2:10
- Fluoro-dehydroascorbic acid (F-DHA), and metabolomic mapping of vitamin C in DM, 760-770
- FM, *see* Fat mass
- FM-VP4 (disodium ascorbyl phytostanyl phosphate), effects of, on plasma cholesterol and atherosclerotic lesion formation in apo E deficiency, 425-431
- Fn (fibronectin), cellular, in EC injury, transient hyperhomocysteinemia and changes in, 501-507
- Folate
- in HTN, HCT effects on, 262
 - in NIDDM with nephropathy and macroangiopathy, 1518-1521
 - serum, in GDM, serum homocysteine and, 721
- Food intake, *see* Diet; Food intake in NIDDM
- Food intake in NIDDM
- effects of, on 24-hour profile of circulating glycosylated insulin in NIDDM, 631-635
 - and EPA effects on skeletal muscle, 31
- FPG, *see* Fasting plasma glucose
- Frailty in the elderly, role of sarcopenia and visceral protein depletion in, S2:22-26
- Free cholesterol (FC), GHR effects on, in hypopituitarism, 56
- Free fatty acids (FFAs; nonesterified fatty acids)
- effects of intense exercise on, with and without α - and β -adrenergic blockers, 1619
- Free fatty acids (FFAs; nonesterified fatty acids) (*Continued*)
- fasting and steady-state, and PPAR γ_2 Pro12Ala polymorphism effects on insulin clearance, 780
 - in high-fiber diet, 1207, 1209
 - in HIV infection with lipodystrophy, 1346, 1347, 1351
 - ingested glucose effects on, 96-98
 - in insulin resistance, *see* Free fatty acids in insulin resistance
 - insulin secretion after long- and short-term infusions of, in men with risk for developing NIDDM, 885-894
 - in left and right SM, 1573
 - Leu7Pro polymorphism of NPY gene regulating metabolism of, 643-646
 - in NIDDM, *see* Free fatty acids in NIDDM
 - in older subjects, insulin action and, 853, 854, 856
 - rosiglitazone effects on, 1080
 - serum, *see* Serum free fatty acids
 - see also* Free fatty acids in insulin resistance
- Free fatty acids (FFAs; nonesterified fatty acids) in insulin resistance
- in NIDDM, *see* Free fatty acids in NIDDM
 - plasma, *see* Plasma free fatty acids in insulin resistance
 - relation of NA-induced insulin resistance to AT oxidation and, but not to SM lipid content, 699-704
 - see also* Free fatty acids in obesity with insulin resistance
- Free fatty acids (FFAs; nonesterified fatty acids) in NIDDM
- with insulin resistance, 896, 897
 - and PP lipemia after fat ingestion, 1040
 - TZD effects on, 756
- Free fatty acids (FFAs; nonesterified fatty acids) in obesity with insulin resistance
- estrogen and, 660
 - FFA-induced peripheral tissue insulin resistance, obesity effects on susceptibility to, 233-238
 - with hepatic insulin resistance, BDNF effects on, 205
- Free glycerol in left and right skeletal muscle, 1572
- Free-living obese men, energy intake restriction and 16-week exercise effects on body composition and BMI of, 107-115
- Free radicals, intracellular modulation of production of, and metformin effects on oxidative stress, 586-589
- Free testosterone (T)
- in metabolic syndrome with PCOS, 909
 - relation of, to AT, insulin, and risk for MI in men, 785, 786
- Free thyroxine (FT $_4$) in hypothyroidic pregnant women, T $_4$ dose and, 123-125
- Frequently sampled intravenous glucose tolerance (FSIGT) test of Caipo effects in NIDDM, 876-877
- Fructosamine
- effects of HRT on, in PM subjects, 1088
 - in exercising men, PPAR γ Pro12Ala polymorphism and, 210
 - and mannose levels in glucose-tolerant, glucose-intolerant, and diabetic subjects, 1021
- FSIGT (frequently sampled intravenous glucose tolerance) test of Caipo effects in NIDDM, 876-877
- FT $_4$ (free thyroxine) in hypothyroidic pregnant women, T $_4$ dose and, 123-125
- Fuel metabolism
- effects of calpain inhibitor-exposed beta cells on insulin exocytosis and mitochondrial, 528-534
 - see also* Energy intake
- Functional oil (FcTO) containing MCTs, phytosterols, and n-3 PUFAs, effects of supplementation with, on cardiovascular risk in obese women, 771-777
- Furosamine, effects of, on insulin secretion after renal transplantation in older subjects, 573-578

- GAD (glutamic acid decarboxylase), autoantibodies to ICA512/IA-2 and, as IDDM markers and their relationship to residual beta-cell function and glycemic control in young IDDM subjects, 25-29
- Galanin (Gal), plasma, response of, to HUT in recurrent VVS, 315-321
- Gastric banding, minimally invasive, for morbid obesity, metabolic and psychosocial effects of, 1551-1557
- Gastric inhibitory polypeptides, insulin secretory response to, in NIDDM first-degree relatives of NIDDM subjects, 1579-1585
- Gastrointestinal therapeutic system (GITS), metabolic effects of chronic glipizide, on serum glucose, insulin secretion, insulin sensitivity, and hepatic insulin extraction in glucose-tolerant first-degree relatives of African-American NIDDM subjects, 565-572
- GDM (gestational diabetes mellitus), serum homocysteine in, 720-723
- Gender, *see* Sex
- Gene(s)
of aging, S2:5-8
see also specific genes
- Gene expression, *see* mRNA
- Genetic effects, pleiotropic, between AT and SHBG concentrations pre- and post-20-week exercise program, 35-41
- Genetics, *see* Children; DNA-binding activity; Family history of DM; Gene(s); Genetic effects; Genomic scan; Genotype; Hereditary hypertriglyceridemia; mRNA; Mutation(s); Polymorphism; Translocation
- Genomic scan of glucose and insulin metabolism phenotypes, 246-253
- Genotype
ACE DD, circulating E-selectin, and CV damage in central obesity, 999-1004
apo E, interaction between dietary fat intake and, in older subjects, 279-281
endothelial lipase, exercise-dependent HDL-C response to, 1505-1511
MTFHR, effects of, on vitamin B₁₂ effects on MMA and Hcy in hyperhomocysteinemic ESRD, 168-172
of R219K polymorphism of ABCA1 gene by race, 931
- Gestational alcoholism, effects of, on glucose tolerance in offspring, 454-462
- Gestational diabetes mellitus (GDM), serum homocysteine in, 720-723
- GF(s) (growth factors), *see specific growth factors*
- GFR (glomerular filtration rate) in NIDDM, association of, with ADMA, 303-307
- GH, *see* Growth hormone
- GHR (growth hormone replacement), effects of long- and short-term, on Lp composition and apo B100 kinetics in hypopituitarism, 50-59
- Ghrelin, plasma, AT, insulin resistance, smoking and, in men, 1460-1463
- G_i-coupled receptor agonists, leptin release in adipocytes and AT in obesity regulated by insulin, glucocorticoids, pertussis toxin and, 60-68
- GIP (glucose-dependent insulinotropic polypeptide), effects of N-terminal Ala₂-substituted analogs of, on glucose degradation, cAMP production, insulin secretion, and hyperglycemia, 679-687
- GITS (gastrointestinal therapeutic system), metabolic effects of chronic glipizide, on serum glucose, insulin secretion, insulin sensitivity, and hepatic insulin extraction in glucose-tolerant first-degree relatives of African-American NIDDM subjects, 565-572
- GK (glucokinase) mRNA (messenger ribonucleic acid) in hepatic insulin resistance with obesity, 205
- Glc, *see* Glucagon
- GlcN (glucosamine)-induced insulin resistance, impaired SM insulin receptor phosphorylation and, 1092-1095
- Glibenclamide, metformin with, for NIDDM, 862-867
- Gliclazide modified release (MR), effects of, in CV disease of NIDDM, S1:29-34
on beta cells, S1:30-32
clinical efficacy and, S1:29
gliclazide MR binding to SUR and, S1:31-32
on insulin sensitivity, S1:30-31
of once-daily use, S1:29
tolerability and, S1:30
- Gliclazide in NIDDM with CV disease
effects of, on atherosclerosis, S1:13-18
see also Gliclazide modified release, effects of, in CV disease of NIDDM
- Glipizide gastrointestinal therapeutic system (GITS), chronic, metabolic effects of, on serum glucose, insulin secretion, insulin sensitivity, and hepatic insulin extraction in glucose-tolerant first-degree relatives of African-American NIDDM subjects, 565-572
- Gln, *see* Glutamine
- Globulin, *see* HbA_{1c}; Sex-hormone binding globulin
- Glomerular filtration rate (GFR) in NIDDM, association of, with ADMA, 303-307
- GLP-1 (glucagon-like peptide-1) in NIDDM, DPPIV inhibition effects on, 81-86
- Glu (glutamate), effects of, on pancreatic islet mitochondria, 995
- Glucagon (Glc; hyperglycemic-glycogenolytic factor)
effects of, on renal glucose output in DM, 474
effects of intense exercise on, with and without α - and β -adrenergic blockers, 1619
in hepatic insulin resistance with obesity, BDNF effects on, 205
ingested glucose effects on, 96-98
and ornithine α -KG-induced insulin secretion, 344-350
response of, to insulin-induced hypoglycemia after massive weight loss by severely obese subjects, 900-907
- Glucagon-like peptide-1 (GLP-1) in NIDDM, DPPIV inhibition effects on, 81-86
- Glucocorticoids
in aging, *see* Glucocorticoids in aging
leptin release regulated by insulin, G_i-coupled receptor agonists, pertussis toxin and, in adipocytes and AT explants from obese subjects, 60-68
- Glucocorticoids in aging
as mediators of allostasis and allostatic load, S2:10-11
and stress, effects of, on hippocampal structure and function, S2:19
- Glucokinase (GK) mRNA (messenger ribonucleic acid) in hepatic insulin resistance with obesity, 205
- Gluconeogenesis
hepatic, in FFA-induced peripheral tissue insulin resistance, 235
low-dose glyburide on, in impaired glucose tolerance, 407-412
milrinone effects on, 1496-1500
plasma citrulline response to arginine and, 1512-1516
in preterm infants, alanine and, 945-949
in renal cortical tubules, relation between GSH redox state and, 739-746
- Glucosamine (GlcN)-induced insulin resistance, impaired SM insulin receptor phosphorylation and, 1092-1095
- Glucose
blood, *see* Blood glucose

Glucose (*Continued*)

- cardiomyocyte, and taurine transport inhibition, 827-833
- decrease in IGF-1-mediated MAPK in retinal endothelial cells and concentrations of, 547-551
- effects of, on pancreatic islet mitochondria metabolites, 994-995
- effects of high concentrations of, on pheochromocytoma-12 cell dopamine release, 922-926
- effects of HRT on, in PM subjects, 1088
- fasting, *see* Fasting glucose
- high-sucrose diet and TGZ effects on metabolic actions of, on insulin, 978-986
- ingested, *see* Oral glucose
- in insulin resistance and/or MS, *see* Glucose in insulin-resistant subjects
- intravesicular, Mg transport in liver plasma membrane in STZ-DM modulated by, 1464-1470
- kinetics of, *see* Kinetics, glucose
- in NIDDM, *see* Glucose in NIDDM
- in obese women, PP apo A-IV distribution between apo B- and non-apo B-containing Lps and, 1538, 1539
- in older subjects, effects of GH, abdominal VAT, fitness, and insulin on, 76
- oxidation of, and FFA metabolism regulation by NPY gene Leu7Pro polymorphism, 644
- phenotypes of metabolism of, 246-253
- plasma, *see* Plasma glucose
- production of, *see* Gluconeogenesis
- and relation of sex hormones to AT, insulin, and risk for MI in men, 785
- responses of, to 16 months of exercise by obese young adults, 1175-1181
- serum, *see* Serum glucose
- and subcutaneous and visceral AT distribution in PM women, 187
- TGZ effects on metabolism of, in subjects at risk for NIDDM, race and, 1211-1217
- in young men, effects of margarine-enriched phytosterols on, 1374
- see also* [³H]-2-Deoxy-D-glucose; Glucose-dependent insulinotropic polypeptide; Glucose disposal; Glucose-induced insulin secretion; Glucose in insulin-resistant subjects; Glucose in NIDDM; Glucose in obesity; Glucose-6-phosphatase mRNA; Glucose tolerance; Glucose transport; Glucose uptake *entries beginning with elements*: Gluc-, Glyc-
- Glucose-dependent insulinotropic polypeptide (GIP), effects of N-terminal Ala₂-substituted analogs of, on glucose degradation, cAMP production, insulin secretion, and on glycemic effects of, 679-687
- Glucose disposal
 - in NIDDM, TGZ and metformin regulation of SM morphology and, 540-546
 - and serum level of IGF-1, IGFBP-1 and -3 in exercising and sedentary subjects, 821-826
 - see also* Insulin-stimulated glucose disposal
- Glucose-induced insulin secretion (GSIS), potentiation of, by palmitate, 2-bromopalmitate in study of, 1367-1371
- Glucose in insulin-resistant obese subjects
 - in FFA-induced peripheral insulin resistance, 236
 - metformin and diet effects on, 910, 911
 - peripheral tissue insulin resistance with obesity, insulin-stimulated disposal of, 236
- Glucose in insulin-resistant subjects
 - estrogen and, 660
 - with PCOS, 910, 911
 - see also* Glucose in insulin-resistant obese subjects
- Glucose intolerance
 - physiological changes in circulating mannose levels in subjects with, 1019-1027
 - see also* Glucose tolerance
- Glucose in NIDDM
 - EPA effects on, 31
 - TZD effects on metabolism of, 753-759
 - see also* Fasting glucose in Japanese NIDDM subjects
- Glucose in obesity
 - in morbidly obese women, SM FA oxidation and, 736
 - in obese men, effects of weight loss on, 138
 - see also* Glucose in insulin-resistant obese subjects
- Glucose-6-phosphatase (G6Pase) mRNA (messenger ribonucleic acid) in hepatic insulin resistance with obesity, 205
- Glucose tolerance
 - effects of gestational alcoholism on offspring's, 454-462
 - effects of malnutrition in first year of life on adult, 1005-1011
 - in first-degree relatives African-American NIDDM subjects, metabolic effects of chronic glipizide GITS on serum glucose, insulin secretion, insulin sensitivity, and hepatic insulin extraction, 565-572
 - long-term effects of high-fiber diet on, 1206-1210
 - in NIDDM, *see* Glucose tolerance in NIDDM
 - normal, physiological changes in circulating mannose levels in, 1019-1027
 - rosiglitazone effects on, 1080
 - smokeless nicotine effects on HTN, insulin sensitivity or, in young subjects, 67-72
 - see also* Frequently sampled intravenous glucose tolerance; Glucose intolerance; Intravenous glucose tolerance test; Normal glucose tolerance; Oral glucose tolerance test
- Glucose tolerance in NIDDM
 - DPPIV inhibition effects on, 82-83
 - see also* Oral glucose tolerance test in NIDDM
- Glucose transport
 - in BC3H-1 myocytes, captopril effects on, 275-276
 - skeletal muscle insulin-stimulated PI3-K activity and, effects of high-fat diet and leptin on, 1196-1205
 - see also* Glucose uptake; GLUT4
- Glucose uptake
 - insulin-mediated, *see* Insulin-mediated glucose uptake
 - SM, NO effects on, 662-665
- GLUT4 (glucose transporter), effects of gestational alcoholism on, in offspring, 456-457
- Glutamate (Glu), effects of, on pancreatic islet mitochondria metabolites, 995
- Glutamic acid decarboxylase (GAD), autoantibodies to ICA512/IA-2 and, as IDDM markers and their relationship to residual beta-cell function and glycemic control in young IDDM subjects, 25-29
- Glutamine (Gln)
 - acute effects of, on protein and amino acid metabolism in hepatic tissue, 1062-1067
 - effects of, on protein and amino acid metabolism in hepatic tissue, 1064
 - effects of glycerol plus, on renal glucose output in DM, 474
 - and ornithine α -KG effects on insulin secretion, 344-350
- L- γ -Glutamyl-L-cysteinylglycine, *see* Glutathione
- Glutathione (GSH; L- γ -glutamyl-L-cysteinylglycine)
 - in ECs, effects of cholesterol on linoleic acid-induced depletion of, 495
 - FcTO supplementation effects on, in obese women, 775
 - in renal cortical tubules, relation between gluconeogenesis and redox state in, 739-746

- Glutathione peroxidase (GTx), and effects of restricted diet on sarcolemmal lactate transport, 325
- Gly, *see* Glycine
- Glyburide, effects of low-dose, on glucose production in impaired fasting glucose, 407-412
- Glycated (glycosylated) hemoglobin, *see* HbA_{1c}
- Glycated (glycosylated) high-density lipoprotein (HDL), ROS and reactive nitrogen species in HAECs regulated by, 42-49
- Glycated (glycosylated) insulin, 24-hour profile of circulating, in NIDDM, food intake effects on, 631-635
- Glycation end products, *see* Advanced glycation end product(s)
- Glycemia
fasting, in first-degree relatives of NIDDM subjects, 1069
see also Blood glucose; Glycemic control; Hyperglycemia; Hypoglycemia
- Glycemic control
with CLX-9021, 1012-1018
effects of reversal of, on adipocyte insulin resistance, 239-245
of IDDM in young subjects, autoantibodies to ICA512/IA-2 and GAD in, 25-29
of NIDDM, *see* Glycemic control in NIDDM
of STZ-DM with AA and zinc, 7-12
see also specific conditions and therapies
- Glycemic control in NIDDM
ADMA and, 303-307
effects of, on adipocyte insulin resistance, 239-245
effects of, on LDL particle size, 1576-1578
with N-terminal Ala₂-substituted analogs of GIP on, 679-687
and pramlintide effects on A_{1c} and BW, 1638-1642
see also Hyperglycemia in NIDDM with CV disease, effects of treatment on
- Glycerol
blood, glycogen phosphorylase inhibitor effects on, 1423
effects of glutamine plus, on renal glucose output in DM, 474
effects of intense exercise on, with and without α - and β -adrenergic blockers, 1619
17 β -estradiol effects on release of, 385-387
fasting, in hereditary HTG, 1408
free, in left and right skeletal muscle, 1572
- Glycerol-3-phosphate (G3P) in left and right SM, 1573
- Glycine (Gly)
effects of MTFHR genotype and metabolism of plasma, on vitamin B₁₂ effects on Hcy and MMA in hyperhomocysteinemic ESRD, 168-172
glutamine effects on metabolism of, in hepatic tissue, 1064
- Glycogen
effects of ingested glucose and, on net CHO storage, 94-101
hepatic, in insulin resistance with obesity, BDNF effects on, 205
skeletal muscle, captopril effects on insulin-stimulated synthesis of, but not on FA synthesis in AT in hereditary hypertriglyceridemia, 1406-1412
see also Muscle glycogen
- Glycogen phosphorylase inhibitor, effects of, on portal vein insulin, 1418-1425
- Glycogen synthase (GS)
dietary fat effects on activity and mRNA of, 535-539
Met416Val polymorphism of muscle, insulin resistance in NIDDM associated with, 895-899
- Glycosylation, *see entries beginning with term*: Glycated
- GO (Graves's ophthalmopathy), RA- and 4HPR-induced growth arrest and apoptosis of orbital fibroblasts in, 1387-1392
- G3P (glycerol-3-phosphate) in left and right SM, 1573
- G6Pase (glucose-6-phosphatase) mRNA (messenger ribonucleic acid) in hepatic insulin resistance with obesity, 205
- Grape seed extract, effects of, of LDL susceptibility to oxidation in heavy smokers, 1250-1257
- Graves's ophthalmopathy (GO), RA- and 4HPR-induced growth arrest and apoptosis of orbital fibroblasts in, 1387-1392
- Growth
aortic SMC, AGE products stimulating, 1558-1563
RA- and 4HPR-induced apoptosis and arrested, of orbital fibroblasts in GO, 1387-1392
of SNS plasticity in AT as response to fasting, 1621-1626
- Growth factors, *see specific growth factors*
- Growth hormone (GH)
in acromegaly, 181-185
effects of abdominal VAT, fitness, insulin and, on lipids and Lps in older subjects, 73-80
plasma, age-dependent liver thyroid status adaptation and, 1118
serum, *see* Serum growth hormone
synergistic effects of testosterone and, on protein metabolism and body composition in boys, 964-969
see also Growth hormone/insulin-like growth factor-1; Growth hormone replacement therapy
- Growth hormone (GH)/insulin-like growth factor-1 (IGF-1) axis, relationship of between glucose disposal, fitness and, 824
- Growth hormone replacement (GHR) therapy, effects of long- and short-term, on lipoprotein composition and apo B100 kinetics in hypopituitarism, 50-59
- GS, *see* Glycogen synthase
- GSH, *see* Glutathione
- GSIS (glucose-induced insulin secretion), potentiation of, by palmitate, 2-bromopalmitate in study of, 1367-1371
- G1691A factor V Leiden mutation, recurrent pregnancy loss associated with PAI activity, PCOS and, 1627-1632
- GTx (glutathione peroxidase), and effects of restricted diet on sarcolemmal lactate transport, 325
- G1691A factor V Leiden mutation, recurrent pregnancy loss associated with PCOS, PAI activity and, 1627-1632
- Gynoid adiposity, lymphatic function in women with swelling syndrome and, 805-809
- HAECs (human aortic endothelial cells), glycated HDL regulation of ROS and reactive nitrogen species in, 42-49
- Hair loss (baldness) in women, DHT and testosterone production rate in, 927-929
- HASMCs (human aortic smooth muscle cells), gliclazide effects on MCP-1 protein in, in NIDDM with CV disease, S1:16
- HbA_{1c} (glycated hemoglobin)
and ADRB3 Trp64Arg polymorphism effects on LDL particle size, 357, 358
in first-degree relatives of NIDDM subjects, 1069
in glucose-tolerant, glucose-intolerant, and diabetic subjects, mannose levels and, 1021, 1022
in hypertriglyceridemia associated with insulin resistance and normal glucose tolerance, 617, 618
long-term effects of high-fiber diet on, 1207, 1208
in men at risk for developing NIDDM, 888
in nondiabetic obese subjects, plasma SSAO and CV disease risk and, 690, 691
PPAR γ 2 Pro12Ala polymorphism effects on, 780
see also HbA_{1c} in IDDM; HbA_{1c} in NIDDM
- HbA_{1c} (glycated hemoglobin) in IDDM
in obese IDDM children, intracellular platelet Mg and, 469
in young subjects, 27
- HbA_{1c} (glycated hemoglobin) in Japanese NIDDM subjects
non-obese subjects, platelet count and, 1247
with porphyromonas gingivalis and carotid atherosclerosis, 143

- HbA_{1c} (glycated hemoglobin) in Japanese NIDDM subjects
(*Continued*)
as risk for atherosclerosis, 1303, 1304
- HbA_{1c} (glycated hemoglobin) in NIDDM
beraprost sodium effects and, 195
with CV disease, multifactorial intervention and, S1:20
food intake effects on 24-hour profile of, 632
and glibenclamide-metformin therapy, 864
glycemic control and, *see* HbA_{1c} in NIDDM, glycemic control and
in hypoadiponectinemic Japanese NIDDM subjects, 1275
with insulin resistance, 896, 897
in Japanese subjects, *see* HbA_{1c} in Japanese NIDDM subjects
with nephropathy and macroangiopathy, 1518-1521
in NIDDM first-degree relatives of NIDDM subjects, 1580
with obesity, fasting and daylong TGs and, 1046
and phospholipid-dependent procoagulation activity, 103, 104
and PP lipemia after fat ingestion, 1039
with retinopathy, 606
and TZDs, *see* HbA_{1c} in NIDDM, TZDs effects on
in uncomplicated well-controlled NIDDM men, 1058
- HbA_{1c} (glycated hemoglobin) in NIDDM, glycemic control and
adipocyte insulin resistance effects on, 240
ADMA association with GFR and glycemic control, 304
LDL particle size and, 1577
- HbA_{1c} (glycated hemoglobin) in NIDDM, TGZ and
and skeletal muscle morphology regulation with metformin and
TGZ, 541
and TGZ effects on endothelial function, 175, 177
- HbA_{1c} (glycated hemoglobin) in NIDDM, TZD effects on, 754
of rosiglitazone, 732
see also HbA_{1c} in NIDDM, TGZ and
- HC, *see* Hypercholesterolemia
- HCT (hydrochlorothiazides), effects of, on tHcy in hypertension,
261-263
- Hcy, *see* Homocysteine
- HD (hemodialysis), Lp changes induced by, in diabetic and
nondiabetic ESRD subjects, 116-121
- HDL(s), *see* High-density lipoprotein(s)
- HDL-C, *see* High-density lipoprotein-cholesterol
- Head-up tilt (HUT) in recurrent VVS, plasma galanin response to,
315-321
- Healthy food in NIDDM with CV disease, S1:22-23
- Heart
in STZ-DM, vascular endothelial growth factor mRNA in, 675-
678
see also Coronary heart disease; Heart failure; Heart rate and
entries beginning with element: Card-
- Heart failure, ischemic, insulin withdrawal in DM and prevention of,
with exercise, 791-797
- Heart rate (HR; pulse rate)
and insulin resistance, 1595
in PHP, 160
serum leptin, HDL-C, and QTc interval of associated with CRPs
in young men, 1113-1116
in subjects on high-sucrose diet, TGZ effects on, 980
see also Heart rate, exercise effects on; Heart rate in obesity
- Heart rate (HR; pulse rate), exercise effects on
 α - and β -adrenergic blockade and, 1617
in DM with insulin withdrawal, 794
running and/or cycling effects on, 749
- Heart rate (HR; pulse rate) in obesity
in central obesity, 1000, 1001
in morbid obesity, 1552-1554
see also Heart rate in obesity, weight loss effects on
- Heart rate (HR; pulse rate) in obesity, weight loss effects on
of massive weight loss, 901, 903
in obese men, 138
relation of sex hormones to AT, insulin, and MI in men, 784-790
- Heart weight, and bosentan effects on renal AVP V₂ receptor, 1142
- Heavy smokers, grape seed extract effects on LDL susceptibility to
oxidation in, 1250-1257
- Height
and cycling effects on serum level of IGF-1, IGFBP-1 and -3, 822
of DM subjects with CAN, 816
estrogen and medroxyprogesterone acetate effects on, 1331
exercise effects and, *see* Height, and exercise effects
of insulin-resistant subjects, *see* Height of insulin-resistant subjects
of men at risk for developing NIDDM, 888
and Mg-creatine supplementation effects on body water, 1137
of nondiabetic obese subjects, plasma SSAO and CV disease risk
and, 690
of obese men, and diet restriction and 16-week exercise effects on
BMI and body composition in, 109
of older subjects, *see* Height of older subjects
of PM women, *see* Height of PM women
- Height, and exercise effects
effects of acute endurance exercise on skeletal muscle UCP-3
mRNA, 154
on plasma prebeta-1 HDLs, 439
- Height of insulin-resistant subjects
with liver dysfunction, 1097
of PCOS subjects, 714
- Height of older subjects
effects of GH, abdominal VAT, fitness, and insulin on lipids and
Lps and, 76
of older women, and IGF-1 effects on glucose kinetics or insulin
sensitivity, 1184
- Height of PM women
and racial differences in subcutaneous and visceral AT
distribution, 187
total and regional AT and, 286, 287
- Hematocrit
and bosentan effects on renal AVP V₂ receptor, 1142
in NIDDM, troglitazone effects on, 177
- Hemodialysis (HD), Lp changes induced by, in diabetic and
nondiabetic ESRD subjects, 116-121
- Hemoglobin, *see* HbA_{1c}
- Hepatic glucose production (HGP) in FFA-induced peripheral tissue
insulin resistance, 235
- Hepatic glycogen in hepatic insulin resistance with obesity, BDNF
effects on, 205
- Hepatic hepcidin mRNA (messenger ribonucleic acid), dietary Fe
regulating, 1229-1231
- Hepatic insulin, metabolic effects of chronic glipizide GITS on
insulin secretion, insulin sensitivity, serum glucose, and
extraction of, in glucose-tolerant first-degree relatives of
African-American NIDDM subjects, 565-572
- Hepatic insulin-like growth factor-1 (IGF-1) mRNA (messenger
ribonucleic acid), and age-dependent liver thyroid status
adaptation in DM, 1117-1125
- Hepatic insulin resistance, BDNF effects on obesity with, 203-208
- Hepatic lipase (HPL) gene, effects of interaction between C-514T
polymorphism of, and S447X polymorphism in TGs in young
adults, 1337-1342
- Hepatic oxidative stress, hyperglycemia-induced, systemic
inflammation but not activation of hepatic STAT3 or MAPK
due to, 868-874

- Hepatic plasma membrane in STZ-DM, intravesicular glucose modulation of Mg transport in, 1464-1470
- Hepatic protein, IL-1ra effects on synthesis of, in sepsis, 1218-1225
- Hepatic tissue, acute effects of glutamine on protein and amino acid metabolism in, 1062-1067
- Hepatic urea, production of, and relationship to arginine metabolism after burn injury, 1235-1236
- Hepatocytes, insulin and ATP effects on MAPK in, Ca^{2+} and, 590-598
- Hepcidin mRNA (messenger ribonucleic acid), hepatic, dietary Fe regulating, 1229-1231
- Hereditary hypertriglyceridemia (HTG), captopril effects on synthesis of AT in, 1406-1412
- Heredity, *see* Children; DNA-binding activity; Family history of DM; Gene(s); Genetic effects; Genomic scan; Genotype; Hereditary hypertriglyceridemia; mRNA; Mutation(s); Polymorphism; Translocation
- Heterozygous mutation of *CYP17* gene, 17α -hydroxylase/ $17,20$ lyase deficiency and, 488-492
- HF (high-fat) diet, effects of leptin and, on skeletal muscle insulin-stimulated PI3-K activity and glucose transport, 1196-1205
- HGP (hepatic glucose production) in FFA-induced peripheral tissue insulin resistance, 235
- High-altitude exercise, α -adrenergic blocker effects on catecholamine response to, 1471-1477
- High-carbohydrate (CHO) diet
apo E polymorphism effects on plasma lipid response to high-MUFA and, 1454-1459
see also High-carbohydrate diet in obesity
- High-carbohydrate (CHO) diet in obesity
effects of high-fat diet and cardiac autonomy nervous system activity on, 1426-1432
and PP hyperinsulinemia with obesity, 841-842
- High-density lipoprotein(s) (α -lipoprotein; HDL), 42-59
effects of exercise on, 951-953
estrogen and medroxyprogesterone acetate effects on, 1330-1336
glycated, ROS and reactive nitrogen species in HAECs regulated by, 42-49
in hypopituitarism, long- and short-term GHR effects on composition of, 50-59
in obesity, with insulin resistance, profile of, 559-564
plasma prebeta-1, exercise effects on, 437-442
and PON activity, homocysteinylolation effects on, 146-151
in postmenopausal women, estrogen and medroxyprogesterone acetate effects on, 1331-1333
see also High-density lipoprotein-cholesterol; Hyperalphalipoproteinemia; Hypoalphalipoproteinemia
- High-density lipoprotein-cholesterol (α -lipoprotein-cholesterol; HDL-C)
adipocyte-derived plasma adipopectin and, 1613
and ADRB3 Trp64Arg polymorphism effects on LDL particle size, 357, 358
CRP relation to, 1544
and CV disease, *see* High-density lipoprotein-cholesterol, risk for CV disease and
diet effects on, *see* High-density lipoprotein-cholesterol, diet effects on
in DM, *see* High-density lipoprotein-cholesterol in DM
doxazosin effects on, in HTN, 1149
effects of, on endothelial function in hyperlipidemia, 1191-1195
exercise effects on, *see* High-density lipoprotein-cholesterol, exercise effects on
fenofibrate effects on, 352
in first-degree relatives of NIDDM subjects, 1069
- High-density lipoprotein-cholesterol (α -lipoprotein-cholesterol; HDL-C) (*Continued*)
in heavy smokers, grape seed extract effects on, 1250-1257
in hyperalphalipoproteinemia, plasma CRPs, 433
in hypertriglyceridemia associated with insulin resistance and normal glucose tolerance, 617, 618
in hypoalphalipoproteinemia, *see* High-density lipoprotein-cholesterol in hypoalphalipoproteinemia
in insulin resistance and/or MS, *see* High-density lipoprotein-cholesterol in insulin-resistant subjects
in NIDDM, *see* High-density lipoprotein-cholesterol in NIDDM
in nondiabetic ESRD subjects, HD-induced changes in Lps and, 118
in non-obese subjects, *see* High-density lipoprotein-cholesterol in non-obese subjects
in obesity, *see* High-density lipoprotein-cholesterol in obesity
in older subjects, and effects of GH, abdominal VAT, fitness, and insulin on, 76-78
plasma, *see* Plasma high-density lipoprotein-cholesterol
in PM women, *see* High-density lipoprotein-cholesterol in PM women
and PP leukocyte increase, 200
PP triglyceridemia and, 1381, 1384
QTc interval, serum leptin and, associated with CRPs in young men, 1113-1116
and relation of sex hormones to AT, insulin, and risk for MI in men, 785
risk factor for CHD and, 1532-1535
and Taq1B polymorphism with Lp variations, 1565, 1567
see also High-density lipoprotein₂-cholesterol; High-density lipoprotein₃-cholesterol
- High-density lipoprotein-cholesterol (α -lipoprotein-cholesterol; HDL-C), diet effects on
alcohol intake, 131
trans FA intake and, 695, 696
high-CHO and/or high-MUFA diet, 1457
high-fat and/or high-CHO diet in non-obese and obese women, 1428
in hypercholesterolemia, almond, viscous fiber, soy protein, and phytosterol diet effects on hypercholesterolemia, 1479
malnourishment in first year of life, 1006, 1008
margarine-enriched phytosterol diet, 1375
- High-density lipoprotein-cholesterol (α -lipoprotein-cholesterol; HDL-C), exercise effects on
exercise-dependent HDL-C response to endothelial lipase genotype, 1505-1511
in men, PPAR γ Pro12Ala polymorphism and, 210
- High-density lipoprotein-cholesterol (α -lipoprotein-cholesterol; HDL-C), risk for CV disease and
carotid IMT association with LDL receptor mutation and, 1434-1436
plasma cortisol and, 525, 526
- High-density lipoprotein-cholesterol (α -lipoprotein-cholesterol; HDL-C) in DM
and atherogenic role of lysophosphatidylcholine in DM, 311
with ESRD, HD-induced changes in, 118
in GDM, serum homocysteine and, 721
see also High-density lipoprotein-cholesterol in NIDDM
- High-density lipoprotein-cholesterol (α -lipoprotein-cholesterol; HDL-C) in hypoalphalipoproteinemia
plasma CRPs and, 433, 434
in primary hypoalphalipoproteinemia, vascular damage and, 329, 330

- High-density lipoprotein-cholesterol (α -lipoprotein-cholesterol; HDL-C) in insulin-resistant subjects
 in MS with liver dysfunction, 1097
 NA-induced insulin resistance, 701
 in PAI-1-associated insulin resistance, 227
 SHBG and, 726, 727
see also High-density lipoprotein-cholesterol in insulin-resistant subjects with PCOS
- High-density lipoprotein-cholesterol (α -lipoprotein-cholesterol; HDL-C) in insulin-resistant subjects with PCOS
 metformin and diet effects on, 910, 911
 obese PCOS subjects, 716
- High-density lipoprotein-cholesterol (α -lipoprotein-cholesterol; HDL-C) in Japanese NIDDM subjects
 with IGT, beta-cell function, insulin sensitivity in, 477
see also High-density lipoprotein-cholesterol in non-obese Japanese NIDDM subjects
- High-density lipoprotein-cholesterol (α -lipoprotein-cholesterol; HDL-C) in NIDDM
 with carotid atherosclerosis, *see* High-density lipoprotein-cholesterol in NIDDM with carotid atherosclerosis
 in Chinese subjects, 1449, 1450
 in early-onset NIDDM, LPL *HindIII* gene polymorphism-lipid level association and, 339-341
 effects of ADMA association with GFR and glycemic control on, 304
 effects of glycemic control on LDL particle size and, 1577
 with hypocholesterolemia, 1275, 1281
 with insulin resistance, 896, 897
 in Japanese subjects, *see* High-density lipoprotein-cholesterol in Japanese NIDDM subjects
 in NIDDM first-degree relatives of NIDDM subjects, 1580
 with obesity, fasting and daylong TGs and, 1045, 1046
 and phospholipid-dependent procoagulation activity, 103
 plasma, EPA effects on, 31
 and PP lipemia after fat ingestion, 1040
 and PPAR γ Pro12Ala polymorphism association with oxidized LDL and cardiolipin autoantibodies, 215
 with retinopathy, 606
 rosiglitazone effects on, 732
 and troglitazone effects on endothelial function, 175, 177
 in uncomplicated well-controlled NIDDM men, relation of LVDD and CAN to, 1058
- High-density lipoprotein-cholesterol (α -lipoprotein-cholesterol; HDL-C) in NIDDM with carotid atherosclerosis
 beraprost sodium effects on, 195
 and porphyromonas gingivalis in non-obese NIDDM Japanese subjects, 143
- High-density lipoprotein-cholesterol (α -lipoprotein-cholesterol; HDL-C) in non-obese Japanese NIDDM subjects
 platelet count and, 1247
 with porphyromonas gingivalis and carotid atherosclerosis, 143
- High-density lipoprotein-cholesterol (α -lipoprotein-cholesterol; HDL-C) in non-obese subjects
 high-fat or high-CHO diet effects on, 1428
 in non-obese NIDDM Japanese subjects, *see* High-density lipoprotein-cholesterol in non-obese Japanese NIDDM subjects
 with PAI-1-associated insulin resistance, 227
- High-density lipoprotein-cholesterol (α -lipoprotein-cholesterol; HDL-C) in obese women
 effects of supplementation with FcTo on, 772
 high-fat or high-CHO diet effects on, 1428
- High-density lipoprotein-cholesterol (α -lipoprotein-cholesterol; HDL-C) in obese women (*Continued*)
 PP apo A-IV distribution between apo B- and non-apo B-containing Lps and, 1538, 1539
 total fasting plasma, weight loss effects on, 602
- High-density lipoprotein-cholesterol (α -lipoprotein-cholesterol; HDL-C) in obesity
 adiponectin gene mutations and, 882
 with hypercholesterolemia, disturbed cholesterol synthesis effects on monocytes and, 2
 in morbid obesity, 1552-1554
 with and without NIDDM, fasting and daylong TGs and, 1045
 in nondiabetic subjects, plasma SSAO and CV disease risk and, 690, 691
 with normal cholesterol, 380
 in obese men, weight loss effects on, 138
 in obese women, *see* High-density lipoprotein-cholesterol in obese women
- High-density lipoprotein-cholesterol (α -lipoprotein-cholesterol; HDL-C) in PM women
 CETP and LCAT activities and, 284, 285
 with metabolic syndrome, risk for CV disease and, 364, 366-369
 and subcutaneous and visceral AT distribution, 188
- High-density lipoprotein₂-cholesterol (α -lipoprotein₂-cholesterol; HDL₂-C)
 endothelial lipase genotype and, 1508
 in metabolic syndrome, 726
 in older subjects, and effects of GH, abdominal VAT, fitness, and insulin on, 76-78
 in primary hypoalphalipoproteinemia, vascular damage and, 329, 330
 and risk factor for CHD, 1532
 and Taq1B polymorphism with Lp variations, 1565, 1567
- High-density lipoprotein₃-cholesterol (α -lipoprotein₃-cholesterol; HDL₃-C)
 endothelial lipase genotype and, 1508
 in metabolic syndrome, 726, 727
 in older subjects, and effects of GH, abdominal VAT, fitness, and insulin on, 76-78
 in primary hypoalphalipoproteinemia, vascular damage and, 329, 330
 and risk factor for CHD, 1532
 and Taq1B polymorphism with Lp variations, 1565, 1567
- High-dose conjugated linoleic acid (CLA) with ALA, effects of, on insulin action in obesity, 1170-1171
- High-dose preformed vitamin A (retinol), effects of different types and amounts of FAs on retinoid secretion in chylomicrons after supplementation with, 514-519
- High-fat (HF) diet
 effects of high-CHO diet and, on cardiac autonomic nervous system activity in lean and obese women, 1426-1432
 effects of leptin and, on skeletal muscle insulin-stimulated PI3-K activity and glucose transport, 1196-1205
 and lipolysis in skeletal muscle, 1586-1592
- High-fiber diet, long-term effects of, on glucose tolerance and lipid metabolism, 1206-1210
- High-insulinogenic diet, obesity, metabolic syndrome and, 840-844
- High-monounsaturated fatty acid (MUFA) diet, apo E polymorphism effects on plasma lipid response to high-CHO and, 1454-1459
- High-sucrose (S) diet, and TGZ effects on vascular and glucose metabolic actions of insulin, 978-986
- HindVDR* III polymorphism of LPL gene, lipid levels associated with, in early-onset NIDDM, 338-343

- Hippocampus, aging and stress effects on structure and function of, S2:17-21
- Hispanic subjects
with controlled NIDDM, pramlintide effects on A_{1c} and BW in controlled NIDDM, 1638-1642
see also Hispanic women, PM
- Hispanic women, PM
with metabolic syndrome, risk for CV disease in, 362-371
total and regional AT in, associated with CETP and LCAT activities, 282-289
- Histidine (His), glutamine effects on protein and amino acid metabolism in hepatic tissue, 1064
- HIV, *see* Human immunodeficiency virus infection
- HL (hepatic lipase) gene, effects of interaction between C-514T H⁺/Na⁺ exchanger, *see* Na⁺/H⁺ exchanger
- HOMA (homeostasis model assessment) insulin resistance index and ADRB3 Trp64Arg polymorphism effects on LDL particle size, 357, 358
in exercising men, PPAR γ Pro12Ala polymorphism and, 210
GHR effects on, in hypopituitarism, 54, 55
in HIV infection with lipodystrophy, 1351
insulin resistance in HIV-positive subjects measured with, 858-861
in NIDDM, *see* HOMA insulin resistance index in NIDDM
in obesity, *see* HOMA insulin resistance index in obesity
in PAI-1-associated insulin resistance, 227, 228
see also HOMA insulin resistance index in PM women
- HOMA (homeostasis model assessment) insulin resistance index in Japanese NIDDM subjects
with impaired glucose tolerance, 476-481
in hypoadiponectinemic Japanese subjects, 1275, 1276
with insulin resistance, platelet count and, 1247
- HOMA (homeostasis model assessment) insulin resistance index in NIDDM
with impaired glucose tolerance, 476-481
in Japanese subjects with insulin resistance, platelet count and, 1247
with and without obesity, fasting and daylong TGs and, 1046
and PP lipemia after fat ingestion and, 1040
see also HOMA insulin resistance index in Japanese NIDDM subjects
- HOMA (homeostasis model assessment) insulin resistance index in obesity
with NIDDM, fasting and daylong TGs and, 1046
in obese insulin-resistant PCOS subjects, CV disease risk and, 713-714
in obese men, effects of weight loss on, 138
in obese women, PP apo A-IV distribution between apo B- and non-apo B-containing Lps and, 1538-1540
- HOMA (homeostasis model assessment) insulin resistance index in PM women
HRT effects on, 1088
and subcutaneous and visceral AT distribution in PM women, 188
- Homeostasis model assessment insulin resistance index, *see* HOMA insulin resistance index
- Homocysteine (Hcy)
effects of diet composed of almonds, viscous fiber, soy protein, and phytosterols on, 1479
FcTO supplementation effects on, in obese women, 775
MTFHR genotype effects on vitamin B₁₂ effects on methylmalonic acid and, in hyperhomocysteinemic ESRD, plasma glycine level and, 168-172
plasma TM and plasma, in NIDDM with nephropathy and macroangiopathy, 1517-1522
serum, in GDM, 720-723
- Homocysteine (Hcy) (*Continued*)
total, HCT effects on, in hypertension, 261-263
see also Hyperhomocysteinemia
- Homocystinylation, effects of, on paraoxonase-HDL activity, 146-151
- Hormone replacement therapy (HRT)
and IGF-1 effects on glucose kinetics and insulin sensitivity, 1186, 1188
see also Estrogen with MPA in PM women
- Hormone-sensitive lipase (HSL), effects of 17 β -estradiol and ICI: compound 182,780 on expression of, in SC abdominal adipocytes, 383-388
- HPR ([N-(4-hydroxyphenyl)-retinamide], growth arrest and apoptosis of orbital fibroblasts induced RA and, in GO, 1387-1392
- HR, *see* Heart rate
- HRT, *see* Hormone replacement therapy
- HSL (hormone-sensitive lipase), effects of 17 β -estradiol and ICI: compound 182,780 on expression of, in SC abdominal adipocytes, 383-388
- HTG, *see* Hypertriglyceridemia
- HTN, *see* Hypertension
- Human aortic endothelial cells (HAECs), glycated HDL regulation of ROS and reactive nitrogen species in, 42-49
- Human aortic smooth muscle cells (HASMCs), gliclazide effects on MCP-1 protein in, in NIDDM with CV disease, S1:16
- Human immunodeficiency virus (HIV) infection
1- μ g and 250- μ g ACTH stimulation tests of adrenal function in AIDS, 647-651
effects of lipodystrophy on beta cells in, 1343-1353
measurement of insulin resistance in subjects positive for, 858-861
see also Lipodystrophy in HIV infection
- Human umbilical endothelial cells (HUVECs)
beraprost sodium effects on VCAM-1 expression in, and on circulating VCAM-1 in NIDDM with carotid atherosclerosis, 192-198
transient hyperhomocysteinemia and changes in markers of injury to, 501-507
- HUT (head-up tilt) in recurrent VVS, plasma galanin response to, 315-321
- HUVECs, *see* Human umbilical endothelial cells
- Hydrochlorothiazides (HCT), effects of, on tHcy in hypertension, 261-263
- Hydrocortisone, *see* Cortisol
- Hydroimidazolone, serum level of MG-derived, in NIDDM, 163-167
- Hydrolases/thioesterases, acyl CoA, liver induction of mitochondrial and cytosolic, in DM and fasting, 1527-1529
- Hydrolyzed casein-based diet, effects of short-term, on IDDM development, 333-337
- β (beta)-Hydroxybutyrate (β -OHB), concentrations of, after recovery from anorexia nervosa, 297
- 3-Hydroxybutyrate (3-OHB)
and effects of glycogen level and ingested glucose on net CHO storage, 96, 97
hepatic induction of cytosolic CoA hydrolases/thioesterases, 1528
- 5 β (beta)-Hydroxy-cortisol, rosiglitazone effects on urinary excretion of, 231
- 8-Hydroxy-2'-deoxyguanosine (8-OHdG) in exacerbated pediatric atopic dermatitis, 1601-1603
- 7 α -Hydroxylase, oxysterol, regulation of, 636-642
- 17 α (alpha)-Hydroxylase/17,20 lyase deficiency, heterozygous mutation of *CYP17* gene and, 488-492
- [N-(4-hydroxyphenyl)-retinamide (HPR), growth arrest and apoptosis in orbital fibroblasts induced by 4HPR and RA in GO, 1387-1392

- 17-Hydroxyprogesterone, and 17 α -hydroxylase/17,20 lyase deficiency, 489
- 25 Hydroxyvitamin D [25(OH)D], estrogen receptor α gene and collagen IA1 gene effects on relation of PTH and, to BMD in PM women, 1129-1135
- 25 Hydroxyvitamin D₃ [25(OH)D₃], and BMD in chronic pancreatitis, 579-584
- Hyperalphalipoproteinemia, plasma CRPs in, 432-436
- Hypercholesterolemia (HC)
- almonds combined with viscous fiber, soy protein, and phytosterols for, 1478-1483
 - doxazosin effects on progression of advanced atherosclerotic lesions in, 1240-1245
 - with obesity, effects of disturbed cholesterol synthesis in monocytes on, 1-6
- Hyperglycemia
- hepatic oxidative stress induced by, causes systemic inflammation but not activation of hepatic STAT3 or MAPK, 868-874
 - see also* Glycemic control; Hyperglycemia in NIDDM with CV disease, effects of treatment on
- Hyperglycemia in NIDDM with CV disease, effects of treatment on macrovascular and microvascular complications, S1:21
- prevention of, S1:24-25
- Hyperglycemic-glycogenolytic factor, *see* Glucagon
- Hyperhomocysteinemia
- ESRD with, effects of MTFHR genotype on vitamin B₁₂ effects on methylmalonic acid and Hcy in, plasma glycine level and, 168-172
 - and IH following CEA in NIDDM, 834-839
 - in syndrome X, 1491-1495
 - transient, changes in markers of EC injury in, 501-507
- Hyperinsulinemia in obesity with metabolic syndrome, high-insulinogenic diet and, 840-844
- Hyperlipidemia
- HDL-C effects on endothelial function in, 1191-1195
 - profile of Lp subclasses in, NMRS measurement of, 916-921
- Hyperparathyroidism, primary, plasma AM in, 159-162
- Hyperplasia, intimal, following CEA, in insulin-resistant subjects, 834-839
- Hypertension (HTN)
- alcohol intake and, 131
 - doxazosin effects on insulin action and endothelial function in, 1147-1152
 - exchangeable Mg pool masses in, 626-630
 - trans* FA intake and, 695, 696
 - HCT effects on Hcy in, 261-263
 - in MS with liver dysfunction and, 1097, 1098
 - in NIDDM, *see* Hypertension in NIDDM
 - in postmenopausal women, estrogen and medroxyprogesterone acetate effects on, 1331
 - salt-sensitive, plasma FA response to central volume expansion in, 508-513
 - smokeless nicotine effects on glucose tolerance, insulin sensitivity or, in young subjects, 67-72
 - see also* Hypotensive effects and *specific antihypertensive agents*
- Hypertension (HTN) in NIDDM
- effects of glycemic control on, 1577
 - in Japanese subjects with IGT, beta-cell function, insulin sensitivity and, 477
 - and risk for atherosclerosis, 1303-1304
 - see also* Hypertension in NIDDM with CV disease
- Hypertension (HTN) in NIDDM with CV disease
- ADVANCE prevention of, S1:25
 - carotid atherosclerosis, beraprost sodium effects on, 195
 - Hypertension (HTN) in NIDDM with CV disease (*Continued*)
 - multifactorial intervention effects on, S1:21-22
- Hypertriglyceridemia (HTG), 609-619
- effects of apo C-III deficiency on development of, in STZ-DM, 1354-1359
 - hereditary, captopril effects on synthesis of AT in, 1406-1412
 - insulin resistance-associated, with normal glucose tolerance, 616-619
 - postprandial sucrose-induced, in olive oil-fed subjects, atorvastatin effects on, 609-617
- Hypoadinopectinemia in insulin-resistant NIDDM Japanese subjects, visceral AT in, 1274-1278
- Hypoalphalipoproteinemia, plasma CRPs in, 432-436
- Hypoalphalipoproteinemia
- early vascular damage in primary, 328-332
 - plasma CRPs in, 432-436
- Hypoglycemia
- non-insulin-induced, portal vein insulin decrease and alpha-cell responses to, 1418-1425
 - see also* Hypoglycemia, insulin-induced
- Hypoglycemia, insulin-induced
- counterregulatory responses to, after massive weight loss in severely obese subjects, 900-907
 - leptin effects of catecholamine response to, 1484-1490
- Hypogonadism, hypogonadotropic, in obese men, testolactone effects on, 1126-1128
- Hypogonadotropic hypogonadism in obese men, testolactone effects on, 1126-1128
- Hypopituitarism, long- and short-term GHR effects on Lp composition and apo B kinetics in, 50-59
- Hypotensive effects
- of stevioside in DM, 372-378
 - see also specific antihypertensive agents*
- Hypothyroidism, primary, during pregnancy, T₄ dose and, 122-128
- Hysterectomy-related nonthyroidal illness, L-T₄ effects on decline of serum T₃ due to L-T₄ effects on, 1307-1312
- Ibrolipim (NO-1886), effects of, on expression of FA oxidation-related enzymes, 1547-1550
- ICA512/IA-2, autoantibodies to GAD and, as IDDM markers and their relationship to residual beta-cell function and glycemic control in young IDDM subjects, 25-29
- ICAM-1 (intercellular cell adhesion molecule-1), DNA-binding activity for NF- κ B in, in NIDDM with CV disease, S1:16
- ICI:compound 182,780, effects of 17 β -estradiol and, on LPL and HSL expression in SC abdominal adipocytes, 383-388
- IDDM, *see* Insulin-dependent diabetes mellitus
- IDL-C (intermediate-density lipoprotein-cholesterol) in diabetic and nondiabetic ESRD subjects, HD-induced changes in, 118
- IFG (impaired fasting glucose), effects of low-dose glyburide on glucose production in, 407-412
- IGF-1, *see* Insulin-like growth factor-1
- IGT (impaired glucose tolerance) in NIDDM Japanese subjects, beta-cell function and insulin sensitivity in, 476-481
- IH (intimal hyperplasia) following carotid endarterectomy in insulin resistance, 834-839
- IL-1ra (interleukin-1 receptor antagonist), effects of, on SM, renal, and hepatic protein synthesis during sepsis, 1218-1225
- IL-6, *see* Interleukin-6
- IL-18 (interleukin-18), serum TNF- α and serum, in NIDDM with diabetic retinopathy, 605-608
- Ile (isoleucine), glutamine effects on protein and amino acid metabolism in hepatic tissue, 1064
- IMC (intramyocellular) lipids, effects of short-term rosiglitazone on, in obesity with insulin resistance, 218-225

- IMCD (inner medullary collecting duct), angiotensin II effects on
AVP V₂ mRNA in, 290-295
- IMGU, *see* Insulin-mediated glucose uptake
- Immunity, role of glucocorticoids in, S2:10-11
- Immunosuppression, effects of, on insulin secretion after renal
transplantation in older subjects, 573-578
- Imopea batatas* (Caipo) in NIDDM, mode of action of, 875-880
- Impaired fasting glucose (IFG), low-dose glyburide effects on
glucose production in, 407-412
- Impaired glucose tolerance (IGT) in NIDDM Japanese subjects,
beta-cell function and insulin sensitivity in, 476-481
- IMT, *see* Intima-media thickness, carotid artery
- Incidence
of metabolic syndrome with PCOS, 908-915
see also specific conditions
- Incremental area under response curve, dietary fat in NIDDM and
healthy subjects described with, 1034-1037
- Infarction, risk for myocardial, relation of sex hormones to AT,
insulin and, in men, 784-790
- Infertility in varicocele, coenzyme Q10 and, 402-406
- Inflammation
role of glucocorticoids in, aging and, S2:10-11
systemic, due to hyperglycemia-induced hepatic oxidative stress,
868-874
- Inflammatory systems, activation of, in the elderly, frailty and, S2:
22-23
- Ingested glucose, *see* Oral glucose
- Inheritance, *see* Children; DNA-binding activity; Family history of
DM; Gene(s); Genetic effects; Genomic scan; Genotype;
Hereditary hypertriglyceridemia; mRNA; Mutation(s);
Polymorphism; Translocation
- Injury
burn, metabolism of extrahepatic arginine after, burn injury, 1232-
1239
EC, in transient hyperhomocysteinemia, changes in markers of,
501-507
- Inner medullary collecting duct (IMCD), angiotensin II effects on
AVP V₂ mRNA in, 290-295
- Inosine, and gluconeogenesis-GSH redox state relation in renal
cortical tubules, 742
- Insulin
aging or abdominal AT effects on action of, 850-857
BC3H-1 myocyte, captopril effects on, 273-278
captopril effects on glycogen synthesis in skeletal muscle
stimulated by, in hereditary hypertriglyceridemia, 1406-1412
ceramide effects on PKC ζ translocation induced by, in adipocytes,
19-24
doxazosin effects on action of, in HTN, 1147-1152
effects of ATP and, on MAPK in liver cells, Ca²⁺ and, 590-598
effects of intense exercise on, with and without α - and β -
adrenergic blockers, 1619
effects of lipodystrophy in HIV infection on, 1343-1353
exocytosis of, effects of calpain inhibitor-exposed beta cells on,
528-534
gestational alcoholism effects on, in offspring, 456-458
and GH, abdominal VAT, and fitness effects on lipids and Lps in
older subjects, 73-80
high-sucrose diet and TGZ effects on, 978-986
HRT effects on, in PM subjects, 1088
hypoglycemia and, *see* Insulin-induced hypoglycemia; Non-
insulin-induced hypoglycemia
ingested glucose effects on, 96-98
left and right SM response to, 1572-1573
- Insulin (*Continued*)
methylallyl thiosulfinate effects on PDGF-stimulated VSMC
migration potentiated by, 254-259
in obese women, PP apo A-IV distribution between apo B- and
non-apo B-containing Lps and, 1538, 1539
phenotypes of metabolism of, 246-253
plasma, *see* Plasma insulin
Pro12Ala polymorphism of PPAR- γ and clearance of, 778-783
pulsatile and continuous insulin delivery effects on, compared,
1050-1055
risk for CV disease and, *see* Insulin, risk for CV disease and
in salt-sensitive HTN, 509
serum, *see* Serum insulin
and subcutaneous and visceral AT distribution in PM women, 187,
188
see also Diabetes mellitus; Insulin-dependent diabetes mellitus;
Insulin-like growth factor-1; Insulin-mediated glucose uptake;
Insulin in obesity; Insulin release and secretion; Insulin
resistance; Insulin sensitivity; Insulin signaling; Insulin-
stimulated glucose disposal; Insulin-stimulated glucose
transport; Insulin-stimulated glycogen synthesis; Non-insulin-
dependent diabetes mellitus *and entries beginning with terms:*
Insulin-like, Insulin receptor
- Insulin, risk for CV disease and, 1296, 1297
for myocardial infarction in men, relation of sex hormones to AT
and, 784-790
- Insulin-dependent diabetes mellitus (IDDM)
obesity in, *see* Insulin-dependent diabetes mellitus, obesity in
short-term hydrolyzed casein-based diet effects on development
of, 333-337
in young subjects, autoantibodies to ICA512/IA-2 and GAD as
markers for, and their relationship to residual beta-cell
function and glycemic control of, 25-29
- Insulin-dependent diabetes mellitus (IDDM), obesity in
influence of microangiopathic complications, obesity, and duration
of, on CAN, 815-820
obese children with, intracellular platelet Mg in, 468-471
- Insulin-induced hypoglycemia, counterregulatory responses to, after
massive weight loss in severely obese subjects, 900-907
- Insulin-like growth factor-1 (IGF-1)
in acromegaly, 182-183
effects of β -estradiol and, on eNOS activity in aortic endothelial
cells, 482-487
GHR effects on, in hypopituitarism, 53, 54
MAPK activation in retinal endothelial cells mediated by, high
glucose effects on, 547-551
in older subjects, *see* Insulin-like growth factor-1 in older subjects
serum, *see* Serum insulin-like growth factor-1
- Insulin-like growth factor-1 (IGF-1) mRNA (messenger ribonucleic
acid), serum and hepatic, age-dependent liver thyroid status
adaptation in DM and, 1117-1125
- Insulin-like growth factor-1 (IGF-1) in older subjects
effects of, on glucose kinetics or insulin sensitivity in older
women, 1182-1190
GH, abdominal VAT, fitness, and insulin effects on, 76
- Insulin-mediated glucose uptake (IMGU)
and insulin-induced oxidation inhibition, adipocyte-tyrosine
phosphatase and, 705-712
insulin resistance in HIV-positive subjects measured with, 858-861
nervous blockade effects on, 413-417
in NIDDM, TGZ and metformin regulation of SM morphology in
NIDDM and, 540-546

Insulin in obesity

- AT in obesity regulated by insulin, glucocorticoids, G_i-coupled receptor agonists, and pertussis toxin, 68
- effects of CLA interaction with α -lipoic acid on, 1167-1174
- in morbidly obese women, SM FA oxidation and, 736
- in nondiabetic subjects, plasma SSAO, CV disease risk and, 690, 691
- in obese men, effects of weight loss on, 138
- response of, in young adults after 16 weeks of exercise, 1175-1181
- see also* Insulin resistance in obesity

Insulin receptor (IR)

- myocyte, captopril effects on tyrosine phosphorylation of, 274-275
- see also* Insulin receptor phosphorylation

Insulin receptor (IR) phosphorylation

- GlcN-induced insulin resistance and impaired SM, 1092-1095
- see also* Insulin receptor tyrosine phosphorylation

Insulin receptor substrate-1 (IRS-1) tyrosine phosphorylation

- in myocytes, captopril effects on, 274-275
- and vanadate and rapamycin effects on insulin-mediated glucose uptake, 671

Insulin receptor (IR) tyrosine phosphorylation

- effects of exercise-enhanced PKC ζ and, on NIDDM, 1028-1033
- IR β -subunit, ceramide effects on insulin-induced PKC ζ translocation in adipocytes and, 19-24
- IRS-1, *see* Insulin receptor substrate-1 tyrosine phosphorylation

Insulin release and secretion, 565-578

- chronic GITS metabolic effects on insulin sensitivity, serum glucose, hepatic insulin extraction and, in glucose-tolerant first-degree relatives of African-American NIDDM subjects, 565-572
- effects of nateglinide and rosiglitazone on, compared, 1393-1399
- effects of N-terminal Ala₂-substituted analogs of GIP on, 679-687
- glucose-induced, palmitate potentiation of, 1367-1371
- after long- and short-term FFA infusions in men at risk for developing NIDDM, 885-894
- milrinone effects on, 1496-1500
- in NIDDM, *see* Insulin release and secretion in NIDDM
- NO and glutamine involvement in, ornithine α -KG effects on, 344-350
- potentiation of glucose-induced, by palmitate, 2-bromopalmitate in study of, 1367-1371
- after renal transplantation in older subjects, 573-578
- study of anaplerosis in insulin secretion with pancreatic islet mitochondria metabolites, 993-998

Insulin release and secretion in NIDDM

- relatively preserved, in non-obese NIDDM subjects, 1038-1043
- as response to gastric inhibitory polypeptides in NIDDM first-degree relatives of NIDDM subjects, 1579-1585

Insulin resistance

- adiponectin expression relation to, 960
- apo B, ovariectomy effects on, 659-661
- effects of, on ET-1 level, 845-849
- GlcN-induced, and impaired SM insulin receptor phosphorylation, 1092-1095
- in HIV-positive subjects, measurement of, 858-861
- IH after CEA in, 834-839
- in NIDDM, *see* Insulin resistance in NIDDM
- in obesity, *see* Insulin resistance in obesity
- PAI-1-associated, in non-obese Japanese subjects, 226-229
- plasma ghrelin, smoking and, in men, 1460-1463
- PPAR γ Pro12Ala polymorphism and exercise-mediated changes in, in men, 209-212

Insulin resistance (*Continued*)

- relation of NA-induced, to circulating FFAs and AT oxidation but not to SM lipid content, 699-704
- TNF- α activity and, 1593-1596
- see also* HOMA insulin resistance index; Insulin sensitivity; Metabolic syndrome

Insulin resistance in NIDDM

- adipocyte, effects of hyperglycemia reversal on, 239-245
- beta-cell function and, in Japanese NIDDM subjects with impaired glucose tolerance, 476-481
- EPA effects on SM lipid accumulation and, 30-34
- and glibenclamide-metformin therapy, 864
- Met416Val muscle GS associated with, 895-899
- see also* Japanese subjects, NIDDM insulin-resistant

Insulin resistance in obesity

- effects of, on risk for CV disease in PCOS, 713-719
- estrogen and gender differences in, 659-661
- FFA-induced peripheral tissue, 233-238
- hepatic, BDNF effects, 203-208
- hyperinsulinemia with, 841
- Lp abnormalities in, 559-564
- short-term rosiglitazone effects on IMC lipids in, 218-225

Insulin resistance syndrome, *see* Metabolic syndromeInsulin secretion, *see* Insulin release and secretionInsulin sensitivity (S_i)

- chronic GITS metabolic effects on insulin secretion, serum glucose, hepatic insulin extraction and, in glucose-tolerant first-degree relatives of African-American NIDDM subjects, 565-572
- cycling effects on, 823
- gliclazide MR effects on, S1:30-31
- IGF-1 effects on, in older women, 1182-1190
- in NIDDM, *see* Insulin sensitivity in NIDDM
- in obesity, *see* Insulin sensitivity in obesity
- PPAR γ 2 Pro12Ala polymorphism effects on, 780, 781
- smokeless nicotine effects on HTN, glucose tolerance or, in young subjects, 67-72
- see also* Insulin resistance

Insulin sensitivity (S_i) in NIDDM

- and AT distribution in lean and obese NIDDM Thai women, 1444-1447
- beta-cell function and, in NIDDM Japanese subjects with impaired glucose tolerance, 476-481
- with CV disease, gliclazide MR effects on, S1:31-32

Insulin sensitivity (S_i) in obesity

- and AT distribution in NIDDM Thai women, 1444-1447
- muscle, rosiglitazone effects on, irrespective of TG content, 1078-1083

see also Insulin sensitivity in obesity, weight loss effects on

Insulin sensitivity (S_i) in obesity, weight loss effects on

- in obese men, 138
- in obese PM women, 602
- Insulin signaling via Shc in breast cancer, 1606-1611
- Insulin-stimulated glucose transport, effects of high-fat diet and leptin on PI3-K activity and, 1196-1205

Insulin-stimulated glycogen synthesis, SM, captopril effects on, 1406-1412

Insulinemia

- in first-degree relatives of NIDDM subjects, 1069
- hyperinsulinemia in obesity with MS, high-insulinogenic diet and, 840-844

Insulinogenic diet, high-, obesity, metabolic syndrome and, 840-844

Insulinomas, intra-arterial Ca stimulation test in detection of, 1320-1329

- Intact parathyroid hormone (i-PTH) in PHP, 160
- Intense exercise, effects of α - and β -adrenergic blockers on regulation of glucose kinetics during, 1615-1620
- Intercellular cell adhesion molecule-1 (ICAM-1), DNA-binding activity for NF- κ B in, in NIDDM with CV disease, S1:16
- Interleukin-1 receptor antagonist (IL-1ra), effects of, on SM, renal, and hepatic protein synthesis during sepsis, 1218-1225
- Interleukin-6 (IL-6)
in ECs, cholesterol effects on linoleic acid-mediated production of, 497
in NIDDM with diabetic retinopathy, 606, 607
release of skeletal muscle TNF- α and, in NIDDM subjects at rest and during exercise, 939-944
- Interleukin-18 (IL-18), serum TNF- α and serum, in NIDDM with diabetic retinopathy, 605-608
- Intermediate-density lipoprotein-cholesterol (IDL-C) in diabetic and nondiabetic ESRD subjects, HD-induced changes in, 118
- Interstitial compartments of vascular system, aging effects on, S2:33
- Intima-media thickness (IMT), carotid artery
associated with LDL receptor mutation independently, risk for CV disease and, 1433-1438
in central obesity, 1000, 1001
in primary hypoalphalipoproteinemia, 328-332
see also Intima-media thickness, carotid, in NIDDM
- Intima-media thickness (IMT), carotid, in NIDDM
beraprost sodium effects on, 194-195
with porphyromonas gingivalis in non-obese Japanese subjects, 143
- Intimal hyperplasia (IH) following carotid endarterectomy in insulin resistance, 834-839
- Intolerance, *see* Impaired glucose intolerance; Lysine intolerance
- Intra-arterial Ca (calcium) stimulation test, insulinomas detected with, 1320-1329
- Intracellular magnesium (Mg), platelet, in obese IDDM and/or NIDDM children, 468-471
- Intracellular pH, neutrophil, and Na⁺/H⁺ exchanger activity in pre-eclampsia, 87-93
- Intracellular triglycerides (TGs) in left and right SM, 1574
- Intramyocellular (IMC) lipids, short-term rosiglitazone effects on, in obesity with insulin resistance, 218-225
- Intravenous glucose tolerance test (IVGTT)
of insulin release after long- and short-term FFA infusions in men at risk for developing NIDDM 885-894
of subjects at risk for NIDDM, 1213
- Intravesicular glucose, Mg transport in liver plasma membrane of STZ-DM subjects modulated by, 1464-1470
- Intron 4 of endothelial constitutive nitric oxide synthase (ECNOS) gene, serum uric acid levels and 27-bp repeat polymorphism of, in Chinese NIDDM subjects, 1448-1453
- Invasive management of ACS in NIDDM, noninvasive versus, S1:9
- i-PTH (intact parathyroid hormone) in PHP, 160
- IR, *see* Insulin receptor
- Iron (Fe), dietary, hepatic hepcidin mRNA regulation by, 1229-1231
- Ischemia in NIDDM with CV disease
sulfonylureas for, S1:3-5
see also Coronary artery disease in NIDDM
- Ischemic heart failure, insulin withdrawal in DM and prevention of, with exercise, 791-797
- Islets of Langerhans, *see* Alpha cells; Beta cell(s)
- Isoleucine (Ile), glutamine effects on protein and amino acid metabolism in hepatic tissue, 1064
- IVGTT, *see* Intravenous glucose tolerance test
- Japanese subjects
Taq1B polymorphism with Lp variations in, CETP associated with, 1564-1570
- Japanese subjects (*Continued*)
see also Japanese subjects, NIDDM
- Japanese subjects, NIDDM
with hypoadiponectinemia, visceral AT, and insulin resistance in, 1274-1278
with impaired glucose tolerance, beta-cell function and insulin sensitivity in, 476-481
risk factors for asymptomatic atherosclerosis in, without diabetic microvascular complications, 1302-1306
see also Japanese subjects, NIDDM insulin-resistant; Japanese subjects, NIDDM non-obese
- Japanese subjects, NIDDM insulin-resistant
with hypoadiponectinemia, visceral AT, and insulin resistance in, 1274-1278
with PAI-1-associated insulin resistance, 226-229
- Japanese subjects, NIDDM non-obese
and insulin resistance, platelet count associated with, 1246-1249
with PAI-1-associated insulin resistance, 226-229
porphyromonas gingivalis and carotid atherosclerosis in, 142-145
- Jejunal proteins, L-NAME and L-NNA effects on synthesis of, alcohol and, 397-401
- K (potassium)
effects of supplementation with, on natriuretic response to central volume expansion in primary aldosteronism, 1597-1600
and 17 α -hydroxylase/17,20 lyase deficiency, 489
see also K_{ATP} channels, beta cell, in NIDDM with CV disease
- K_{ATP} (adenosine triphosphate-dependent potassium channels), beta-cell, in NIDDM with CV disease
and cardiac cell K_{ATP}, acyl CoA activating acyl CoA esters in side-chain length-specific manner, 1313-1319
as target of sulfonylureas in NIDDM with CV disease, S1:3
- α (alpha)-Ketoglutarate (KG), ornithine, insulin secretion induced by, NO and glutamine involvement in, 344-350
- 2-Keto[1-¹³C]isocaproate breath test, mitochondrial response to calorie-restricted diet in obese women assessed with, 463-467
- KG (α -ketoglutarate), ornithine, insulin secretion induced by, NO and glutamine involvement in, 344-350
- Kidney
effects of pre-pregnancy protein-restricted diet on weight of offspring, 15
see also Diabetic nephropathy; End-stage renal disease; Renal glucose
- Kinase, *see* Glucokinase; Phosphatidylinositol 3-kinase; 6-Phosphokinase; Protein kinase; Threonine kinase
- Kinetics
apo B-100, long- and short-term GHR effects on, in hypopituitarism, 50-59
of F-ASA degradation under oxidative conditions, 762
glucose, *see* Kinetics, glucose
protein, effects of, testosterone and GH on, in boys, 966
- Kinetics, glucose
effects of α - and β -adrenergic blockade on regulation of, during intense exercise, 1615-1620
IGF-1 effects on, in older women, 1182-1190
modeling of, with WinSAAM, 1161-1163
in preterm infants, alanine and, 947
- Korean subjects with NIDDM, rosiglitazone effects of serum Lp(a) in, 731-734
- Lactate
blood, glycogen phosphorylase inhibitor effects on, 1423
fasting, in hereditary HTG, 1408
formation of, in adipocytes and AT in obesity, 62

Lactate (*Continued*)

- in HIV infection with lipodystrophy, 1351
- ingested glucose effects on, 97, 98
- NO effects on, 663
- restricted diet effects on sarcolemmal transport of, 322-327
- Lactate dehydrogenase (LDH), effects of restricted diet on, 325
- Language, WinSAAM, 1153-1154
- Late non-insulin-dependent diabetes mellitus (NIDDM), troglitazone effects on endothelial function in, 173-180

Lathosterol

- in NIDDM with hypoadinopectinemia, 1281
- in obese men, effects of weight loss on, 138

LBM, *see* Lean body mass

- LCAT (lecithin:cholesterol acyltransferase), total and regional AT associated with activities of CETP and, in PM women, race and ethnicity and, 282-289

LDH (lactate dehydrogenase), effects of restricted diet on, 325

LDL(s), *see* Low-density lipoprotein(s)LDL-C, *see* Low-density lipoprotein-cholesterol

Lean body mass (LBM)

- exercise effects on, *see* Lean body mass, exercise effects on
- in gynoid adiposity with swelling syndrome, 806, 807
- of HIV infection patients with lipodystrophy, 622, 1346
- in men at risk for developing NIDDM, 888
- of older subjects, *see* Lean body mass in older subjects
- and TNFR2 concentration in first-degree relatives of NIDDM subjects, 1069

see also Lean body mass in obesity

Lean body mass (LBM), exercise effects on

- endurance exercise effects, 154
- in men with CAD, 1414, 1415

Lean body mass (LBM) in obese women

- on calorie-restricted diet, 464
- in PM women, effects of weight loss on, 601

Lean body mass (LBM) in obesity

- BPD effects on, 552-558
- in free-living obese men, energy intake restriction and 16-week exercise program effects on, 107-115
- in morbid obesity, 1552-1554
- see also* Lean body mass in obese women

Lean body mass (LBM) in older subjects

- effects of GH, abdominal VAT, fitness, and insulin on, 76
- insulin action and, 853

Lean subjects, *see* Non-obese subjects

- Lecithin:cholesterol acyltransferase (LCAT), total and regional AT associated with activities of CETP and, in PM women, race and ethnicity and, 282-289

Left skeletal muscle (SM), substrate concentrations and metabolism in, 1571-1575

- Left ventricular diastolic dysfunction (LVDD), relation of CAN and, to preclinical diabetic cardiomyopathy in men with uncomplicated well-controlled NIDDM, 1056-1061

Left ventricular function in DM with insulin withdrawal, effects of exercise on, 792

Leptin

- effects of, on catecholamine response to insulin-induced hypoglycemia, 1484-1490
- effects of high-fat diet and, on skeletal muscle insulin-stimulated PI3-K activity and glucose transport, 1196-1205
- in first-degree relatives of NIDDM subjects, 1069
- in NIDDM, TZD effects on, 756
- release of, in adipocytes in obese subjects regulated by insulin, glucocorticoids, G_i-coupled receptor agonists, and pertussis toxin, 60-68

Leptin (*Continued*)*see also* Serum leptin

- Leucine (Leu), glutamine effects on metabolism of, in hepatic tissue, 1064

Leukocyte(s), PP increase of, in healthy subjects, 199-202

- Leu7Pro polymorphism of NPY gene, FFA metabolism regulated by, 643-646

LH (luteinizing hormone), and 17 α -hydroxylase/17,20 lyase deficiency, 489Life span, *see* Longevity

- Light alcohol intake, effects of, on paraoxonase by liver mRNA upregulation, 1287-1294

Linoleate, retinyl, effects of different types and amounts of FAs on PP secretion of, in chylomicrons, 516

Linoleic acid

- cholesterol supplementation effects on EC activation induced by, 493-500
- effects of α -lipoic acid interaction with conjugated, on insulin action in obesity, 1167-1174

Lipase, *see* Endothelial lipase genotype; Hepatic lipase gene;

- Hormone-sensitive lipase; Lipoprotein lipase; Lipoprotein lipase gene; Phospholipase A₂; Phospholipase C

Lipemia, *see* Blood lipids, diet effects on; Dyslipoproteinemia; Hyperlipidemia; Normolipidemia; Postprandial lipemia; Triglyceridemia

Lipids

- blood, *see* Blood lipids, diet effects on; Dyslipoproteinemia; Hyperlipidemia; Normolipidemia; Postprandial lipemia; Triglyceridemia
- in early-onset NIDDM associated with LPL *HindIII* gene polymorphism, 338-343
- intramyocellular, short-term rosiglitazone effects on, in obesity with insulin resistance, 218-225
- long-term effects of high dietary fiber intake on, 1206-1210
- metabolism of, in primary monocyte-derived macrophages, effects of PPAR activators on mRNA of genes involved in, 652-657
- in older subjects, effects of GH, abdominal VAT, fitness, and insulin on Lps and, 73-80
- oxidation of, low-dose glyburide effects on, 411
- plasma, *see* Plasma lipids
- in SM, *see* Lipids in SM
- and risk for NIDDM, 1214
- see also* Phospholipids *entries beginning with element: Lip- and specific lipids*

Lipids in SM

- EPA effects on insulin resistance and SM accumulation of, 30-34
- relationship of NA-induced insulin resistance to AT oxidation but not to content of, 699-704

Lipodystrophy in HIV infection

- effects of, on insulin action and on beta cells, 1343-1353
- TEE and CHO oxidation in, 620-625

Lipogenesis, liver, restricted salt intake effects on age-related changes in, 1072-1077

- α (alpha)-Lipoic acid (ALA), effects of CLA interaction with, on insulin action in obesity, 1167-1174

Lipolysis

- milrinone effects on, 1496-1500
- in NIDDM, TZD effects on, 756
- in SM, high-fat diet and, 1586-1592

Lipoprotein (Lp)

- in apo A-I and apo A-II, race and risk for CHD and, 1530-1536
- effects of estrogen and medroxyprogesterone acetate on, in PM women, 1330-1336

Lipoprotein (Lp) (*Continued*)

- HD-induced changes in, in diabetic and nondiabetic ESRD subjects, 116-121
- long- and short-term GHR effects on composition of, in hypopituitarism, 50-59
- in obesity, *see* Lipoprotein in obesity
- in older subjects, effects of GH, abdominal VAT, fitness, and insulin on lipids and, 73-80
- profile of subclasses of, in hyperlipidemia, measurement with NMRS, 916-921
- Taq1B polymorphism with variations in, in Japanese subjects, CETP associated with, 1564-1570
- see also* Dyslipoproteinemia; High-density lipoprotein(s); Lipoprotein lipase; Lipoprotein(a); Low-density lipoprotein(s); Very-low-density lipoprotein(s)
- Lipoprotein (Lp) in obesity
 - apo B- and non-apo B-containing, PP apo A-IV distribution between, in obese women, 1537-1541
 - with insulin resistance, 559-564
- Lipoprotein(a) [Lp(a)]
 - in adults malnourished in first year of their life, 1006
 - in postmenopausal women, estrogen and medroxyprogesterone acetate effects on, 1332
 - serum, in Korean NIDDM subjects, rosiglitazone effects on, 731-734
- Lipoprotein lipase (LPL)
 - effects of 17 β -estradiol and ICI:compound 182,780 on expression of, in
 - effects of ibrolipim as activator of, on expression of FA oxidation-related enzymes, 1547-1550
 - see also* Lipoprotein lipase gene; Lipoprotein lipase in NIDDM
- Lipoprotein lipase (LPL) gene, interaction effects of C-514T polymorphism of hepatic lipase gene and serine447Stop polymorphism of, on serum TGs in young adults, 1337-1342
- Lipoprotein lipase (LPL) in NIDDM
 - in early-onset NIDDM, lipid levels associated with *HindIII* gene polymorphism of, 338-343
 - PP lipemia after fat ingestion and, 1040
- Liver
 - gluconeogenesis and arginine effects on, 1514-1515
 - induction of cytosolic and mitochondrial acyl coenzyme A hydrolases/thioesterases by, in DM and fasting, 1527-1529
 - pre-pregnancy protein-restricted diet effects on weight of offspring's, 15
 - restricted salt intake effects on age-related changes in lipogenesis of, 1072-1077
 - see also* entries beginning with term: Liver and element: Hepat-
- Liver dysfunction, aldehyde dehydrogenase 2 and ADRB3 Trp64Arg polymorphism associated with metabolic syndrome and, 1096-1101
- Liver mRNA (messenger ribonucleic acid), effects of light alcohol intake on PON by upregulation of, 1287-1294
- Liver thyroid status adaptation, age-dependent, in DM, serum and hepatic IGF-1 expression and, 1117-1125
- Long-term effects
 - of gliclazide MR in NIDDM with CV disease, S1:29
 - of high fiber intake on glucose tolerance and lipid metabolism, 1206-1210
 - short-term effects and, of FFA infusions on insulin secretion in men at risk for NIDDM, 885-894
- Long-term growth hormone replacement (GHR), effects of short- and, on Lp composition and apo B-100 kinetics in hypopituitarism, 50-59

Longevity

- life span genes and, S2:6
- prolongation of, S2:7-8
- Low-density lipoprotein(s) (β -lipoprotein; LDL)
 - alcohol intake influence on, 131
 - in DM, PLA₂ effects on atherogenic role of lysophosphatidylcholine in, 308-314
 - effects of PP triglyceridemia variations on particle size of, 1379-1386
 - in heavy smokers, grape seed extract effects on, 1250-1257
 - in hypopituitarism, long- and short-term GHR effects on composition of, 50-59
 - in margarine-enriched phytosterols, 1375
 - in NIDDM, *see* Low-density lipoprotein(s) in NIDDM
 - oxidized, *see* Oxidized low density lipoprotein
 - particle size of, *see* Particle size of LDLs
 - profile of, in obesity with insulin resistance, 559-564
 - size of, *see* Low-density lipoprotein-cholesterol, LDL size and susceptibility of, to LDL oxidation in heavy smokers, grape seed extract effects on, 1250-1257
 - see also* Low-density lipoprotein-cholesterol; Low-density lipoprotein receptor; Very-low-density lipoprotein-cholesterol
- Low-density lipoprotein(s) (LDL; lipoprotein) in NIDDM
 - with CV disease, effects of gliclazide on oxygenated LDL-induced monocyte adhesion to ECs, S1:15
 - with nephropathy and macroangiopathy, 1519
 - PP lipemia after fat ingestion and size of, 1040
- Low-density lipoprotein(s) (LDL; lipoprotein) receptor
 - atorvastatin effects on apo B-48 activity of, in normolipidemia with CAD, 1279-1286
 - carotid IMT associated with mutation of, independently of CV risk factors, 1433-1438
- Low-density lipoprotein-cholesterol (LDL-C; β -lipoprotein-cholesterol)
 - adipocyte-derived plasma adipoectin and, 1613
 - CRP and, *see* Low-density lipoprotein-cholesterol, CRPs and diet effects on, *see* Low-density lipoprotein-cholesterol, diet effects on
 - in DM, *see* Low-density lipoprotein-cholesterol in DM
 - doxazosin effects on, in HTN, 1149
 - exercise effects on endothelial lipase genotype and, 1508
 - fenofibrate effects on, 352
 - in first-degree relatives of NIDDM subjects, 1069
 - in heavy smokers, grape seed extract effects on, 1252
 - in hyperalphalipoproteinemia, plasma CRPs and, 433
 - in hypoalphalipoproteinemia, *see* Low-density lipoprotein-cholesterol in hypoalphalipoproteinemia
 - in insulin resistance and/or MS, *see* Low-density lipoprotein-cholesterol in insulin-resistant subjects
 - and LDL size, *see* Low-density lipoprotein-cholesterol, LDL size and
 - in metabolic syndrome, 726, 727
 - in nondiabetic ESRD subjects, HD-induced changes in, 118
 - in obesity, *see* Low-density lipoprotein-cholesterol in obesity
 - in older subjects, effects of GH, abdominal VAT, fitness, and insulin on, 76-78
 - oxidized, in hyperlipidemia, 1192, 1193
 - in PM women, *see* Low-density lipoprotein-cholesterol in PM women
 - PP triglyceridemia and, 1381, 1384
 - and risk factor for CHD, 1532-1534
 - as risk factor for CV disease, *see* Low-density lipoprotein-cholesterol, as risk factor for CV disease
 - see also* Very-low-density lipoprotein-cholesterol

- Low-density lipoprotein-cholesterol (LDL-C; β -lipoprotein-cholesterol), CRPs and
CRP relation to, 1544
in young men and, 1114
- Low-density lipoprotein-cholesterol (LDL-C; β -lipoprotein-cholesterol), diet effects on
high-CHO and/or high-MUFA diet, 1457
high-fat and/or high-CHO diet effects in non-obese and obese women, 1428
of malnourishment in first year of life, 1006, 1008
- Low-density lipoprotein-cholesterol (LDL-C; β -lipoprotein-cholesterol), as risk factor for CV disease, 1296, 1297, 1434-1436
for atherosclerosis and, 1303, 1304
plasma SSAO and CV risk factor in nondiabetic subjects, 690-691
- Low-density lipoprotein-cholesterol (LDL-C; β -lipoprotein-cholesterol) in DM
with ESRD, HD-induced changes in, 118
see also Low-density lipoprotein-cholesterol in NIDDM
- Low-density lipoprotein-cholesterol (LDL-C; β -lipoprotein-cholesterol) in hypoalphalipoproteinemia
plasma CRPs and, 433
in primary hypoalphalipoproteinemia, vascular damage and, 329, 330
- Low-density lipoprotein-cholesterol (LDL-C; β -lipoprotein-cholesterol) in insulin-resistant subjects
in NA-induced insulin resistance, 701
see also Low-density lipoprotein-cholesterol in obese insulin-resistant women with PCOS
- Low-density lipoprotein-cholesterol (LDL-C; β -lipoprotein-cholesterol) in NIDDM
in Chinese subjects, 1449-1451
with CV disease, *see* Low-density lipoprotein-cholesterol in NIDDM with CV disease
early-onset NIDDM, LPL *HindIII* gene polymorphism-lipid level association and, 339-341
and effects of glycemic control on LDL particle size, 1577
with hypoadipopectinemia, 1281
in NIDDM first-degree relatives of NIDDM subjects, 1580
in non-obese subjects, *see* Low-density lipoprotein-cholesterol in nonobese subjects
oxidized, *see* Oxidized low-density lipoprotein
and phospholipid-dependent procoagulation activity, 103
and PP lipemia after fat ingestion, 1040
rosiglitazone effects on, 732
troglitazone effects on, 175, 177
in uncomplicated well-controlled NIDDM men with preclinical diabetic cardiomyopathic, 1058
see also Low-density lipoprotein-cholesterol in NIDDM with carotid atherosclerosis
- Low-density lipoprotein-cholesterol (LDL-C; β -lipoprotein-cholesterol) in NIDDM with carotid atherosclerosis
beraprost sodium effects on, 195
in non-obese NIDDM subjects with porphyromonas gingivalis, 143
- Low-density lipoprotein-cholesterol (LDL-C; β -lipoprotein-cholesterol) in NIDDM with CV disease
multifactorial intervention and, S1:20
see also Low-density lipoprotein-cholesterol in NIDDM with carotid atherosclerosis
- Low-density lipoprotein-cholesterol (LDL-C; β -lipoprotein-cholesterol) in nonobese subjects
with carotid atherosclerosis and porphyromonas gingivalis, 143
Japanese NIDDM subjects, platelet count and, 1247
- Low-density lipoprotein-cholesterol (LDL-C; β -lipoprotein-cholesterol) in obese insulin-resistant women with PCOS
effects of insulin resistance and obesity on PCOS, 716
and MS, metformin and diet effects on, 910
- Low-density lipoprotein-cholesterol (LDL-C; β -lipoprotein-cholesterol) in obese women
effects of FcTO supplementation on, 380
high-fat and/or high-CHO diet effects on, 1428
PP apo A-IV distribution between apo B- and non-apo B-containing Lps and, 1538-1540
see also Low-density lipoprotein-cholesterol in obese insulin-resistant women with PCOS
- Low-density lipoprotein-cholesterol (LDL-C; β -lipoprotein-cholesterol) in obesity
fasting and daylong TGs and, 1045, 1046
with hypercholesterolemia, and disturbed cholesterol synthesis effects on monocytes, 2
in morbid obesity, 1552-1554
without NIDDM, fasting and daylong TGs and, 1045
in nondiabetic subjects, plasma SSAO and CV disease risk factor and, 690, 691
with normal cholesterol, 380
see also Low-density lipoprotein-cholesterol in obese women
- Low-density lipoprotein-cholesterol (LDL-C; β -lipoprotein-cholesterol) in PM women
CETP and LCAT activities and, 284, 285
with metabolic syndrome, risk factors for CV disease and, 364, 366-369
and subcutaneous and visceral AT distribution, 188
- Low-dose conjugated linoleic acid (CLA) and ALA, effects of, on insulin action in obesity, 1170-1171
- Low-dose glyburide, effects of, on glucose production in impaired fasting glucose, 407-412
- Lp, *see* Lipoprotein
- LPL, *see* Lipoprotein lipase
- Luteinizing hormone (LH), and 17 α -hydroxylase/17,20 lyase deficiency, 489
- LVDD (left ventricular diastolic dysfunction), relation of CAN and, to preclinical diabetic cardiomyopathy in men with uncomplicated well-controlled NIDDM, 1056-1061
- Lyase deficiency, 17 α -hydroxylase/17,20, heterozygous mutation of *CYP17* gene and, 488-492
- Lycopene, plasma, in heavy smokers, grape seed extract effects on, 1255
- Lymphatic function in women with gynoid adiposity and swelling syndrome, 805-809
- Lysine (Lys)
glutamine effects on metabolism of, in hepatic tissue, 1064
oral, supplementation with, for lysine intolerance, 935-938
serum level of N^ω-(carboxymethyl)-, in NIDDM, 163-167
Lysine intolerance, lysine supplementation for, 935-938
- Lysophosphatidylcholine (lyso-PC) in DM, PLA₂ effects on atherogenic role of, in LDLs, 308-314
- Macroangiopathy, NIDDM, plasma Hcy and plasma TM in, 1517-1522
- Macrophages, primary monocyte-derived, effects of PPAR activators on mRNA levels of genes involved in lipid metabolism in, 652-657
- Macrovascular complications in NIDDM, effects of hyperglycemia control of on, S1:21
- Magnesium (Mg)
effects of supplementation of creatine with, on body water, 1136-1140

Magnesium (Mg) (*Continued*)

- intracellular platelet, in obese IDDM and/or NIDDM children, 468-471
- transport of, in intravesicular liver plasma membrane in STZ-DM, glucose modulation of, 1464-1470
- Magnesium (Mg) pool masses, exchangeable, in HTN, 626-630
- Magnetic resonance spectroscopy (NMR), ¹⁹F, metabolomic mapping of vitamin C with F-ASA and, 760-770
- Malate, effects of, on metabolites from pancreatic islet mitochondria, 996
- Malnutrition in first year of life, effects of, on adult plasma insulin and glucose tolerance, 1005-1011
- Mannose, physiological changes in circulating levels of, in normal glucose tolerance, glucose intolerance, and DM, 1019-1027
- MAPK, *see* Mitogen-activated protein kinase activity
- Margarine-enriched phytosterols, effects of, on blood lipids, platelet function, and fibrinogen level in young men, 1373-1378
- Massive weight loss by severely obese subjects, counterregulatory responses to, after massive weight loss, 900-907
- MAT (methylallyl thiosulfinate), effects of, on insulin-potentiated PDGF-stimulated VSMC migration, 254-259
- Maternal protein-restricted diet, effects of pre-pregnancy, on offspring's vital organs, 13-18
- Maximum oxygen consumption, *see* V_{O₂}max in exercise
- MCP-1 protein, gliclizide effects on, in HASMCs in NIDDM with CV disease, S1:16
- MCTs (medium-chain triacylglycerols), effects of supplementation with FcTO containing phytosterols, n-3 PUFAs and, on cardiovascular risk in obese women, 771-777
- Meals, *see* Diet
- Medium-chain triacylglycerols (TAGs), effects of supplementation with FcTO containing phytosterols, n-3 PUFAs and, on CV disease risk in obese women, 771-777
- Medroxyprogesterone acetate, *see* Estrogen with MPA in PM women
- Medullary collecting duct, inner, angiotensin II effects on AVP V₂ mRNA in, 290-295
- Men
 - exercise effects in, *see* Men, exercise effects on
 - middle-age, exercising, serum level of IGF-1, IGFBP-1 and -3 and, glucose disposal and, 821-826
 - obese, *see* Men, obese
 - plasma ghrelin, AT, and insulin resistance in, smoking and, 1460-1463
 - relation of sex hormones to insulin, AT, and risk factors for myocardial infarction in, 784-790
 - at risk for developing NIDDM, insulin secretion in, after long- and short-term FFA infusions, 885-894
 - testosterone in, *see* Testosterone in men
 - with uncomplicated well-controlled NIDDM, relation of LVDD and CAN to preclinical diabetic cardiomyopathy in, 1056-1061; *see also* Non-insulin-dependent diabetes mellitus
 - young, *see* Young men
 - see also* Sex and specific conditions
- Men, exercise effects on
 - insulin-resistant, PPAR γ Pro12Ala polymorphism and, 209-212
 - in men with CAD, 1413-1417
 - young men, effects on serum level of IGF-1, IGFBP-1 and -3 in young, glucose disposal and, 821-826
 - see also* Exercise; Men, obese, exercise effects on
- Men, obese
 - with hypogonadotropic hypogonadism, testolactone effects on, 1126-1128
 - see also* Men, obese, exercise effects on; Obesity
- Men, obese, exercise effects on

Men, obese, exercise effects on (*Continued*)

- in free-living obese men, energy intake restriction and 16-week exercise effects on BMI and body composition in, 107-115
- on postprandial lipemia and LDL receptor binding, 136-141
- Messenger ribonucleic acid, *see* mRNA
- Met (methionine), glutamine effects on metabolism of, in hepatic tissue, 1064
- Metabolic abnormalities
 - after recovery from anorexia nervosa, 296-302
 - see also* specific conditions
- Metabolic effects of minimally invasive gastric banding for morbid obesity, 1551-1557
- Metabolic syndrome (insulin resistance syndrome; MS; syndrome X)
 - adipocyte-derived plasma adinoplectin concentrations associated with small-dense LDL particles and, 1612-1614
 - aldehyde dehydrogenase 2 and ADRB3 Trp64Arg polymorphism associated with liver dysfunction and, 1096-1101
 - hyperhomocysteinemia in, 1491-1495
 - obesity and, and high-insulinogenic diet, 840-844
 - with PCOS, 908-915
 - relation of sex hormones to AT, insulin, and risk factors for MI in men with, 784-790
 - risk of, in NIDDM parents' offspring from childhood to young adulthood, 443-453
 - risk factors for CV disease in PM women with, race and, 362-371
 - SHBG and, 724-730
 - see also* Insulin resistance
- Metabolites, pancreatic islet mitochondria, as means to study
 - anaplerosis in insulin secretion, 993-998
- Metabolomic mapping of vitamin C with F-ASA and ¹⁹F-NMR spectroscopy in DM, 760-770
- Metformin (dimethylbiguanide)
 - diet and, in management of metabolic syndrome with PCOS, 908-915
 - intracellular modulation of free radical production and effects of, on oxidative stress, 586-589
 - for morbid obesity, 1551-1557
 - see also* Metformin in NIDDM
- Metformin (dimethylbiguanide) in NIDDM
 - combined glibenclamide and, 862-867
 - TGZ and skeletal muscle morphology regulation with, 540-546
- Methionine (Met), glutamine effects on metabolism of, in hepatic tissue, 1064
- Methylallyl thiosulfinate (MAT), effects of, on insulin-potentiated PDGF-stimulated VSMC migration, 254-259
- Methylenetetrahydrofolate reductase (MTFHR) genotype, effects of, on vitamin B₁₂ effects on MMA and Hcy in hyperhomocysteinemic ESRD, 168-172
- Methylglyoxal (MG)-derived hydroimidazolone, serum level of, in NIDDM, 163-167
- Methylmalonic acid (MMA), MTFHR genotype effects on effects of vitamin B₁₂ on Hcy and, in hyperhomocysteinemic ESRD, plasma glycine level and, 168-172
- Met416Val polymorphism of muscle GS, insulin resistance in NIDDM associated with, 895-899
- Mg, *see* Magnesium; Magnesium pool masses
- MG (methylglyoxal)-derived hydroimidazolone, serum level of, in NIDDM, 163-167
- MI (myocardial infarction), relation of sex hormones to AT, insulin, and risk factors for, in men, 784-790
- Microalbuminuria in NIDDM
 - with CV disease, multifactorial intervention in, S1:19-23

- Microalbuminuria in NIDDM (*Continued*)
 in men with uncomplicated well-controlled NIDDM, relation of LVDD and CAN to preclinical diabetic cardiomyopathy in, 1058
- Microangiopathic complications, influence of obesity, duration of DM and, on CAN, 815-820
- Microvascular complications in NIDDM with CV disease
 effects of glycemic control of NIDDM on, S1:21
 risk factors for asymptomatic atherosclerosis without, in Japanese NIDDM subjects, 1302-1306
- Middle-age men, exercising, serum level of IGF-1, IGFBP-1 and -3 and, glucose disposal and, 821-826
- Milrinone, effects on lipolysis, glucose production, and insulin secretion, 1496-1500
- Minimally invasive gastric banding for morbid obesity, metabolic and psychosocial effects of, 1551-1557
- Mitochondria
 metabolites of pancreatic islet, anaplerosis in insulin secretion studied with, 993-998
see also entries beginning with term: Mitochondrial
- Mitochondrial acyl coenzyme A (CoA) hydrolases/thioesterases, hepatic induction of, in DM and fasting, 1527-1529
- Mitochondrial fuel metabolism, effects of beta cell exposure to calpain inhibitors on insulin exocytosis and, 528-534
- Mitochondrial response to calorie-restricted diet by obese women, 2-keto[1-¹³C]isocaproate breath test assessing, 463-467
- Mitogen-activated protein kinase (MAPK)
 hyperglycemia-induced hepatic oxidative stress does not activate hepatic STAT3 or, 868-874
see also Mitogen-activated protein kinase activity
- Mitogen-activated protein kinase (MAPK) activity
 IGF-1-mediated, in retinal endothelial cells, high glucose effects on, 547-551
 lack of effects of hyperglycemia-induced hepatic oxidative stress on activation of hepatic STAT3 or, 868-874
 in liver cells, insulin and ATP effects on, Ca²⁺ and, 590-598
- MMA (methylmalonic acid), MTFHR genotype effects on vitamin B₁₂ effects on Hcy and, in hyperhomocysteinemic ESRD, plasma glycine level and, 168-172
- Modeling, *see* WinSAAM
- Molecular mechanisms of gliclazide effects on AGE product-induced monocyte adhesion to ECs in NIDDM with CV disease, S1:15-16
- Molybdenum cofactor sulftransferase gene, point mutation of, in xanthinuria type II, 1501-1504
- Monocytes
 effects of PPAR activators on mRNA levels of genes involved in lipid metabolism in primary macrophages derived from, 652-657
 gliclazide effects on AGE product-induced adhesion of, to ECs, in NIDDM with CV disease, S1:13-18
 in obesity with hypercholesterolemia, effects of disturbed cholesterol synthesis on, 1-6
- Monophosphate, *see* cAMP
- Monounsaturated fatty acids (MUFAs)
 apo E polymorphism effects on plasma lipid response to high-CHO diet and diet high in, 1454-1459
 in high-fiber diet, 1207
 LDL size and intake of, 695, 696
 in margarine-enriched phytosterols, 1374
- Morbid obesity
 metabolic and psychosocial effects of minimally invasive gastric banding for, 1551-1557
 SM FA oxidation in morbidly obese women, race and, 735-738
- Morphology, SM, in NIDDM, TGZ and metformin regulating, 540-546
- MPA (medroxyprogesterone acetate), *see* Estrogen with MPA in PM women
- mRNA (messenger ribonucleic acid)
 adiponectin, in AT, 958-963
 AVP V₂ and AQP-2, in IMCD, angiotensin II effects on, 290-295
 EC adhesion molecule, glycated albumin effects on, in NIDDM with CV disease, S1:15-16
 of FA oxidation-related enzymes, effects of ibrolipim on, 1547-1550
 of genes involved in lipid metabolism in primary monocyte-derived macrophages, effects of PPAR activators on, 652-657
 G6Pase, PEPCK, and GK, in hepatic insulin resistance with obesity, 205
 GS, effects of dietary fat on, 535-539
 heart VEGF, in STZ-DM, 675-678
 hepatic hepcidin, dietary Fe regulating, 1229-1231
 liver, effects of light alcohol intake on PON by upregulation of, 1287-1294
 LPL and HSL, in SC abdominal adipocytes, effects of 17 β -estradiol and ICI:compound 182,780 on, 383-388
 resistin, in AT, fenofibrate effects on plasma cholesterol and, 351-355
 serum and hepatic IGF-1, in DM, age-dependent liver thyroid status adaptation, 1117-1125
 skeletal muscle UCP-3, acute endurance exercise effects on, in untrained subjects, 152-158
 VCAM-1, in HUVECs and on circulating VCAM-1 in NIDDM with carotid atherosclerosis, beraprost sodium effects on, 192-198
- MS, *see* Metabolic syndrome
- MTFHR (methylenetetrahydrofolate reductase) genotype, effects of, on vitamin B₁₂ effects on MMA and Hcy in hyperhomocysteinemic ESRD, 168-172
- 1- μ g (and 250- μ g) corticotropin (adrenocorticotropin hormone; ACTH) stimulation tests of adrenal function in AIDS, 647-651
- MUFAs, *see* Monounsaturated fatty acids
- Multifactorial intervention of CV disease in NIDDM, outcome and, S1:19-23
- Muscle, *see* Skeletal muscle *entries beginning with term: Muscle and element: Myo-*
- Muscle cells (myocytes)
 BC3H-1, effects of captopril on insulin action in, 273-278
 human aortic endothelial, gliclazide effects on MCP-1 protein in NIDDM with CV disease, S1:16
see also Smooth muscle cells
- Muscle glycogen
 effects of restricted diet on sarcolemmal lactate transport and, 325
 skeletal, *see* Skeletal muscle glycogen
- Muscle glycogen synthase (GS), Met416Val polymorphism of, insulin resistance in NIDDM associated with, 895-899
- Muscle insulin sensitivity (S_i), rosiglitazone effects on, irrespective of TG content in obesity, 1078-1080
- Muscle proteins, Ca²⁺-regulatory, alcohol effects of, 1102-1112
- Mutation(s), 1433-1443
 adiponectin gene, in lean and obese subjects, 881-884
 of CYP2D6, tramadol pharmacokinetics and, 1439-1443
 G1691A factor V Leiden, recurrent pregnancy loss associated with PCOS, PAI activity and, 1627-1632
 heterozygous CYP17 gene, 17 α -hydroxylase/17,20 lyase deficiency and, 488-492
 LDL receptor, carotid IMT associated with, 1433-1438

- Mutation(s), 1433-1443 (*Continued*)
 point, of molybdenum cofactor sulftransferase gene in xanthinuria type II, 1501-1504
see also Polymorphism
- Myocardial infarction (MI), relation of sex hormones to AT, insulin, and risk factors for, in men, 784-790
- Myocardial revascularization for stable NIDDM with CV disease, S1:8-9
- Myocytes, *see* Muscle cells
- Myopathy, alcoholic, 1102-1112
- N, *see* Nitrogen; Nitrogen species
- NA (nicotinic acid), relation of insulin resistance induced by, to circulating FFAs and AT oxidation but not to SM lipid content, 699-704
- Na⁺/H⁺ exchanger (NHE; sodium-hydrogen exchanger)
 neutrophil intracellular pH and activity of, in pre-eclampsia, 87-93
 platelet, and phospholipid-dependent procoagulation activity in NIDDM, 102-106
- NAC (N-acetylcysteine), effects of, on GSH redox state-gluconeogenesis relation in renal cortical tubules, 742-743
- NADPH (nicotinamide adenine dinucleotide phosphate) oxidase, effects of, insulin-stimulated glucose disposal, 709
- L-NAME (L- ω -nitro-L-arginine methyl ester), effects of L-NNA and, on skeletal muscle and jejunal protein synthesis, role of alcohol in, 397-401
- Nateglinide, effects of rosiglitazone and, on insulin secretion and phospholipase C activation, compared, 1393-1399
- Native Americans (American Indians), alcohol intake and glycemia in, 129-135
- Natriuretic response to central volume expansion in primary aldosteronism, K supplementation effects on, 1597-1600
- NE, *see* Norepinephrine
- NEFAs (nonesterified fatty acids), *see* Free fatty acids
- Nephropathy, diabetic, *see* Diabetic nephropathy
- Nervous blockade, effects of, on IMGU, 413-417
- Nervous system
 central, in aging, role glucocorticoids in, S2:11
 sympathetic, *see* Sympathetic nervous system
see also Nervous blockade and entries beginning with element: Neur-
- Net carbohydrate (CHO) storage, effects of glycogen level and ingested glucose on, 94-101
- Neuropathy, cardiac autonomic, *see* Cardiac autonomic neuropathy in DM
- Neuropeptide Y (NPY) gene, FFA metabolism regulated by Leu7Pro polymorphism of, 643-646
- Neutrophils, intracellular pH of, and Na⁺/H⁺ exchanger activity in pre-eclampsia, 87-93
- NF- κ B, *see* Nuclear factor- κ B
- NHE, *see* Na⁺/H⁺ exchanger
- Nicotinamide adenine dinucleotide phosphate (NADPH) oxidase, effects of, insulin-stimulated glucose disposal, 709
- Nicotine, effects of smokeless, on HTN, glucose tolerance, and insulin sensitivity in young subjects, 67-72
- Nicotinic acid (NA), relation of insulin resistance induced by, to circulating FFAs and AT oxidation but not to SM lipid content, 699-704
- NIDDM, *see* Non-insulin-dependent diabetes mellitus
- NIP-22, effects of, on urinary albumin excretion in STZ-DM, 1633-1637
- Nitric oxide (NO)
 effects of, on glucose uptake, 662-665
 and ornithine α -KG effects on insulin secretion, 344-350
- Nitric oxide (NO) (*Continued*)
 vascular, effects of, on atherogenic role of lysophosphatidylcholine in LDLs in DM, 308-314
- Nitric oxide synthase, *see* Endothelial nitric oxide synthase in ECs; Nitric oxide synthase gene
- Nitric oxide synthase (NOS) gene, 27-bp repeat polymorphism in intron 4 of endothelial constitutive, serum uric acid levels and, in Chinese NIDDM subjects, 1448-1453
- N(G)-Nitro-L-arginine (L-NNA), effects of L-NAME and, on skeletal muscle and jejunal protein synthesis, role of alcohol in, 397-401
- L- ω -Nitro-L-arginine methyl ester (L-NAME), effects of L-NNA and, on skeletal muscle and jejunal protein synthesis, role of alcohol in, 397-401
- Nitrogen (N), oral lysine supplementation effects on, in lysine intolerance, 937
- Nitrogen (N) species, reactive, glycated HDL regulation of ROS and, in HAECs, 42-49
- NMR, *see* Nuclear magnetic resonance spectroscopy
- L-NNA [N(G)-nitro-L-arginine], effects of L-NAME and, on skeletal muscle and jejunal protein synthesis, role of alcohol in, 397-401
- NO, *see* Nitric oxide
- NO-1886 (ibrolipim), effects of, on expression of FA oxidation-related enzymes, 1547-1550
- Non-apolipoprotein B (apo B)-containing lipoproteins (Lps), PP apo A-IV distribution between apo B and, in obese women, 1537-1541
- Nondiabetic subjects
 with ESRD, HD-induced Lp alterations in, 116-121
 obese, plasma SSAO as CV disease risk factor in, 688-692
 PPAR γ Pro12Ala polymorphism associated with oxidized LDL and cardioprotein autoantibodies in, 213-217
- Nonesterified fatty acids, *see* Free fatty acids
- Non-insulin-dependent diabetes mellitus (NIDDM; type 2 diabetes mellitus), 213-217
 atherosclerosis in, *see* Atherosclerosis in NIDDM; Carotid atherosclerosis in NIDDM
 Caipo mode of action in, 875-880
 in Chinese subjects, 27-bp repeat polymorphism in intron 4 of ECNOS gene and serum uric acid levels in, 1448-1453
 with CV disease, *see* Non-insulin-dependent diabetes mellitus, risk for CV disease in
 early-onset, *see* Early-onset non-insulin-dependent diabetes mellitus
 enteroinsular axis and DPPIV inhibition in, 81-86
 exercise in, *see* Exercise in NIDDM
 first-degree relatives of subjects with, *see* First-degree relatives of NIDDM subjects
 glucose tolerance in, *see* Glucose tolerance in NIDDM
 glycemic control in, *see* Glycemic control in NIDDM
 insulin resistance in, *see* Insulin resistance in NIDDM
 insulin sensitivity in, *see* Insulin sensitivity in NIDDM
 in Japanese subjects, *see* Japanese subjects, NIDDM
 metformin in, *see* Metformin in NIDDM
 microvascular complications of, *see* Microvascular complications in NIDDM with CV disease
 with nephropathy and macroangiopathy, plasma Hcy and plasma TM in, 1517-1522
 in non-obese subjects, *see* Non-obese subjects, NIDDM
 with obesity, *see* Non-insulin-dependent diabetes mellitus with obesity
 parental, and risk of metabolic syndrome from childhood to young adulthood in offspring, 443-453

- Non-insulin-dependent diabetes mellitus (NIDDM; type 2 diabetes mellitus), 213-217 (*Continued*)
 platelet Na^+/H^+ exchanger and phospholipid-dependent procoagulation activity in, 102-106
 PPAR γ Pro12Ala polymorphism associated with oxidized LDL and cardiolipin autoantibodies in, 213-217
 with retinopathy, *see* Diabetic retinopathy, NIDDM
 risk for, *see* Risk for NIDDM
 rosiglitazone effects of serum Lp(a) in Korean subjects with, 731-734
 serum methylglyoxal-derived hydroimidazolone level in, 163-167
 skeletal muscle in, *see* Skeletal muscle in NIDDM
 TNF- α in, *see* Tumor necrosis factor- α in NIDDM
 troglitazone in, *see* Troglitazone in NIDDM
 24-hour profile of circulating glycated insulin in, food intake effects on, 631-635
 uncomplicated well-controlled, relation of LVDD and CAN to preclinical diabetic cardiomyopathy in men with, 1056-1061
see also Streptozotocin-induced diabetes mellitus
- Non-insulin-dependent insulin diabetes mellitus (NIDDM; type 2 diabetes mellitus), risk for CV disease in, S1:34
 ADMA and, 303-307
 ADVANCE prevention of, S1:24-28
 AT distribution in lean and obese NIDDM Thai women and, 1444-1447
 gliclazide for, *see* Gliclazide in NIDDM with CV disease
 introduction to, S1:1-2
 ischemia in, *see* Coronary artery disease in NIDDM
 multifactorial intervention in, S1:19-23
 sulfonylureas for, *see* Gliclazide in NIDDM with CV disease
- Non-insulin-dependent diabetes mellitus (NIDDM; type 2 diabetes mellitus) with obesity
 daylong and fasting TGs in, 1043-1049
 influence of microangiopathic complications, obesity, and duration of, on CAN, 815-820
 in obese NIDDM children, intracellular platelet Mg and, 468-471
 in Thai women, abdominal AT in, 1444-1447
- Non-insulin-induced hypoglycemia, portal vein insulin decrease and alpha-cell responses to, 1418-1425
- Noninvasive management of ACS in NIDDM with CV disease, invasive versus, S1:9
- Non-obese (lean) subjects
 adiponectin expression in, 959
 adiponectin gene mutations in, 881-884
 American Indian, relationship between alcohol intake and glycemia in, 132, 133
 with PAI-1-associated insulin resistance, 226-229
see also Non-obese women
- Non-obese (lean) subjects, NIDDM
 with relatively preserved insulin secretion, 1038-1043
 Thai women, abdominal AT in, 1444-1447
see also Japanese subjects, NIDDM non-obese
- Non-obese (lean) women
 effects of high-fat and/or high-CHO diet, on cardiac autonomic nervous system activity in obese women and, compared, 1426-1432
 NIDDM Thai, abdominal AT in, 1444-1447
- Nonthyroidal illness, decline in serum T_3 in, due to hysterectomy, L-T_4 effects on, 1307-1312
- Norepinephrine (NE; noradrenaline)
 in hepatic insulin resistance with obesity, BDNF effects on, 205
 leptin effects on response of, to insulin-induced hypoglycemia, 1484-1490
 plasma, *see* Plasma norepinephrine
- Norepinephrine (NE; noradrenaline) (*Continued*)
 response of, to insulin-induced hypoglycemia after massive weight loss by severely obese subjects, 900-907
- Normal cholesterol (C), obesity with, serum DHEAS and serum leptin in, 379-381
- Normal glucose tolerance
 in African-American NIDDM subjects, chronic GITS metabolic effects on insulin secretion, insulin sensitivity, serum glucose, and hepatic insulin extraction in glucose-tolerant first-degree relatives of, 565-572
 in insulin resistance associated with hypertriglyceridemia, 616-619
 physiological changes in circulating mannose levels in, 1019-1027
- Normolipidemia with CAD, atorvastatin effects on apo B-48 metabolism and LDL receptor activity in, 1279-1286
- Normoponderal subjects, *see* Non-obese subjects
- NPY (neuropeptide Y) gene, FFA metabolism regulated by Leu7Pro polymorphism of, 643-646
- Nuclear factor- κB (NF- κB)
 DNA-binding activity for, in ELAM-1, ICAM-1, and VCAM-1 in NIDDM with CV disease, S1:16
 in ECs, effects of cholesterol on linoleic acid-induced activation of, 495
- Nuclear magnetic resonance (NMR) spectroscopy
 Lp profile in hyperlipidemia measured with, 916-921
 metabolomic mapping of vitamin with F-ASA and, in DM, 760-770
- Nutritional status, effects of, on oral glucose metabolism, 95-98
- Obesity
 adiponectin expression in, 959
 adiponectin gene mutations in, 881-884
 ASP in, 1360-1366
 body composition in, *see* Fat mass in obese subjects; Lean body mass in obesity
 central, ACE DD genotype, circulating E-selectin, and CV damage in, 999-1004
 cholesterol in, *see* Obesity, cholesterol in
 effects of CLA interaction with α -lipoic acid on insulin action in, 1167-1174
 exercise effects on, *see* Obesity, exercise effects on
 fasting and daylong TGs in, without NIDDM, 1043-1049
 in IDDM, *see* Insulin-dependent diabetes mellitus, obesity in
 insulin resistance in, *see* Insulin resistance in obesity
 leptin release regulation by insulin, G_i -coupled receptor agonists, glucocorticoids, and pertussis toxin in adipocytes and AT in, 60-68
 metabolic syndrome and, and high-insulinogenic diet, 840-844
 morbid, *see* Morbid obesity
 in MS with liver dysfunction and, 1097, 1098
 in NIDDM, *see* Non-insulin-dependent diabetes mellitus with obesity
 nondiabetic subjects with, plasma SSAO and risk for CV disease in, 688-692
 rosiglitazone effects on muscle S_i irrespective of TG content in, 1078-1083
 weight loss in, *see* Weight loss by obese subjects
see also Men, obese; Women, obese
- Obesity, cholesterol in
 disturbed cholesterol synthesis effects on monocytes in hypercholesterolemic obesity, 1-6
 serum DHEAS and serum leptin in obesity with normal cholesterol, 379-381
- Obesity, exercise effects on
 glucose and insulin responses to 16 months of exercise in young adults, 1175-1181

- Obesity, exercise effects on (*Continued*)
 see also Men, obese, exercise effects on
- OC, *see* Osteocalcin, BMD and
- Offspring, 443-462
 gestational alcoholism and glucose tolerance in, 454-462
 with NIDDM parents, risk of insulin resistance syndrome from childhood to young adulthood in, 443-453
 pre-pregnancy restricted-protein diet effects on vital organs of, 13-18
 see also Children
- OGTT, *see* Oral glucose tolerance test
- OHB, *see* 3-Hydroxybutyrate
- β -OHB (beta-hydroxybutyrate), concentrations of, after recovery from anorexia nervosa, 297
- 1,25(OH)₂D₃ (vitamin D₃), and BMD in chronic pancreatitis, 579-584
- 25(OH)D (25 hydroxyvitamin D), estrogen receptor α gene and collagen IA1 gene effects on relation of PTH and, to BMD in PM women, 1129-1135
- 25(OH)D₃ (25 hydroxyvitamin D₃), and BMD in chronic pancreatitis, 579-584
- 8-OHdG (8-hydroxy-2'-deoxyguanosine) in exacerbated pediatric atopic dermatitis, 1601-1603
- Oil
 corn, in short-term hydrolyzed casein-based diet, 334
 functional, containing MCTs, phytosterols, and n-3 FAs, effects of supplementation with, on cardiovascular risk in obese women, 771-777
 olive, atorvastatin effects on sucrose-induced postprandial hypertriglyceridemia after ingestion of, 609-617
- OKG (ornithine α -ketoglutarate), NO and glutamine involvement in insulin secretion induced by, 344-350
- Older (elderly) subjects
 abdominal AT or age effects on insulin action, 850-857
 apo E genotype-dietary fat intake interaction in, 279-281
 determinants of insulin secretion in, after renal transplantation in older subjects, 573-578
 effects of GH, abdominal VAT, fitness, and insulin on lipids and Lps in, 73-80
 IGF-1 effects in, *see* Insulin-like growth factor-1 in older subjects
 older women, IGF-1 effects on glucose kinetics or insulin sensitivity in, 1182-1190
 see also Aging
- Oleate/palmitate, effects of different types and amounts of Fas on PP secretion of, in chylomicrons, 515-516
- Olive oil, atorvastatin effects on sucrose-induced PP hypertriglyceridemia after ingestion of, 609-617
- Omega (ω)-3 polyunsaturated fatty acid(s) (PUFAs)
 effects of, FcTO containing MCTS, phytosterols and, on CV disease risk in obese women, 771-777
 EPA as, effects of, on skeletal muscle lipid accumulation and insulin resistance in NIDDM, 30-34
- Once-daily use of gliclazide MR for CV disease in NIDDM, S1:29
- Ophthalmopathy, Graves', RA- and 4HPR-induced growth arrest and apoptosis of orbital fibroblasts in, 1387-1392
- Oral (ingested) glucose
 effects of glycogen level and, on net CHO storage, 94-101
 see also Oral glucose tolerance test
- Oral glucose tolerance test (OGTT)
 acromegaly remission assessed with, 181-185
 of at-risk subjects for NIDDM, 1213
 of exercising young obese adults, 1177
 of glycogen level and ingested glucose effects on net CHO storage, 94-101
- Oral glucose tolerance test (OGTT) (*Continued*)
 long-term effects of high-fiber diet on, 1207
 in NIDDM, *see* Oral glucose tolerance test in NIDDM
 of plasma cortisol, cardiovascular risk prediction with, 524-527
 of PPAR γ ₂ Pro12Ala effects on insulin clearance, 778-783
 of smokeless nicotine effects, 67-72
 see also Glucose tolerance
- Oral glucose tolerance test (OGTT) in NIDDM
 of Caipo effects, 877-879
 in Japanese subjects with IGT, 476-481
- Oral lysine supplementation for lysine intolerance, 935-938
- Orbital fibroblasts in GO, RA- and 4HPR-induced growth arrest and apoptosis of, 1387-1392
- Organ weight
 in DM, metabolomic mapping of vitamin C and, 762
 heart, bosentan effects on renal AVP V₂ receptor and, 1142
 liver, and glutamine effects on protein and amino acid metabolism in hepatic tissue, 1063, 1064
 of offspring, effects of pre-pregnancy protein-restricted diet on, 15, 16
- Ornithine α (alpha)-ketoglutarate (OKG), NO and glutamine involvement in insulin secretion induced by, 344-350
- Osteocalcin (OC), BMD and
 in chronic pancreatitis, 579-581
 in PM women, estrogen receptor gene α and collagen IA1 gene effects on relation of 25(OH)D and PTH to, 1131, 1132
- OTZ (2-oxo-4-thiazolidinecarboxylic acid), effects of, on GSH redox state- gluconeogenesis relation in renal cortical tubules, 742-743
- Ovariectomy, effects of, on insulin resistance in apo B, 659-661
- Overweight, *see* Obesity
- Oxidase
 NADPH, effects of, insulin-mediated glucose uptake, 709
 plasma semicarbazide-sensitive amine and risk for CV disease nondiabetic obese subjects, 688-692
- Oxidation
 dietary fat, dietary protein, and glycogen, ingested glucose effects on 96, 97
 of FAs, *see* Oxidation, FA
 glucose, and FFA metabolism regulation by NPY gene Leu7Pro polymorphism, 644
 IMGU and adipocyte PTPase, and insulin-induced inhibition of, 705-712
 kinetics of F-ASA degradation and, 762, 764
 LDL susceptibility to, in heavy smokers, grape seed extract effects on, 1250-1257
 palmitate, 1369
 see also Oxidation, AT; Oxidation, CHO; Oxidative stress; Redox state and entries beginning with term: Oxidized
- Oxidation, AT
 effects of running and/or cycling on, 747-752
 relation of NA-induced insulin resistance to circulating NEFAs and, but not to SM lipid content, 699-704
- Oxidation, CHO
 low-dose glyburide effects on, 410, 411
 TEE and, in HIV lipodystrophy syndrome, 620-625
- Oxidation, FA
 ibrolipim effects on mRNA enzymes related to, 1547-1550
 SM FAs in morbidly obese black and white women, 735-738
- Oxidative stress
 hyperglycemia-induced hepatic, systemic inflammation but not activation of hepatic STAT3 or MAPK due to, 868-874
 intracellular modulation of free radical production and metformin effects on, 586-589

- Oxidative stress (*Continued*)
 and urinary excretion of pentosidine in children with acute exacerbation of atopic dermatitis, 1601-1605
- Oxidized low-density lipoprotein (ox-LDL)
 autoantibodies to, PPAR γ Pro12Ala polymorphism associated with cardiolipin autoantibodies and, in nondiabetics and in NIDDM, 213-217
 glialazipide effects on monocyte adhesion to ECs induced by, in NIDDM with CV disease, S1:15
- Oxidized low-density lipoprotein-cholesterol (LDL-C) in hyperlipidemia, 1192, 1193
- oxLDLs, *see* Oxygenated low-density lipoproteins
- Oxysterol 7 α -hydroxylase (CYP7B1), regulation of, 636-642
- P (phosphorus) in PHP, 160
- PAI (plasminogen activator inhibitor), recurrent pregnancy loss associated with G1691A factor V Leiden mutation, PCOS, and activity of, 1627-1632
- PAI-1 (plasminogen activator inhibitor-1), insulin resistance associated with, in non-obese Japanese subjects, 226-229
- Palmitate
 GSIS potentiated by, 2-bromopalmitate in study of, 1367-1371
 oxidation of, in morbidly obese women, 736
- Palmitate/oleate, retinyl, effects of different types and amounts of Fas on PP secretion of, in chylomicrons, 515-516
- Palmitoyl-carnitine, oxidation of, in morbidly obese women, 736
- Palmitoyl-CoA (coenzyme A), oxidation of, in morbidly obese women, 736
- Pancreas, offspring
 effects of gestational alcoholism on, 456-458
 effects of pre-pregnancy protein-restricted diet on weight of, 15
- Pancreatic cells, *see* Alpha cells; Beta cell(s)
- Pancreatic islet mitochondria metabolites, study of anaplerosis in insulin secretion with, 993-998
- Pancreatic peptides, response of, to intra-arterial Ca stimulation test in detection of insulinomas, 1320-1329
- Pancreatic polypeptide (PAP)
 glycogen phosphorylase inhibitor effects on, 1422
 response of, to insulin-induced hypoglycemia after massive weight loss by severely obese subjects, 900-907
- Pancreatitis, chronic, BMD and, 579-585
- PAP, *see* Pancreatic polypeptide
- Paraoxonase (PON), effects of light alcohol intake on, by upregulation of liver mRNA, 1287-1294
- Paraoxonase (PON)-high-density lipoprotein (HDL), effects of homocysteinylation on activity of, 146-151
- Parathyroid hormone (PTH)
 and BMD in chronic pancreatitis, 579-581, 584
 estrogen receptor α receptor gene and collagen IA1 gene effects on relation of 25(OH)D $_3$ and, to BMD in PM women, 1129-1135
 intact, in PHP, 160
 primary hyperparathyroidism, plasma AM in, 159-162
- Parents, NIDDM, and risk of insulin resistance syndrome from childhood to young adulthood in offspring of, 443-453
- Particle size of LDLs
 adipocyte-derived plasma adinoplectin concentrations associated with MS and small-dense, 1612-1614
 ADRB3 Trp64Arg polymorphism effects on, 356-361
 effects of PP variations in triglyceridemia on, 1379-1386
 exercise effects on, 439
trans FA intake and, in Costa Rican population, 693-698
 in NIDDM, glycemic control effects on, 1576-1578
- PCOS, *see* Polycystic ovary syndrome
- PDGF (platelet-derived growth factor), methylallyl thiosulfate effects on insulin-potentiated VSMC migration stimulated by, 254-259
- Pentosidine, urinary excretion of, in children with acute exacerbation of atopic dermatitis, oxidative stress and, 1601-1605
- PEPCK (phosphoenol pyruvate carboxykinase) mRNA (messenger ribonucleic acid) obesity with hepatic insulin resistance, BDNF effects on, 205
- Peptides, *see specific peptides*
- Peripheral tissue insulin resistance, obesity effects on FFA-induced, 233-238
- Peroxidase, glutathione, restricted diet effects on sarcolemmal lactate transport and, 325
- Peroxisome proliferator-activated receptor (PPAR)
 effects of activators of, on mRNA of genes involved in primary monocyte-derived macrophage lipid metabolism, 652-657
see also Pro12Ala polymorphism of PPAR γ ; Pro12Ala polymorphism of PPAR γ_2 and *specific PPAR agonists*; for example: NIP-222, Troglitazone
- Pertussis toxin, leptin release in adipocytes and AT in obesity regulated by insulin, G $_i$ -coupled receptor agonists, glucocorticoids and, 60-68
- P53 protein, levels of, during RA and 4HPR therapy of GO, 1391
- PFK (6-phosphokinase), effects of restricted diet on sarcolemmal lactate transport and, 325
- pH, neutrophil intracellular, and Na $^+$ /H $^+$ exchanger activity in pre-eclampsia, 87-93
- Pharmacodynamics, changes in, in aging, S2:28-30
- Pharmacokinetics
 changes in, in aging, S2:27-28
 tramadol, and CYP2D6 mutation, 1439-1443
- Phe, *see* Phenylalanine
- Phenotypes of glucose and insulin metabolism, 246-253
- Phenylalanine (Phe)
 brain, effects of acute exposure to alcohol on synthesis of, 391
 glutamine effects on metabolism of, in hepatic tissue, 1064
- Phenylephrine, and α -adrenergic blocker effects on catecholamine response to high-altitude exercise, 1472
- Pheochromocytoma-12 cells, effects of high glucose concentrations on dopamine release by, 922-926
- Phosphatase
 adipocyte protein-tyrosine, IMGU and insulin-induced oxidative inhibition and, 705-712
 alkaline, *see* Alkaline phosphatase
 mRNA of glucose-6-, in hepatic insulin resistance with obesity, 205
- Phosphate, *see* ATP; cAMP; Disodium ascorbyl phytostanyl phosphate; Glycerol-3-phosphate; Nicotinamide adenine dinucleotide phosphate oxidase
- Phosphatidylinositol 3-kinase (PI3-K)
 and captopril effects on phosphorylation of IRS-1 in BC3H-1 myocytes, 274-275
 and ceramide effects on insulin-induced PKC ζ translocation in adipocytes, 19-24
 effects of β -estradiol and IGF-1 on phosphorylation of p85 subunit of, 482-487
 effects of high-fat diet and leptin on skeletal muscle insulin-stimulated glucose transport and activity of, 1196-1205
- Phosphoenol pyruvate carboxykinase (PEPCK) mRNA (messenger ribonucleic acid) in hepatic insulin resistance with obesity, 205
- 6-Phosphokinase (PFK), and effects of restricted diet on lactate transport, 325

- Phospholipase A₂ (PLA₂), effects of, on atherogenic role of lysophosphatidylcholine in LDLs in DM, 308-314
- Phospholipase C (PLC), effects of nateglinide and rosiglitazone on activation of, compared, 1393-1399
- Phospholipids (PLs)
GHR effects on, in hypopituitarism, 56
platelet Na⁺/H⁺ exchanger and procoagulation activity in NIDDM dependent on, 102-106
- Phosphorus (P) in PHP, 160
- Phosphorylase inhibitor, effects of glycogen, on portal vein insulin, 1418-1425
- Phosphorylation
MAPK, in liver cells, insulin and ATP effects on, 592, 593
p85 subunit of PI3-K, effects of β -estradiol and IGF-1 on, 482-487
see also Insulin receptor phosphorylation
- PHP (primary hyperparathyroidism), plasma AM in, 159-162
- Physical exercise, *see* Exercise
- Physiological changes in circulating mannose levels in normal glucose tolerance, glucose intolerance, and DM, 1019-1027
- Phytosterols
combined with soy protein, viscous fiber, and almonds for hypercholesterolemia, 1478-1483
effects of margarine-enriched, on blood lipids, platelet function, and fibrinogen level in young men, 1373-1378
effects of supplementation with FcTO containing MCTs, on PUFAs and, on cardiovascular risk in obese women, 771-777
- PI3-K, *see* Phosphatidylinositol 3-kinase
- Pituitary, *see* Hypopituitarism and specific pituitary hormones
- PKC ζ , *see* Protein kinase C ζ
- PL(s), *see* Phospholipids
- PLA₂ (phospholipase A₂), effects of, on atherogenic role of lysophosphatidylcholine in LDLs in DM, 308-314
- Placenta, effects of pre-pregnancy protein-restricted diet effects on weight of, 15
- Plant sterols, *see* Phytosterols
- Plasma adipopectin, concentrations of adipocyte-derived, associated with MS and small-dense LDL particles, 1612-1614
- Plasma adrenomedullin (AM) in PHP, 159-162
- Plasma alanine (Al) in HIV infection with lipodystrophy, 1346
- Plasma aldosterone
in primary aldosteronism, 1598
in salt-sensitive HTN, 509
- Plasma amino acids, oral lysine supplementation effects on, in lysine intolerance, 936-937
- Plasma aminothiols, effects of FcTO supplementation on, 775
- Plasma apolipoprotein A-I (apo A-I), exercise effects on, 439
- Plasma β (beta)-carotene in heavy smokers, grape seed extract effects on, 1255
- Plasma catecholamines in recurrent VVS, 317-318
- Plasma cholesterol (C)
effects of FM-VP4 on atherosclerotic lesion formation and, in apo E deficiency, 425-431
fenofibrate effects on, and resistin expression in AT, 351-355
total, *see* Total plasma cholesterol
- Plasma citrulline, gluconeogenesis and response of, to arginine, 1512-1516
- Plasma cortisol (hydrocortisone)
glycogen phosphorylase inhibitor effects on, 1422
in HIV infection with lipodystrophy, 1346
prediction of cardiovascular risk due to, with OGTT, 524-527
- Plasma C-peptides (CPs; connecting peptides)
in HIV infection with lipodystrophy, 1346, 1351
massive weight loss effects on, 901
- Plasma C-peptides (CPs; connecting peptides) (*Continued*)
in older subjects, insulin action and, 853, 854
- Plasma C-reactive proteins (CRPs) in hypoalbuminemia and hyperalbuminemia, 432-436
- Plasma dipeptidyl peptidase IV (DPP-IV), DPP-IV inhibition effects on, in NIDDM, 82
- Plasma endothelin (ET), and bosentan effects on renal AVP V₂, 1142
- Plasma epinephrine (adrenaline)
 α -adrenergic blocker effects on response of, to high-altitude exercise, 1471-1477
glycogen phosphorylase inhibitor effects on, 1422
and massive weight loss effects on response of, to insulin-induced hypoglycemia and on cognitive function, 901, 902
- Plasma fatty acids (FAs)
response of, to central volume expansion in salt-sensitive hypertension, 508-513
see also Plasma free fatty acids in insulin resistance
- Plasma free fatty acids (FFAs; nonesterified acids)
glycogen phosphorylase inhibitor effects on, 1423
see also Plasma free fatty acids in insulin resistance
- Plasma free fatty acids (FFAs; nonesterified acids) in insulin resistance
fasting, and hyperglycemia reversal effects on insulin-resistant adipocytes, 240
in FFA-induced peripheral tissue insulin resistance, 235
- Plasma galanin (Gal), response of, to head-up tilt in recurrent VVS, 315-321
- Plasma ghrelin, AT, insulin resistance and, in men, smoking and, 1460-1463
- Plasma glucose
and CV disease risk prediction, 525
dietary fat effects on, 536
fasting, *see* Fasting plasma glucose
in FFA-induced peripheral tissue insulin resistance, 234, 235
in hyperlipidemia, 919
in NIDDM, *see* Fasting plasma glucose in NIDDM
in non-insulin-induced hypoglycemia, 1419-1420
in older subjects, 853, 854
rosiglitazone effects on, 1080
steady-state, insulin resistance in HIV-positive subjects measured with, 858-861
in STZ-DM, and effects of apo C-III deficiency on hypertriglyceridemia development, 1355
- Plasma glycine (Gly), and vitamin B₁₂ effects on Hcy and MMA in hyperhomocysteinemic ESRD, MTHFR genotype and, 168-172
- Plasma growth hormone (GH), age-dependent liver thyroid status adaptation and, 1118
- Plasma high-density lipoprotein (HDL), prebeta-1, exercise effects on, 437-442
- Plasma high-density lipoprotein-cholesterol (HDL-C)
exercise effects on, 439
in HIV infection with lipodystrophy, 1346, 1351
in NIDDM, EPA effects on, 31
total fasting, in obese women, weight loss effects on, 602
- Plasma homocysteine (Hcy), plasma TM and, in NIDDM with nephropathy and macroangiopathy, 1517-1522
- Plasma insulin
adipocyte-derived plasma adipopectin and, 1613
adult, effects of malnutrition in first year of life on, 1005-1011
age-dependent liver thyroid status adaptation and, 1118
and CV disease risk prediction, 525
dietary fat effects on, 536

- Plasma insulin (*Continued*)
 fasting, *see* Fasting plasma insulin
 in FFA-induced peripheral tissue insulin resistance, 235
 in older subjects, 853, 854
 plasma ghrelin and, 1461
see also Plasma insulin in NIDDM
- Plasma insulin in NIDDM
 and troglitazone effects on endothelial function, 175, 177
see also Fasting plasma insulin in NIDDM
- Plasma lipids
 apo E polymorphism effects on response of, to high-fat CHO and high-MUFA diet, 1454-1459
 EPA effects on, in NIDDM, 31
 exercise effects on, 439
 fasting, in obese PM women, effects of weight loss on, 602
 GHR effects on, 53-54
 HRT effects on, 1331-1332
 in hypercholesterolemia, doxazosin effects on, 1241
 hyperlipidemia effects on profile of, 919
see also specific lipids
- Plasma low-density lipoprotein-cholesterol (LDL-C)
 exercise effects on, 439
 total, in obese PM women, weight loss effects on, 602
- Plasma lycopene in heavy smokers, grape seed extract effects on, 1255
- Plasma membrane, liver, in STZ-DM, intravesicular glucose modulation of Mg transport in, 1464-1470
- Plasma norepinephrine (NE; noradrenaline)
 α -adrenergic blocker effects on response of, to high-altitude exercise, 1471-1477
 glycogen phosphorylase inhibitor effects on, 1422
- Plasma pancreatic polypeptide (PAP), glycogen phosphorylase inhibitor effects on, 1422
- Plasma proinsulin in older subjects, insulin action and, 853
- Plasma renin activity (PRA)
 and 17 α -hydroxylase/17,20 lyase deficiency, 489
 in primary aldosteronism, 1598
 in salt-sensitive HTN, 509
- Plasma retinol in heavy smokers, grape seed extract effects on, 1255
- Plasma thrombomodulin (TM), plasma Hcy and, in NIDDM with nephropathy and macroangiopathy, 1517-1522
- Plasma tocopherol (vitamin E) in heavy smokers, grape seed extract effects on, 1255
- Plasma triglycerides (TGs)
 exercise effects on, 439
 fasting, *see* Fasting plasma triglycerides in obesity
 FM-VP4 effects on, in apo E deficiency, 426, 427
 in HIV infection with lipodystrophy, 1346, 1347, 1351
 short-term rosiglitazone effects on, in obesity with insulin resistance, 220
 in STZ-DM, and effects of apo C-III deficiency on hypertriglyceridemia development, 1355
 total, in hyperlipidemia, 919
see also Plasma triglycerides in NIDDM
- Plasma triglycerides (TGs) in NIDDM
 dietary fat effects on, 1035, 1036
 EPA effects on, 31
 with obesity, fasting and daylong TGs and, 1045
- Plasminogen activator inhibitor (PAI), recurrent pregnancy loss associated with G1691A factor V Leiden mutation, PCOS, and activity of, 1627-1632
- Plasminogen activator inhibitor-1 (PAI-1), insulin resistance association with, in non-obese Japanese subjects, 226-229
- Plasticity, developmental, as SNS response to fasting in adipose tissue, 1621-1626
- Platelet-derived growth factor (PDGF), methylallyl thiosulfate effects on insulin-potentiated VSMC migration stimulated by, 254-259
- Platelet function, effects of margarine-enriched phytosterols on blood lipids, fibrinogen level and, in young men, 1373-1378
- Platelet magnesium (Mg), intracellular, in obese IDDM and/or NIDDM children, 468-471
- Platelet Na⁺/H⁺ exchanger (NHE), and phospholipid-dependent procoagulation activity in NIDDM, 102-106
- PLC (phospholipase C), effects of nateglinide and rosiglitazone on activation of, compared, 1393-1399
- Pleiotropic genetic effects between adipose tissue and SHBG concentrations before and after 20-week exercise program, 35-41
- PM women, *see* Bone mineral density in PM women; Estrogen with MPA in PM women; Postmenopausal women, race and ethnicity of *and entries beginning with term*: Postmenopausal
- Pneumonitis, dysphagia with aspiration, in Alzheimer's disease, S2: 36-38
- Point mutation of molybdenum cofactor sulfurase gene in xanthinuria type II, 1501-1504
- Polycystic ovary syndrome (PCOS)
 effects of insulin resistance and obesity on, 713-719
 with metabolic syndrome, 908-915
 recurrent pregnancy loss associated with G1691A factor V Leiden mutation, PAI activity and, 1627-1632
- Polymorphism
 ADRB3 Trp64Arg, *see* β_3 -Adrenergic receptor Trp64Arg polymorphism
 apo E, effects of, on plasma lipid response to high-CHO diet and high-MUFA diet, 1454-1459
 aromatase Arg²⁶⁴Cys, effects of interaction between VDR polymorphism and, on BMD of PM African-American women, 521-523
 effects of interaction between HL gene C-514T, and of LPL gene S447X, on serum TGs in young adults, 1337-1342
 endothelial lipase, HDL-C response to exercise dependent on, 1505-1511
 LPL *HindIII* gene, lipid levels associated with, in early-onset NIDDM, 338-343
 Met416Val muscle GS, insulin resistance in NIDDM associated with, 895-899
 NPY gene Leu7Pro, and FFA metabolism regulation by, 643-646
 Pro12Ala, *see* Pro12Ala polymorphism of PPAR γ ; Pro12Ala polymorphism of PPAR γ_2
 R219K, of serum TG and HCL-C ABCA1 gene, 930-934
 Taq1B, and Lp variations in Japanese subjects, CETP associated with, 1564-1570
 27-bp repeat, in intron 4 of ECNOS gene and serum uric acid levels in Chinese NIDDM subjects, 1448-1453
- Polypeptides
 gastric inhibitory, insulin secretory response to, in NIDDM first-degree relatives of NIDDM subjects, 1579-1585
see also specific polypeptides
- Polyunsaturated fatty acids (PUFAs)
 in high-fiber diet, 1207
 LDL size and intake of, 695, 696
 in margarine-enriched phytosterols, 1374
 omega-3, *see* Omega-3 polyunsaturated fatty acid(s)
- PON, *see* Paraoxonase; Paraoxonase-high-density lipoprotein
- Porphyromonas gingivalis, carotid atherosclerosis and, in non-obese Japanese NIDDM subjects, 142-145

- Portal vein insulin, effects of decreased, on alpha-cell responses to non-insulin-induced hypoglycemia, 1418-1425
- Postmenopausal women, *see* Bone mineral density in PM women; Estrogen with MPA in PM women; Postmenopausal women, race and ethnicity of *and entries beginning with term*: Postmenopausal
- Postmenopausal (PM) women, race and ethnicity of and adrenocortical responses to submaximal exercise, 1643-1647 and effects of interaction between VDR and aromatase Arg²⁶⁴Cys polymorphism of aromatase on, 521-523 insulin resistance syndrome relationship to cardiovascular disease and, 362-371 *see also* Postmenopausal women, race and ethnicity of, and AT distribution
- Postmenopausal (PM) women, race and ethnicity of, and AT distribution
- CETP and LCAT activities associated with total and regional AT distribution in, 282-289
- of subcutaneous and visceral AT, 186-191
- Postprandial (PP) apolipoprotein A-IV (apo A-IV) distribution between apo B- and non-apo B-containing Lps in obese women, 1537-1541
- Postprandial (PP) blood glucose of DM subjects with CAN, 816
- Postprandial (PP) C-peptides (Cps; connecting peptides) in young IDDM subjects, 27
- Postprandial (PP) hyperinsulinemia in obesity with MS, high-carbohydrate diet and, 841-842
- Postprandial (PP) hypertriglyceridemia (HTG), sucrose-induced, in olive oil-fed subjects, 609-617
- Postprandial (PP) leukocytes, increase of, in healthy subjects, 199-202
- Postprandial (PP) lipemia (lipidemia)
- in healthy and non-obese NIDDM subjects with relatively preserved insulin secretion, 1038-1043
- in obese men, effects of weight loss and, on LDL receptor binding and, 136-141
- prior exercise effects on, 418-424
- Postprandial (PP) retinoid, secretion of, in chylomicrons in response to different types and amounts of Fas, 514-519
- Postprandial (PP) triglyceride(s) (TGs) in hereditary HTG, 1408
- Postprandial (PP) triglyceridemia, effects of variations of, on LDL particle size, 1379-1386
- Postprandial distribution of apo A-IV between apo B- and non-apo B-containing Lps in obese women, 1537-1541
- Potassium, *see* K
- Potato starch, effects of raw, on butyrate formation in colon, colonocyte apoptosis and shift to stem cell compartment due to, 1400-1405
- PP, *see entries beginning with term*: Postprandial
- PPAR, *see* Peroxisome proliferator-activated receptor
- PRA, *see* Plasma renin activity
- Pramlintide, effects of, on A_{1c} and BW in controlled NIDDM, 1638-1642
- Preadipocytes, apoptosis of abdominal, before and after differentiation into adipocytes, 987-992
- Prebeta-1 high-density lipoprotein (HDL), plasma, exercise effects on, 437-442
- Preclinical diabetic cardiomyopathy in men with uncomplicated well-controlled NIDDM, relation of LVDD and CAN, 1056-1061
- Pre-eclampsia, neutrophil intracellular pH and activity of Na⁺/H⁺ exchanger activity in, 87-93
- Preformed vitamin A (retinol) supplementation, high-dose, effects of different types and amounts of Fas on retinoid secretion in chylomicrons after, 514-519
- Pregnancy
- effects of alcohol exposure during, on glucose tolerance in offspring, 454-462
- effects of protein-restricted diet prior to, on offspring's vital organs, 13-18
- neutrophil intracellular pH and activity of Na⁺/H⁺ exchanger activity in pre-eclampsia, 87-93
- primary hypothyroidism during, T₄ dose and, 122-128
- recurrent loss of, associated with PAI activity, PCOS, and factor V Leiden G1691A mutation, 1627-1632
- Pregnanetriol, rosiglitazone effects on urinary excretion of, 231
- Preterm infants, alanine and gluconeogenesis in, 945-949
- Prevalence of sarcopenia, frailty of the elderly and, S2:23-24
- Prevention of CV disease in NIDDM
- of CAD, S1:7-8
- secondary, S1:24-28
- Primary aldosteronism, K supplementation effects on natriuretic response to central volume expansion in, 1597-1600
- Primary defect, hyperinsulinemia as, in obesity with MS, 840
- Primary hyperalphalipoproteinemia, vascular damage in, 328-332
- Primary hyperparathyroidism (PHP), plasma AM in, 159-162
- Primary hypothyroidism during pregnancy, T₄ dose and, 122-128
- Primary monocyte-derived macrophages, effects of PPAR activators on mRNA levels of genes involved in lipid metabolism in, 652-657
- Prior exercise, effects of, on PP lipemia, 418-424
- Pro12Ala polymorphism of PPAR γ , 209-217
- associated with oxidized LDL and cardiolipin autoantibodies in nondiabetics and in NIDDM, 213-217
- and exercise-mediated changes in insulin-resistant men, 209-212
- Pro12Ala polymorphism of PPAR γ ₂, insulin clearance and, 778-783
- Procoagulation activity, PL-dependent, in NIDDM, platelet Na⁺/H⁺ exchanger and, 102-106
- Progesterone
- α -adrenergic blocker effects on, in high-altitude exercise, 1473
- and 17 α -hydroxylase/17,20 lyase deficiency, 489
- Proglucagon in NIDDM, DPPIV inhibition effects on, 83-84
- Proinsulin, plasma, in older subjects, insulin action and, 853
- Project management with WinSAAM, 1163-1165
- Proteasome, activity of, inhibited by amino acids, 810-814
- Protein
- acute effects of glutamine on metabolism of, in hepatic tissue, 1062-1067
- acylation-stimulating precursor, in AT of obese subjects, 1360-1366
- Ca²⁺-regulatory muscle, alcohol effects of, 1102-1112
- hepatic, IL-1ra effects on synthesis of, in sepsis, 1218-1225
- in high-fiber diet, 1207
- levels of Bcl-2 and p53 during RA and 4HPR therapy of GO, 1391
- MCP-1, in HASMCs, gliclazide effects on, in NIDDM with CV disease, S1:16
- sarcopenia and depletion of visceral, frailty in the elderly and, S2:22-26
- soy, combined with viscous fiber, almonds, and phytosterols for hypercholesterolemia, 1478-1483
- synergistic effects of testosterone and GH on body composition and metabolism of, in boys, 964-969
- see also* Cholesteryl ester transfer protein; C-reactive proteins; Dietary protein; Lipoprotein; Protein, alcohol effects on; Protein-3 gene expression; Protein kinase; Protein kinase C ζ ; Protein-tyrosine phosphatase; Proteinuria; Skeletal muscle protein *and specific proteins*
- Protein, alcohol effects on, 389-401

- Protein, alcohol effects on, 389-401 (*Continued*)
 on SM and jejunal, L-NAME and L-NNA effects on, 397-401
 synthesis of brain, acute alcohol exposure effects on, 389-396
- Protein-3 gene expression, uncoupling, acute endurance exercise effects on skeletal muscle, in untrained subjects, 152-158
- Protein kinase
 effects of, on AVP V_2 expression in IMCD, 293
see also Mitogen-activated protein kinase
- Protein kinase C ζ (PKC ζ)
 ceramide effects on insulin-induced translocation of, in adipocytes, 19-24
 exercise effects on activity of, NIDDM and, 1028-1033
- Protein-tyrosine phosphatase (PTPase), adipocyte, insulin-mediated glucose uptake, insulin-induced oxidative inhibition and, 705-712
- Proteinuria
 in pre-eclampsia, neutrophil intracellular pH and activity of Na⁺/H⁺ exchanger activity in, 88
see also Albuminuria in DM
- Protocols, experimental, simulating, with WinSAAM, 1155-1156
- Psychosocial effects of minimally invasive gastric banding for morbid obesity, 1551-1557
- PTH, *see* Parathyroid hormone
- PTPase (protein-tyrosine phosphatase), adipocyte, insulin-mediated glucose uptake and insulin-induced oxidative inhibition and, 705-712
- PUFAs, *see* Polyunsaturated fatty acids
- Pulsatile insulin delivery, effects of continuous and, on insulin action, compared, 1050-1055
- Pulse rate, *see* Heart rate
- Pyruvate, effects of, on pancreatic islet mitochondria metabolites, 995, 996
- QTc interval, serum leptin, and HDL-C associated with CRPs in young men, 1113-1116
- RA (all-*trans* retinoic acid), growth arrest and apoptosis of orbital fibroblasts induced by 4HPR and, in GO, 1387-1392
- Race and ethnicity
 alcohol intake-blood glucose relation in American Indian subjects, 129-135
 CRP relation to, 1542-1546
 and endothelial lipase genotype effects, 1507
trans FA intake and LDL size in Costa Rican subjects, 693-698
 of PM women, *see* Postmenopausal women, race and ethnicity of risk for CV disease and, 1295-1301
 R219K polymorphism of serum HDL-C and TG ABCA1 gene related to age, AT, and race, 930-934
 and TGZ effects on glucose metabolism subjects at risk for NIDDM, 1211-1217
see also Race and ethnicity of NIDDM subjects; Race and ethnicity of obese women
- Race and ethnicity of NIDDM subjects
 Chinese subjects, 27-bp repeat polymorphism in intron 4 of ECNOS gene and serum uric acid levels in, 1448-1453
 Japanese subjects, *see entries beginning with term:* Japanese
 Korean NIDDM subjects, rosiglitazone effects of serum Lp(a) in, 731-734
 lean Thai women, abdominal AT in, 1444-1447
 Lp content in apo A-I and apo A-I:A-II and risk for CHD, 1530-1536
 and metabolic effects of chronic glipizide GITS on serum glucose, hepatic insulin extraction, insulin sensitivity, and insulin secretion in glucose-tolerant first-degree relatives of, 565-572
- Race and ethnicity of NIDDM subjects (*Continued*)
 of well-controlled NIDDM subjects, pramlintide effects on A_{1c} and BW and, 1638-1642
- Race and ethnicity of obese women
 of morbidly obese women, SM FA oxidation in, 735-738
 Thai women, abdominal AT in, 1444-1447
- Rapamycin, effects of vanadate and, on insulin-mediated glucose uptake in SM, 666-674
- Raw potato starch, effects of, on butyrate formation in colon, colonocyte apoptosis and shift to stem cell compartment and, 1400-1405
- RBCs, *see* Red blood cells
- RCT (reverse cholesterol transport), exercise effects on, 950-957
- Reactive nitrogen species, glycated HDL regulation of ROS and, in HAECs, 42-49
- Reactive oxygen species (ROS), glycated HDL regulation of reactive nitrogen species and, in HAECs, 42-49
- Recovery from anorexia nervosa, metabolic and endocrine abnormalities after, 296-302
- Recurrent pregnancy loss associated with PAI activity, PCOS, and factor V Leiden G1691A mutation, 1627-1632
- Recurrent vasovagal syncope (VVS), plasma galanin response to head-up tilt in, 315-321
- Red blood cells (RBCs; erythrocytes)
 effects of supplementation with FcTO on FA content of, in obese women, 775
 in hypercholesterolemia, effects of phytosterols, viscous fibers, soy protein, and almonds on, 1480
- Redox state
 GSH, relation between gluconeogenesis and, in renal cortical tubules, 739-746
see also Oxidation
- Reductase, effects of methylenetetrahydrofolate reductase genotype on vitamin B₁₂ effects on MMA and Hcy in hyperhomocysteinemic ESRD, 168-172
- Regional adipose tissue (AT)
 associated with CETP and LCAT activities in PM women, ethnicity and, 282-289
see also Subcutaneous adipose tissue; Visceral adipose tissue
- Regulatory muscle proteins, Ca²⁺, alcohol effects on, 1101-1112
- Relatives, *see* First-degree relatives of NIDDM subjects
- Remission of acromegaly assessed with OGTT, 181-185
- Renal arginine-vasopressin (AVP; vasopressin) V_2 receptor, bosentan effects on, 1141-1146
- Renal cortical tubules, gluconeogenesis-GSH redox state in, 739-746
- Renal glucose, output of, in DM, 472-475
- Renal protein, IL-1ra effects on synthesis of, in sepsis, 1218-1225
- Renal transplantation in older subjects, determinants of insulin secretion after, 573-578
- Reproduction, role of glucocorticoids in, S2:11
- RER, *see* Resting energy expenditure
- Residual beta (β)-cell function in young IDDM subjects, relationship of autoantibodies to ICA512/IA-2 and GAD to, 25-29
- Resilience in aging, mediators of allostasis and allostatic load and, S2:10-16
- Resistin (FIZZ3)
 effects of gestational alcoholism on, in offspring, 456-457
 fenofibrate effects on plasma cholesterol and expression of, in AT, 351-355
- Respiratory quotient (RQ)
 EPA effects on, in NIDDM, 31
 of obese women on calorie-restricted diet, 464
- Resting energy expenditure (RER)
 BPD effects on, 552-558

- Resting energy expenditure (RER) (*Continued*)
 endurance exercise effects on, 154
 of obese women on calorie-restricted diet, 464
- Restricted diet, *see* Dietary restriction
- Restricted salt intake, effects of, on age-related changes in AT and liver lipogenesis, 1072-1077
- Retinal endothelial cells (ECs), high glucose effects on IGF-1-MAPK activation in, 547-551
- all-*trans* Retinoic acid (RA), growth arrest and apoptosis of orbital fibroblasts induced by 4HPR and, in GO, 1387-1392
- Retinoids, effects of different types and amounts of FAs on PP secretion of, in chylomicrons after high-dose preformed vitamin A supplementation, 514-519
- Retinol, *see* Vitamin A
- Retinopathy, diabetic, *see* Diabetic retinopathy, NIDDM
- Retinyl linoleate, effects of different types and amounts of FAs on PP secretion of, in chylomicrons, after high-dose preformed vitamin A supplementation, 516
- Retinyl palmitate/oleate and stearate, effects of different types and amounts of FAs on PP secretion of in chylomicrons, effects of different types and amounts of FAs on, 515-516
- Revascularization, myocardial, for stable NIDDM with CAD, S1:8-9
- Reverse cholesterol transport (RCT), exercise effects on, 950-957
- Ribonucleic acid, *see* mRNA
- Rice, long-term effects of high intake of, on glucose tolerance and lipid metabolism, 1206-1210
- Right skeletal muscle (SM), concentrations and metabolism of substrates in, 1571-1575
- Risk
 for coronary artery disease, *see* Risk for CAD
 for insulin resistance syndrome from childhood to young adulthood in offspring of NIDDM parents, 443-453
see also Cardiovascular disease, risk for; Risk for NIDDM
- Risk for CAD
 effects of diet composed of almonds, viscous fiber, soy protein, and phytosterols on risk for, 1480
 with NIDDM, therapeutic modification of, S1:7-8
- Risk for NIDDM
 for asymptomatic atherosclerosis in Japanese NIDDM subjects without diabetic microvascular complications, 1302-1306
 with CAD, therapeutic modification of, S1:7-8
 for development of NIDDM, insulin secretion in men at, after long- and short-term FFA infusions, 885-894
 troglitazone effects on glucose metabolism in subjects at risk for NIDDM, race and, 1211-1217
- Rodent models of aging genetics, S2:6
- ROS (reactive oxygen species), glycated HDL regulation of reactive nitrogen species and, in HAECs, 42-49
- Rosiglitazone, effects of
 on DHT and T production, in men, 230-232
 effects of nateglinide and, on insulin secretion and phospholipase C activation, compared, 1393-1399
 on muscle insulin sensitivity irrespective of TG content in obesity, 1078-1083
 potential adipogenic effects of, 1015
 on serum Lp(a) in Korean NIDDM subjects, 731-734
 short-term effects on IMC lipids in obesity with insulin resistance, 218-225
- RQ, *see* Respiratory quotient
- R219K polymorphism of serum HDL-C and TG ABCA1 genes related to age, AT, and race, 930-934
- Running, effects of cycling and/or, on AT oxidation, 747-752
- S, *see* Sucrose
- Safety of pramlintide, 1640-1641
- Salt intake, effects of restricted, on age-related changes in AT and liver lipogenesis, 1072-1077
- Salt-sensitive hypertension (HTN), plasma FA response to central volume expansion in, 508-513
- Sarcolemmal transport of lactate, restricted diet effects on, 322-327
- Sarcopenia, visceral protein depletion and, and frailty in the elderly, S2:22-26
- SAT, *see* Subcutaneous adipose tissue
- Saturated fatty acids (SFAs)
 in high-fiber diet, 1207
 LDL size and intake of, 695, 696
 in margarine-enriched phytosterols, 1374
- SBP (systolic blood pressure), *see* Blood pressure
- SC (subcutaneous) abdominal adipocytes, effects of 17 β -estradiol and ICI:compound 182,780 on HSL and LPL expression in, 383-388
- Secondary prevention of CV disease in NIDDM, S1:7-8, S1:24-28
- Sedentary subjects (untrained subjects), serum IGF-1, IGFBP-1, and IGFBP-3 level in, glucose disposal and, 821-826
- E-Selectin, circulating, ACE DD genotype, and CV damage in central obesity, 999-1004
- Semicarbazide-sensitive amine oxidase (SSAO), plasma, and risk for CV disease in nondiabetic obese subjects, 688-692
- Sepsis, effects of IL-1ra on SM, renal, and hepatic protein synthesis during, 1218-1225
- Serine447Stop (S447X) polymorphism of LPL gene, interaction effects of C-514T polymorphism of hepatic lipase gene and, on serum TGs in young adults, 1337-1342
- Serum albumin
 in diabetic and nondiabetic ESRD subjects, HD-induced changes in, 117
 in GDM, sHcy and, 721
- Serum cholesterol (C)
 in morbid obesity, 1551-1554
 plasma ghrelin and, 1461
- Serum C-peptide (CPs; connecting peptides) in hypoadinopectinemic Japanese NIDDM subjects, 1275
- Serum creatinine in DM
 in NIDDM with carotid atherosclerosis, beraprost sodium effects on, 195
 and in nondiabetic subjects, HD-induced changes in, 117
- Serum dehydroepiandrosterone sulfate (DHEAS), serum leptin and, in obesity with normal cholesterol, 379-381
- Serum folate in GDM, serum homocysteine and, 721
- Serum free fatty acids (FFAs; nonesterified fatty acids)
 and hepatic induction of mitochondrial and cytosolic acyl CoA hydrolases/thioesterases, 1527-1529
 in older subjects, insulin action and, 853, 854
- Serum glucose
 chronic glipizide GITS metabolic effects on insulin secretion, insulin sensitivity, hepatic insulin extraction and, in glucose-tolerant first-degree relatives of African-American NIDDM subjects, 565-572
 in diabetic and nondiabetic ESRD subjects, HD-induced changes in, 117
 fasting, PPAR γ_2 Pro12Ala polymorphism effects on, 780
 and hepatic induction of mitochondrial and cytosolic acyl CoA hydrolases/thioesterases, 1527-1529
- Serum growth hormone (GH)
 in acromegaly, 183
 effects of massive weight loss on, 901, 902
- Serum high-density lipoprotein-cholesterol (HDL-C)
 in NIDDM, in hypoadinopectinemic Japanese subjects, 1275

Serum high-density lipoprotein-cholesterol (HDL-C) (*Continued*)
 R219K polymorphism of ABCA1 gene of, related to age, AT, and race, 930-934

Serum homocysteine (sHcy) in GDM, 720-723

Serum insulin
 fasting, *see* Fasting serum insulin
 in obesity, adiponectin gene mutations and, 882

Serum insulin-like growth factor-1 (IGF-1)
 in acromegaly, 183, 184
 level of serum IGFBP-1 and -3 and, in exercising subjects and in sedentary subjects, glucose disposal and, 821-826

Serum insulin-like growth factor-1 (IGF-1) mRNA (messenger ribonucleic acid) in DM, age-dependent liver thyroid status adaptation and, 1117-1125

Serum insulin-like growth factor-binding protein-1 and -3 (IGFBP-1 and IGFBP-3) in exercising and sedentary subjects, glucose disposal in, compared, 821-826

Serum interleukin-18 (IL-18), serum TNF- α and, in NIDDM with diabetic retinopathy, 605-608

Serum leptin
 exercise and Pro12Ala PPAR γ gene polymorphism and, in men, 210
 in NIDDM Japanese subjects with hypoadiponectinemia, 1275
 QTc interval, HDL-C and, associated with CRPs in young men, 1113-1116
 serum DHEAS and, in obesity with normal cholesterol, 379-381

Serum lipoprotein(a) [Lp(a)] in Korean NIDDM subjects, rosiglitazone effects on, 731-734

Serum methylglyoxal (MG)-derived hydroimidazolone in NIDDM, 163-167

Serum thyroxine (T₄), age-dependent liver thyroid status adaptation and, 1118, 1120

Serum total cholesterol (TC) in NIDDM, in Japanese subjects with hypoadiponectinemia, 1275

Serum triglycerides (TG)
 in elderly renal transplant recipients, 574
 in FFA-induced peripheral tissue insulin resistance, 235
 in GDM, serum homocysteine and, 721
 and hepatic induction of mitochondrial and cytosolic acyl CoA hydrolases/thioesterases, 1527-1529
 in hypoadiponectinemic Japanese subjects, 1275
 interaction effects of serine447Stop polymorphism of LPL gene and C-514T polymorphism of hepatic lipase gene on, in young adults, 1337-1342
 in morbid obesity, 1552-1554
 in older subjects, insulin action and, 853
 plasma ghrelin and, 1461
 R219K polymorphism of ABCA1 gene of, related to age, AT, and race, 930-934

Serum triiodothyronine (T₃)
 age-dependent liver thyroid status adaptation and, 1118
 decline in, due to nonthyroidal illness due to hysterectomy, L-T₄ effects on, 1307-1312

Serum tumor necrosis factor- α (TNF- α), serum IL-18 and, in NIDDM with diabetic retinopathy, 605-608

Serum urea in diabetic and nondiabetic ESRD subjects, HD-induced changes in, 117

Serum uric acid
 in GDM, serum homocysteine and, 721
 27-bp repeat polymorphism in intron 4 of ECNOS gene and levels of, in Chinese NIDDM subjects, 1448-1453

Serum vitamin B₁₂ in GDM, serum homocysteine and, 721

Sex
 of acromegalic subjects, 182

Sex (*Continued*)
 and ADRB3 Trp64Arg polymorphism effects on LDL particle size, 357, 358
 alcohol intake, glycemia and, 131
 CRP relation to, 1542-1546
 of diabetic nephropathy subjects, 1259
 of DM subjects, *see* Sex of DM subjects
 estrogen and sex differences in insulin resistance with obesity, 659-661
 exercise effects and, *see* Sex, exercise effects and
 of HTN subjects, and HCT effects on tHcy, 262
 of hyperalphalipoproteinemic subjects, CRPs and, 433
 of hyperlipidemic subjects, 1192, 1193
 of hypoalphalipoproteinemic subjects, *see* Sex of hypoalphalipoproteinemic subjects
 and hypopituitarism, 51
 of insulin-resistant non-obese Japanese subjects, 1247
 of lysine-intolerant subjects, 936
 of obese subjects, *see* Sex of obese subjects
 of older subjects, *see* Sex of older subjects
 of PHP subjects, 160
 and plasma galanin response to HUT in recurrent VVS, 316
 of PM women, CETP and LCAT activities and, 284
 and risk for CV disease, 1434-1436
 and risk of NIDDM, 1213
 and TNFR2 concentration in first-degree relatives of NIDDM subjects, 1069
see also Boys; Men; Women

Sex, exercise effects and
 on plasma prebeta-1 HDLs, 439
 and prior exercise effects on PP lipemia, 419-421
 in young obese adults, 1177-1179

Sex of DM subjects
 and atherogenic role of lysophosphatidylcholine in LDLs, 311
see also Sex of IDDM subjects; Sex of NIDDM subjects

Sex hormone(s)
 in men, relation between insulin, AT, and risk for myocardial infarction, 784-790
see also specific sex hormones

Sex hormone-binding globulin (SHBG)
 pleiotropic genetic effects between AT and concentrations of, before and after 20-week exercise, 35-41
see also Sex hormone-binding globulin in MS

Sex hormone-binding globulin (SHBG) in MS, 724-730
 in men, relation of, to AT, insulin, and risk for MI, 785

Sex of hypoalphalipoproteinemic subjects
 plasma CRPs and, 433
 of primary hypoalphalipoproteinemic subjects, vascular damage and, 329, 330

Sex of IDDM subjects
 with CAN, 816
 of obese IDDM children, intracellular platelet Mg and, 469

Sex of NIDDM subjects
 and ADMA association with GFR and glycemic control, 304
 with carotid atherosclerosis, *see* Sex of NIDDM subjects with carotid atherosclerosis
 Chinese subjects, 1449, 1450
 with early-onset NIDDM, LPL *HindIII* gene polymorphism-lipid level association and, 339, 340
 effects of glycemic control on LDL particle size NIDDM men, 1577
 and FFA metabolism regulation by NPY gene Leu7Pro polymorphism, 644

- Sex of NIDDM subjects (*Continued*)
 and food intake effects on 24-hour profile of circulating glycated insulin, 632
 and glibenclamide-metformin therapy, 864
 of Japanese NIDDM subjects, risk for atherosclerosis and, 1303, 1304
 with nephropathy and macroangiopathy, 1518-1521
 of NIDDM first-degree relatives of NIDDM subjects, 1580
 obese, *see* Sex of obese NIDDM subjects
 PP lipemia after fat ingestion and, 1039
 and pramlintide effects on A_{1c} and BW, 1639
 and Pro12Ala PPAR γ gene polymorphism association with oxidized LDL and cardiolipin autoantibodies, 215
 and TZD effects, *see* Sex of NIDDM subjects, and TZD therapy effects
- Sex of NIDDM subjects, and TGZ therapy effects
 on endothelial function, 175
 and SM morphology regulation with metformin and TGZ, 541
- Sex of NIDDM subjects, and TZD therapy effects
 on FA and glucose metabolism, 754
 rosiglitazone effects on serum Lp(a), 732
see also Sex of NIDDM subjects, and TGZ therapy effects
- Sex of NIDDM subjects with carotid atherosclerosis
 beraprost sodium effects and, 195
 of nondiabetic obese subjects, plasma SSAO and CV disease risk and, 690
 and porphyromonas gingivalis in non-obese Japanese NIDDM subjects, 143
- Sex of obese NIDDM subjects
 with central obesity, 1001
 fasting and daylong TGs and, 1045
 NIDDM children, intracellular platelet Mg and, 469
- Sex of obese subjects
 with FFA-induced peripheral tissue insulin resistance, 234
 nondiabetic subjects, plasma SSAO and CV disease risk and, 690, 691
 of obese IDDM children, intracellular platelet Mg and, 469
 of young obese adults, exercise effects on, 1177-1179
see also Sex of obese NIDDM subjects
- Sex of older subjects
 CETP and LCA activities and, 284
 interaction between dietary fat intake and apo E genotype and, 280
- SFAs, *see* Saturated fatty acids
- S447X (serine447Stop) polymorphism of LPL gene, interaction effects of C-514T polymorphism of hepatic lipase gene and, on serum TGs in young adults, 1337-1342
- SHBG, *see* Sex hormone-binding globulin
- Shc, insulin signaling in breast cancer via, 1606-1611
- sHcy (serum homocysteine) in GDM, 720-723
- Short-term free fatty acid (FFA; nonesterified acids) infusions, insulin secretion after, in men at risk for developing NIDDM, 885-894
- Short-term growth hormone replacement (GHR), effects of long- and, on Lp composition and apo B-100 kinetics in hypopituitarism, 50-59
- Short-term hydrolyzed casein-based diet, effects of, on IDDM development, 333-337
- Short-term rosiglitazone therapy, effects of, on IMC lipids in insulin-resistant obesity, 218-225
- S_i, *see* Insulin sensitivity
- Side-chain length-specific manner, acyl CoA activating acyl CoA esters in, cardiac and beta-cell K_{ATP} channels in, 1313-1319
- Side effects of troglitazone, 176
- Signal transducer and activator of transcription-3 (STAT3), hyperglycemia-induced hepatic oxidative stress activates neither hepatic MAPK nor, 865-874
- Simulation, *see* WinSAAM
- 16-month exercise program, glucose and insulin responses to, by young obese adults, 1175-1181
- 16-week exercise program, effects of energy intake restriction and, on BMI and body composition in free-living obese men, 107-115
- Skeletal muscle (SM)
 FA oxidation by, in morbidly obese black and white women, 735-738
 high-fat diet and lipolysis in, 1586-1592
 high-sucrose effects on [³H]-2-deoxy-D-glucose uptake by, 982
 left and right, substrate concentrations and metabolism in, 1571-1575
 lipid content of, *see* Lipids in SM
 vanadate rapamycin effects on glucose uptake by, 666-674
see also Skeletal muscle in NIDDM; Skeletal muscle insulin; Skeletal muscle insulin receptor; Skeletal muscle protein
- Skeletal muscle (SM) glycogen
 captopril effects on insulin-stimulated glycogen synthesis of, but not on FA synthesis in AT in hereditary hypertriglyceridemia, 1406-1412
 in NIDDM, EPA effects on, 31
- Skeletal muscle (SM) insulin, effects of high-fat diet and leptin on PI3-K activity and glucose transport stimulated by, 1196-1205
- Skeletal muscle (SM) insulin receptor phosphorylation, GlcN-induced insulin resistance and impaired, 1092-1095
- Skeletal muscle (SM) in NIDDM
 EPA effects on glycogen of, 31
 EPA effects on insulin resistance and lipid accumulation in, 30-34
 and release of IL-6 and TNF- α in NIDDM subjects at rest and during exercise, 939-944
 troglitazone and metformin regulating morphology of, 540-546
- Skeletal muscle (SM) protein
 alcohol and effects of L-NAME and L-NNA on synthesis of, 397-401
 effects of acute endurance exercise on UCP-3 gene expression in untrained subjects, 152-158
 IL-1ra effects on synthesis of, in sepsis, 1218-1225
- SM, *see* Skeletal muscle
- Small dense low-density lipoprotein (LDL), adipocyte-derived plasma adinopectin concentration associated with, 1612-1614
- SMCs, *see* Smooth muscle cells
- SMGU (steady-state plasma glucose), insulin resistance in HIV-positive subjects measured with, 858-861
- Smokeless nicotine, effects of, on HTN or glucose tolerance and insulin sensitivity in young subjects, 67-72
- Smoking
 in DM, *see* Smoking in DM
 heavy, grape seed extract effects on LDL susceptibility to oxidation in, 1250-1257
 by men, plasma ghrelin, AT, insulin resistance and, 1460-1463
 in MS with liver dysfunction, 1098
 by non-obese subjects with and PAI-1-associated insulin resistance, 227
 and PP leukocyte increase, 200
 and risk for CV disease, 1434-1436
 and Taq1B polymorphism with Lp variations, 1565, 1568
- Smoking in DM
 with CAN, 806
see also Smoking in NIDDM

Smoking in NIDDM

- alcohol intake, blood glucose and, 131
- and effects of glycemic control on LDL particle size, 1577
- and PP lipemia after fat ingestion, 1039
- see also* Smoking in NIDDM with CV disease

Smoking in NIDDM with CV disease

- with carotid atherosclerosis, 195
- and effects of smoking cessation on CV disease, S1:22
- as risk for atherosclerosis, 1303, 1304

Smooth muscle cells (SMCs)

- aortic, *see* Aortic smooth muscle cells
- vascular, methylallyl thiosulfate effects on insulin-potenti-
PDGF-stimulated migration of, 254-259

SNS, *see* Sympathetic nervous systemSodium-proton exchanger, *see* Na⁺/H⁺ exchanger

Soluble vascular cell adhesion molecule-1 (sVCAM-1) in EC injury,

- transient hyperhomocysteinemia and changes in, 501-507

Somatomedin C, *see* Insulin-like growth factor-1

Soy protein combined with viscous fiber, almonds, and phytosterols

- for hypercholesterolemia, 1478-1483

Spectroscopy, ¹⁹F-NMR, metabolomic mapping of vitamin C with

- F-ASA and, in DM, 760-770

SSAO (semicarbazide-sensitive amine oxidase), plasma, as CV

- disease risk in nondiabetic obese subjects, 688-692

Stable non-insulin-dependent diabetes mellitus (NIDDM) with CV

- disease, myocardial revascularization for, S1:8-9

Starch

- effects of raw potato, on butyrate formation in colon, colonocyte
apoptosis and shift to stem cell compartment due to, 1400-
1405

see also Cornstarch

STAT3 (signal transducer and activator of transcription-3),

- hyperglycemia-induced hepatic oxidative stress activates
neither hepatic MAPK or, 868-874

Steady-state C-peptides (connecting peptides), and PPAR_γ

- Pro12Ala polymorphism effects on, 781

Steady-state free fatty acids (FFAs; nonesterified fatty acids), and

- PPAR_γ Pro12Ala polymorphism effects on, 780

Steady-state insulin, PPAR_γ Pro12Ala polymorphism effects on,

- 780

Steady-state plasma glucose (SMGU), insulin resistance in HIV-

- positive subjects measured with, 858-861

Stearate, retinyl, PP secretion of, in chylomicrons, effects of

- different types and amounts of FAs on, after high-dose
preformed vitamin A supplementation, 515-516

Stem cell compartment, colonocyte apoptosis and shift to, due to raw

- potato starch effects on butyrate formation in colon, 1400-
1405

Steroids, *see* Glucocorticoids and specific steroids

Stevioside, antihyperglycemic and hypotensive effects of, in DM,

- 372-378

Storage, net CHO, effects of glycogen level and ingested glucose on,

- 94-101

Streptozotocin-induced diabetes mellitus (STZ-DM)

- antidiabetic effects of AA and zinc in, 7-12
- effects of apo C-III deficiency on hypertriglyceridemia
development in, 1354-1359
- heart VEGF mRNA in, 675-678
- intravesicular glucose hepatic plasma membrane Mg transport in,
1464-1470
- NIP-22 effects on urinary excretion of albumin in, 1633-1637

Stress

- effects of aging and, on hippocampal structure and function, S2:
17-21

Stress (*Continued*)

see also Oxidative stress

STZ-DM, *see* Streptozotocin-induced diabetes mellitusSubcutaneous (SC) abdominal adipocytes, effects of 17 β -estradiol

- and ICI:compound 182,780 on HSL and LPL expression in,
383-388

Subcutaneous adipose tissue (SAT)

- in PM women, racial differences in, 186-191
- and PP triglyceridemia, 1381, 1394
- relation of sex hormones to insulin, risk for MI and, in men 785

Submaximal exercise, adrenocortical responses to, by PM women,

- race and, 1643-1647

Succinate, effects of, on pancreatic islet mitochondria metabolites,

- 995, 996

Sucrose (S)

- atorvastatin effects on PP hypertriglyceridemia induced by, in
olive oil-fed subjects, 609-617

- high-sucrose diet and TGZ effects on vascular and glucose
metabolic actions of insulin, 978-986

- in short-term hydrolyzed casein-based diet, 334

Sulfonylurea(s), *see* Gliclazide in NIDDM with CV disease;

- Glipizide gastrointestinal therapeutic system; Metformin;
Sulfonylurea receptor

Sulfonylurea receptor (SUR), effects of gliclazide MR binding to, on

- CV disease in NIDDM, S1:31-32

Supplementation

- cholesterol, effects of, on linoleic acid-induced EC activation,
493-500

- effects of K, on natriuretic response to central volume expansion
in primary aldosteronism, 1597-1600

- effects of Mg-creatine, on body water, 1136-1140

- with FcTO containing MCTs, PUFAs, and phytosterols, effects of,
on cardiovascular risk in obese women, 771-777

- high-dose preformed vitamin A, effects of different types and
amounts of FAs on PP retinoid secretion in chylomicrons
after, 514-519

- oral lysine, in lysine intolerance, 935-938

SUR (sulfonylurea receptor), effects of gliclazide MR binding to, on

- CV disease in NIDDM, S1:31-32

sVCAM-1 (soluble vascular cell adhesion molecule-1) in EC injury,

- transient hyperhomocysteinemia and changes in, 501-507

Swallowing disorders (dysphagia), aspiration pneumonitis with, in

- elderly patients with AD, S2:36-38

Swelling syndrome, lymphatic function in women with gynoid

- adiposity and, 805-809

Sympathetic nervous system (SNS; autonomic nervous system)

- developmental plasticity as response of, to fasting in adipose
tissue, 1621-1626

see also Cardiac autonomic nervous system

Syncope, recurrent head-up tilt vasovagal, plasma galanin in, 315-

- 321

Syndrome X, *see* Metabolic syndrome

Synthase

- citrate, effects of restricted diet on, 325

- eNOS, *see* Endothelial nitric oxide synthase in ECs

- glycogen, dietary fat effects on mRNA and activity of, 535-539

Systemic inflammation due to hyperglycemia-induced hepatic

- oxidative stress, 868-874

Systolic blood pressure, *see* Blood pressureT, *see* TestosteroneT₃ (triiodothyronine), *see* Serum triiodothyronineT₄, *see* Thyroxine; L-Thyroxine

- TAGs (triacylglycerols), medium-chain, effects of supplementation with FcTO containing phytosterols, PUFAs and, on cardiovascular risk in obese women, 771-777
 Taq1B polymorphism with Lp variations in Japanese subjects, CETP associated with, 1564-1570
 Taurine (2-aminoethane sulfonic acid) transport, glucose concentration and inhibition of, in cardiomyocytes, 827-833
 TBW (total body weight), GHR effects on, 53
 TC, *see* Total cholesterol
 TEE (total energy expenditure), carbohydrate oxidation and, in HIV lipodystrophy syndrome, 620-625
 Telomeres (and telomerase), role of, in aging, S2:7
 N-terminal Ala₂-substituted analogs of glucose-dependent insulinotropic polypeptide (GIP), effects of, on glucose degradation, cAMP production, insulin secretion, and hyperglycemia, 679-687
 Testolactone, effects of, on hypogonadotropic hypogonadism in obese men, 1126-1128
 Testosterone (T)
 in older subjects, effects of GH, abdominal VAT, fitness, and insulin on, 76
 in PM women, estrogen receptor α gene and collagen IA1 gene effects on relation of 25(OH)D and PTH to, 1131, 1132
 production rate of, in female hair loss, 927-929
 synergistic effects of GH and, on protein metabolism and body composition in boys, 964-969
 total, in PCOS, 909
 see also Testosterone in men
 Testosterone (T) in men
 relation of, to AT, insulin, and risk for MI, 785, 786
 rosiglitazone effects on production of, 230-232
 Tetrahydrocortisol, rosiglitazone effects on urinary excretion of, 231
 Tetrahydrocortisone, rosiglitazone effects on urinary excretion of, 231
 TG, *see* Triglyceride(s)
 TGZ, *see* Troglitazone
 Thai women, abdominal AT in obese and lean NIDDM, 1444-1447
 tHcy (total homocysteine), HCT effects on, in hypertension, 261-263
 2-oxo-4-Thiazolidinecarboxylic acid (OTZ), effects of, on GSH redox state-gluconeogenesis relation in renal cortical tubules, 742-743
 Thiazolidinedione(s) (TZDs)
 effects of, on glucose and FA metabolism in NIDDM, 753-759
 and effects of cholesterol on linoleic acid-induced activation of NF- κ B in ECs, 495
 see also specific thiazolidinediones
 Thioesterases/hydrolases, acyl CoA, hepatic induction of
 mitochondrial and cytosolic, in DM and fasting, 1527-1529
 Threonine (Threo), glutamine effects on protein and amino acid metabolism in hepatic tissue, 1064
 Threonine (Threo) kinase
 captopril effects on association of IRS-1 with, in BC3H-1 myocytes, 275
 and β -estradiol and IGF-1 effects on eNOS activity in aortic endothelial cells, 482-487
 Thrombin, and phospholipid-dependent procoagulation activity in NIDDM and generation of, 104
 Thrombomodulin (TM), plasma Hcy and plasma, in NIDDM with nephropathy and macroangiopathy, 1517-1522
 Thyroid status, age-dependent adaptation of, liver in DM, serum and hepatic IGF-1 expression and, 1117-1125
 Thyrotropin-stimulating hormone (TSH) in hypothyroidic pregnant women, T₄ dose and, 123-125
 Thyroxine (T₄), dose of, for primary hypothyroidism during pregnancy, 122-128
 L-Thyroxine (T₄), effects of, on hysterectomy-induced decline in serum T₃ due to nonthyroidal illness, 1307-1312
 Tissue selectivity of sulfonylureas in NIDDM with CV disease, S1:3-5
 TNF, *see entries beginning with terms*: Tumor necrosis factor
 Tocopherol, *see* Vitamin E
 Tolerability of sulfonylureas
 of gliclazide MR, S1:30
 of metformin and glibenclamide, 864
 Tolerance, *see* Glucose tolerance
 Total adipose tissue (AT)
 associated with CETP and LCAT activities in PM women, ethnicity and, 282-289
 in HIV infection patients with lipodystrophy patients, 1346, 1347
 Total body bone mineral density (BMD), effects of dietary restriction on, 1265-1273
 Total body protein, sarcopenia versus depletion of, in the elderly, S2:24
 Total body weight (TBW), GHR effects on, 53
 Total cholesterol (TC)
 CRP relation to, 1544
 CRPs in young men and, 1114
 diet effects on, *see* Total cholesterol, diet effects on
 in DM, *see* Total cholesterol in DM
 doxazosin effects on, in HTN, 1149
 exercise effects on, *see* Total cholesterol, exercise effects on
 fenofibrate effects on, 352
 GHR effects on, in hypopituitarism, 56
 in heavy smokers, and grape seed extract effects on LDL oxidation, 1252
 in hyperalphalipoproteinemia, plasma CRPs and, 433
 in hypoalphalipoproteinemia, *see* Total cholesterol in hypoalphalipoproteinemia
 insulin resistance and MS, *see* Total cholesterol in insulin-resistant subjects
 normal, in HTG associated with insulin resistance and, 617, 618
 in obesity, *see* Total cholesterol in obesity
 in PM women, *see* Total cholesterol in PM women
 risk for CV disease and, 1296, 1297
 rosiglitazone effects on, 1080
 swelling syndrome and gynoid adiposity effects on, 806, 807
 and Taq1B polymorphism with Lp variations, 1565, 1567
 see also Total high-density lipoprotein-cholesterol; Total low-density lipoprotein-cholesterol
 Total cholesterol (TC), diet effects on
 alcohol intake, 131
 trans FA intake, LDL size and, 695
 high-CHO and/or high-MUFA diet, 1457
 high-fat and/or high-CHO diet on, in non-obese and obese women, 1428
 long-term effects of high-fiber diet, 1207-1208
 malnourishment in first year of life, 1006, 1008
 margarine-enriched phytosterol diet, 1375
 Total cholesterol (TC), exercise effects on
 endothelial lipase genotype and, 1508
 see also Total cholesterol, exercise effects on, in men
 Total cholesterol (TC), exercise effects on, in men
 Pro12Ala PPAR γ gene polymorphism and, 210
 weight loss effects on, 138
 Total cholesterol (TC) in DM
 atherogenic role of lysophosphatidylcholine and, 311
 in GDM, serum homocysteine and, 721

- Total cholesterol (TC) in DM (*Continued*)
 in STZ-DM, and effects of apo-C-III deficiency on
 hypertriglyceridemia development, 1355
see also Total cholesterol in NIDDM
- Total cholesterol (TC) in hypoalphalipoproteinemia
 plasma CRPs and, 433
 primary hypoalphalipoproteinemia, vascular damage and, 329, 330
- Total cholesterol (TC) in insulin-resistant subjects
 in MS with liver dysfunction, 1097, 1098
 obese women with PCOS, 716
 SHBG and, 727
- Total cholesterol (TC) in Japanese NIDDM subjects
 with hypoadiponectinemia, 1275
see also Total cholesterol in non-obese Japanese NIDDM subjects
- Total cholesterol (TC) in NIDDM
 ADMA association with GFR and glycemic control and, 304
 in Chinese subjects, 1449-1451
 with CV disease, multifactorial intervention effects on, S1:20
 in early-onset NIDDM, LPL *HindIII* gene polymorphism-lipid
 level association and, 339-341
 and effects of glycemic control on LDL particle size, 1577
 in Japanese subjects, *see* Total cholesterol in Japanese NIDDM
 subjects
 in men with uncomplicated well-controlled NIDDM and
 preclinical diabetic cardiomyopathy, 1058
 with nephropathy and macroangiopathy, 1518-1521
 in NIDDM first-degree relatives of NIDDM subjects, 1580
 with obesity, *see* Total cholesterol in obesity
 and phospholipid-dependent procoagulation activity, 103
 plasma, *see* Total plasma cholesterol
 and PP lipemia after fat ingestion, 1040
 with retinopathy, 606
 rosiglitazone effects on, 732
- Total cholesterol (TC) in non-obese Japanese NIDDM subjects
 platelet count and, 1247
 with porphyromonas gingivalis and carotid atherosclerosis, 143
- Total cholesterol (TC) in obese NIDDM subjects
 NIDDM children, intracellular platelet Mg and, 469
 with PAI-1-associated insulin resistance, 227
- Total cholesterol (TC) in obese women
 FcTO supplementation effects on, 772
 in insulin-resistant PCOS women, 716
- Total cholesterol (TC) in obesity
 obese exercising men, effects of weight loss on, 138
 in obese IDDM children, intracellular platelet Mg and, 469
see also Total cholesterol in obese NIDDM subjects; Total
 cholesterol in obese women
- Total cholesterol (TC) in PM women
 estrogen and MPA effects on, 1332, 1333
see also Total cholesterol in PM women, race and ethnicity of
- Total cholesterol (TC) in PM women, race and ethnicity of
 CETP and LCAT activities and, 284, 285
 with metabolic syndrome, 364, 366-369
 plasma, in obese PM women, weight loss effects on, 602
- Total energy expenditure (TEE), carbohydrate oxidation and, in HIV
 lipodystrophy syndrome, 620-625
- Total high-density lipoprotein-cholesterol (HDL-C), fasting plasma,
 in obese PM women, effects of weight loss on, 602
- Total homocysteine (tHcy), HCT effects on, in hypertension, 261-
 263
- Total low-density lipoprotein-cholesterol (LDL-C), fasting plasma, in
 obese PM women, effects of weight loss on, 602
- Total plasma cholesterol (C)
 EPA effects on, 31
- Total plasma cholesterol (C) (*Continued*)
 exercise effects on, 439
 fasting, in obese PM women, effects of weight loss on, 602
 FM-VP4 effects on, in apo E deficiency, 426, 427
 in HIV infection with lipodystrophy, 1346, 1347, 1351
 in hyperlipidemia, 919
- Total plasma high-density lipoprotein-cholesterol (HDL-C) in
 hyperlipidemia, 919
- Total plasma low-density lipoprotein-cholesterol (HDL-C) in
 hyperlipidemia, 919
- Total plasma triglycerides (TG) in hyperlipidemia, 919
- Total testosterone (T) in PCOS, 909
- Total triacylglycerols (TAGs), effects of supplementation with FcTO
 on, in obese women, 772
- Toxin, pertussis, insulin, G_i-coupled receptor agonists,
 glucocorticoids and, regulating leptin release in adipocytes
 and AT in obesity, 60-68
- Training, *see* Exercise
- Tramadol, pharmacokinetics of, and CYP2D6 mutation, 1439-1443
- Transfer protein, *see* Cholesteryl ester transfer protein
- Transient hyperhomocysteinemia, changes in markers of EC injury
 in, 501-507
- Translocation, insulin-induced PI3K, in adipocytes and ceramide
 effects on, 19-24
- Transplantation, renal, determinants of insulin secretion after, 573-
 578
- Treatment of the elderly
 of frailty, S2:25
see also Drug therapy in the elderly *specific conditions and
 therapeutic interventions*
- Triacylglycerols (TAGs), medium-chain, effects of supplementation
 with FcTO containing phytosterols, PUFAs and, on
 cardiovascular risk in obese women, 771-777
- Triglyceride(s) (TG)
 adipocyte-derived plasma adipoectin and, 1613
 blood, *see* Triglyceridemia
 CRP relation to, 1114, 1544
 and CV disease risk prediction, 525, 526
 diet effects on, *see* Triglyceride(s), diet effects on
 in DM, *see* Triglyceride(s) in DM
 doxazosin effects on, in HTN, 1149
 exercise effects on, 1508
 fenofibrate effects on, 352
 in first-degree relatives of NIDDM subjects, 1069
 GHR effects on, in hypopituitarism, 56
 in heavy smokers, grape seed extract effects on, 1252
 in hyperalphalipoproteinemia, plasma CRPs and, 433, 434
 in hyperlipidemia, 1192, 1193
 in hypoalphalipoproteinemia, *see* Triglyceride(s) in
 hypoalphalipoproteinemia
 in insulin resistance and/or MS, *see* Triglyceride(s) in insulin-
 resistant subjects
 intracellular, in left and right SM, 1574
 in men at risk for developing NIDDM, 888, 889
 in nondiabetic ESRD subjects, HD-induced changes in, 118
 in non-obese subjects, *see* Triglyceride(s) in non-obese subjects
 in obesity, *see* Triglyceride(s) in obesity
 in older subjects, *see* Triglyceride(s) in older subjects
 in PM women, *see* Triglyceride(s) in PM women
 PP, in hereditary HTG, 1408
 and PP leukocyte increase, 200
 rich in Lps, estrogen and medroxyprogesterone acetate effects on,
 1330-1336
 and risk factor for CHD, 1532-1534

- Triglyceride(s) (TG) (*Continued*)
 and risk for CV disease, 1296, 1434-1436
 R219K polymorphism of serum HDL-C and TG ABCA1 gene in,
 related to age, AT, and race, 930-934
 serum, *see* Serum triglycerides
 and sex hormone relation to AT, insulin, and risk for MI in men,
 785
 and Taq1B polymorphism with Lp variations, 1565
see also Triglyceridemia
- Triglyceride(s) (TG), diet effects on
 almond, viscous fiber, soy protein, and phytosterol diet effects in
 hypercholesterolemia, 1479
trans FA intake effects on, 695, 696
 high-CHO and/or high-MUFA diet, 1457
 malnourishment in first year of life, 1006, 1008
 margarine-enriched phytosterol diet, 1375
- Triglyceride(s) (TG) in DM
 atherogenic role of lysophosphatidylcholine on, 311
 with ESRD, HD-induced changes in, 118
see also Triglyceride(s) in NIDDM
- Triglyceride(s) (TG) in hypoalphalipoproteinemia
 plasma CRPs and, 433, 434
 in primary hypoalphalipoproteinemia, vascular damage and, 329,
 330
- Triglyceride(s) (TG) in insulin-resistant subjects
 in hypoadiponectinemic NIDDM Japanese subjects, 1275
 with IGT, 477
 in MS with liver dysfunction, 1097, 1098
 in NA-induced insulin resistance, 701
 in NIDDM, 896, 897
 non-obese Japanese NIDDM subjects, platelet count and, 1247
 in PAI-1-associated insulin-resistant Japanese subjects, 227, 228
 with PCOS, 910, 911
 SHBG and, 726, 727
- Triglyceride(s) (TG) in NIDDM
 and ADMA association with GFR and glycemic control, 304
 with carotid atherosclerosis, beraprost sodium effects and, 195
 in Chinese subjects, 1449, 1450
 with CV disease, multifactorial intervention effects on, S1:20
 in early-onset NIDDM, LPL *HindIII* gene polymorphism-lipid
 level association and, 339-341
 fasting and daylong, obesity and, 1043-1049
 with hypoadiponectinemia, 1281
 with insulin resistance, 896, 897
 with nephropathy and macroangiopathy, 1518-1521
 in NIDDM first-degree relatives of NIDDM subjects, 1580
 and phospholipid-dependent procoagulation activity, 103
 plasma, EPA effects on, 31
 in preclinical diabetic cardiomyopathy in uncomplicated well-
 controlled NIDDM men, 1058
 with retinopathy, 606
 rosiglitazone effects on, 732
 and troglitazone effects on endothelial function, 175, 177
- Triglyceride(s) (TG) in non-obese Japanese subjects
 with NIDDM, platelet count and, 1247
 with PAI-1-associated insulin resistance, 227, 228
- Triglyceride(s) (TG) in non-obese subjects
 diabetic and nondiabetic ESRD subjects, HD-induced changes in,
 118
 in Japanese subjects, *see* Triglyceride(s) in non-obese Japanese
 subjects
 women, effects of high-fat and/or high-CHO diet on, 1428
- Triglyceride(s) (TG) in obese women
 effects of high-fat and/or high-CHO diet on, 1428
- Triglyceride(s) (TG) in obese women (*Continued*)
 PP apo A-IV distribution between apo B- and non-apo B-
 containing Lps and, 1538, 1539
- Triglyceride(s) (TG) in obesity
 adiponectin gene mutations and, 882
 fasting and daylong, with and without NIDDM, 1043-1049
 in gynoid adiposity with swelling syndrome, 806, 807
 with hypercholesterolemia, disturbed cholesterol synthesis effects
 on monocytes and, 2
 with insulin resistance, *see* Triglyceride(s) in obesity with insulin
 resistance
 in nondiabetic subjects, plasma SSAO and CV disease risk and,
 690, 691
 with normal cholesterol, 380
 in obese women, *see* Triglyceride(s) in obese women
 rosiglitazone effects on muscle S_i irrespective of content of, 1078-
 1083
 weight loss effects on, 138
- Triglyceride(s) (TG) in obesity with insulin resistance
 estrogen and, 660
 in PCOS subjects, 716
- Triglyceride(s) (TG) in older subjects
 effects of GH, abdominal VAT, fitness, and insulin on, 76-78
 insulin action and, 856
- Triglyceride(s) (TG) in PM women
 CETP and LCAT activities and, 284-287
 with metabolic syndrome, 364, 366-369
 and subcutaneous and visceral AT distribution, 188
- Triglyceridemia
 effects of PP variations in, on LDL particle size, 1379-1386
see also Hypertriglyceridemia
- Triiodothyronine, *see* Serum triiodothyronine
- Triphosphate, *see* ATP
- Troglitazone (TGZ; CS-045)
 effects of, on glucose metabolism of subjects at risk for NIDDM,
 race and, 1211-1217
 effects of, on insulin secretion, 1395-1396
 effects of high-sucrose diet and, on vascular and glucose
 metabolic actions of insulin, 978-986
 in STZ-DM, effects of, on urinary albumin excretion, 1633-1637
see also Troglitazone in NIDDM
- Troglitazone (TGZ; CS-045) in NIDDM
 in early and late NIDDM, effects of, on endothelial function, 173-
 180
 skeletal muscle morphology regulation with metformin and, 540-
 546
- Trp64Arg polymorphism, *see* β_3 Adrenergic receptor Trp64Arg
 polymorphism
- TSH (thyrotropin-stimulating hormone) in hypothyroidic pregnant
 women, 123-125
- Tumor necrosis factor- α (TNF- α)
 insulin resistance and activity of, 1593-1596
see also Tumor necrosis factor- α in NIDDM; Tumor necrosis
 factor- α -863A allele
- Tumor necrosis factor- α (TNF- α) in NIDDM
 with carotid atherosclerosis, beraprost sodium effects on TNF- α -
 induced adhesion of U937 cells to HUVECs and, 193-194
 release of skeletal muscle, in NIDDM subjects at rest and during
 exercise, 939-944
 serum IL-18 and serum, with diabetic retinopathy, 605-608
- Tumor necrosis factor- α -863A (TNF- α -863A) allele, TNF- α
 receptor 2 concentration and, in first-degree relatives of
 NIDDM subjects, 1068-1071

- Tumor necrosis factor- α receptor 2 (TNFR2), TNF- α -863A allele and concentration of, in first-degree relatives of NIDDM subjects, 1068-1071
- 20-week exercise program, pleiotropic genetic effects between adipose tissue and SHBG concentrations before and after, 35-41
- 24-hour circulating glycated insulin profile in NIDDM, food intake effects on, 631-635
- 27-bp repeat polymorphism in intron 4 of ECNOS gene, serum uric acid levels and, in Chinese NIDDM subjects, 1448-1453
- Type I collagen, carboxy-terminal propeptide, and BMD in chronic pancreatitis, 579-581
- Type 1 diabetes mellitus, *see* Insulin-dependent diabetes mellitus
- Type 2 diabetes mellitus, *see* Non-insulin-dependent diabetes mellitus
- Type II xanthinuria, point mutation of molybdenum cofactor sulfase gene in, 1501-1504
- Tyrosine (Tyr)
adipocyte PTPase, IMGU and insulin-induced oxidation inhibition and, 705-712
glutamine effects on metabolism of, in hepatic tissue, 1064
see also Insulin receptor tyrosine phosphorylation
- TZDs, *see* Thiazolidinedione(s)
- UCP-3 (uncoupling protein-3) gene expression, acute endurance exercise effects on skeletal muscle in untrained subjects, 152-158
- Umbilical endothelial cells, *see* Human umbilical endothelial cells
- Uncomplicated well-controlled non-insulin-dependent diabetes mellitus (NIDDM), relation of CAN and LVDD to preclinical diabetic cardiomyopathy in, 1056-1061
- Uncoupling protein-3 (UCP-3) gene expression, acute endurance exercise effects on skeletal muscle in untrained subjects, 152-158
- U937 cells, beraprost sodium effects on TNF- α -induced adhesion of, to HUVECs in NIDDM with carotid atherosclerosis, 193
- Untrained subjects, acute endurance exercise effects on skeletal muscle UCP-3 mRNA in, 152-158
- Urea
hepatic, production of, and relationship to arginine metabolism after burn injury, 1235-1236
serum, in diabetic and nondiabetic ESRD subjects, HD-induced changes in, 117
- Uric acid
in non-obese Japanese subjects with PAI-1-associated insulin resistance, 227, 228
serum, *see* Serum uric acid
- Urinary catecholamines, α -adrenergic blocker effects on, in high-altitude exercise, 1473
- Urinary excretion
of amino acids in lysine intolerance, oral lysine supplementation effects on, 937
of F-ASA, metabolomic mapping of vitamin C in DM and, 764-765
Na, in primary aldosteronism, 1598
of pentosidine in children with acute exacerbation of atopic dermatitis, oxidative stress and, 1601-1605
of steroids by men, rosiglitazone effects on, 231
see also entries ending with suffix: -uria
- Urinary excretion, albumin
in diabetic subjects with CAN, 816, 817
NIP-22 effects on, in STZ-DM, 1633-1637
see also Albuminuria in DM
- Valine (Val), glutamine effects on protein and amino acid metabolism in hepatic tissue, 1064
- Vanadate, effects of rapamycin and, on insulin-mediated glucose uptake, 666-674
- Varicocele, coenzyme Q10 and infertility in, 402-406
- Vascular cell adhesion molecule-1 (VCAM-1)
beraprost sodium effects on expression of, in HUVECs and circulating, in NIDDM with carotid atherosclerosis, 192-198
changes in soluble, in EC injury, transient hyperhomocysteinemia and, 501-507
DNA-binding activity for NF- κ B to, in NIDDM with CV disease, S1:16
- Vascular endothelial cells (ECs), transient hyperhomocysteinemia and changes in markers of injury to, 501-507
- Vascular endothelial growth factor (VEGF) mRNA (messenger ribonucleic acid), heart, in STZ-DM, 675-678
- Vascular metabolic actions of insulin, high-sucrose diet and TGZ effects on, 978-986
- Vascular nitric oxide (NO), effects of, on atherogenic role of lysophosphatidylcholine in LDLs in DM, 308-314
- Vascular reactivity in NIDDM with CV disease, sulfonylurea effects on, S1:3-4
- Vascular smooth muscle cells (VSMCs), methylallyl thiosulfate effects on insulin-potentiating PDGF-stimulated migration of, 254-259
- Vascular system
aging effects on, S2:31-35
early damage to, in primary hypoalphalipoproteinemia, 328-332
see also Microvascular complications in NIDDM with CV disease; *entries beginning with terms:* Cardiovascular, Myocardial; *elements:* Vascu-, Vaso-; *specific blood vessels and conditions*
- Vasculopathy
risk for, in NIDDM, ADMA and, 303-307
see also *specific conditions*
- Vasopressin, *see* Arginine-vasopressin V₂ mRNA; Arginine-vasopressin V₂ receptor
- Vasovagal syncope (VVS), head-up tilt in recurrent, plasma galanin response to, 315-321
- VAT, *see* Visceral adipose tissue
- VCAM-1, *see* Vascular cell adhesion molecule-1
- VDR (vitamin D receptor) gene polymorphism, effects of interaction between aromatase Arg²⁶⁴Cys polymorphism and, on BMD of postmenopausal African-American women, 521-523
- VEGF (vascular endothelial growth factor) mRNA (messenger ribonucleic acid), heart, in STZ-DM, 675-678
- Ventricular diastolic dysfunction, left, relation of CAN and, to preclinical cardiomyopathic men with uncomplicated well-controlled NIDDM, 1056-1061
- Ventricular function, left, in DM with insulin withdrawal, effects of exercise on, 792
- Vertebral bone mineral density (BMD), effects of dietary restriction on, 1265-1273
- Very-low-density lipoprotein(s) (VLDL)
long- and short-term GHR effects on composition of, in hypopituitarism, 50-59
in obesity with insulin resistance, profile of, 559-564
in PM women, estrogen and medroxyprogesterone acetate effects on, 1332, 1333
see also Very-low-density lipoprotein-cholesterol
- Very-low-density lipoprotein-cholesterol (VLDL-C)
in metabolic syndrome, 726, 727
in NIDDM, and PP lipemia after fat ingestion, 1040

- Very-low-density lipoprotein-cholesterol (VLDL-C) (*Continued*)
 in older subjects, effects of GH, abdominal VAT, fitness, and insulin on, 76-78
- Visceral adipose tissue (VAT)
 abdominal, *see* Abdominal adipose tissue
 in HIV lipodystrophy subjects, 622
 in NIDDM, *see* Visceral adipose tissue in NIDDM
 and PP triglyceridemia, 1381, 1384
 and relation of sex hormones to AT, insulin, and risk for MI in men, 785
see also Visceral adipose tissue in PM women
- Visceral adipose tissue (VAT) in NIDDM
 EPA effects on, 31
 in insulin-resistant Japanese subjects with hypoadinopectinemia, 1274-1278
- Visceral adipose tissue (VAT) in PM women
 obese women, weight loss effects on, 599-604
 race and distribution of, 186-191
- Visceral protein depletion, sarcopenia and, and frailty in the elderly, S2:22-26
- Viscous fiber with almonds, soy protein, and phytosterols for hypercholesterolemia, 1478-1483
- Vital organs of offspring, effects of pre-pregnancy protein-restricted diet on, 13-18
- Vitamin A (retinol)
 high-dose preformed, effects of different types and amounts of FAs on PP retinoid secretion in chylomicrons after supplementation with, 514-519
 plasma and LDL-C, in heavy smokers, grape seed extract effects on, 1255
- Vitamin B₁₂
 effects of, on homocysteine and methylmalonic acid in hyperhomocysteinemic ESRD, plasma glycine metabolism and MTHFR genotype effects on, 168-172
 serum, in GDM, serum homocysteine and, 721
- Vitamin C (ascorbic acid), metabolomic mapping of, with F-ASA and ¹⁹F-NMR spectroscopy in DM, 760-770
- Vitamin D, *see* 1,25(OH)₂D₃; 25(OH)D; 25(OH)D₃
- Vitamin D receptor (VDR) gene polymorphism, effects of interaction between aromatase Arg²⁶⁴Cys polymorphism and, on BMD of postmenopausal African-American women, 521-523
- Vitamin E (tocopherol)
 in margarine-enriched phytosterols, 1374
 plasma, in heavy smokers, grape seed extract effects on, 1255
- VLDL, *see* Very-low-density lipoprotein(s)
- VLDL-C, *see* Very-low-density lipoprotein-cholesterol
- Vo₂max in exercise
 cycling effects on, 749, 823
 and endothelial lipase genotype and, 1507
 endurance exercise effects on skeletal muscle UCP-3 mRNA, 154
 in high-altitude exercise, α -adrenergic blocker effects on catecholamine response to, 1471-1477
 intense exercise by PM women, 1644
 running effects on, 749
 by young obese adults, 1178
- Volume expansion, *see* Central volume expansion
- VSMCs (vascular smooth muscle cells), methylallyl thiosulfate effects on insulin-potiated PDGF-stimulated migration of, 254-259
- VVS (vasovagal syncope), head-up tilt in recurrent, plasma galanin response to, 315-321
- Waist-to-hip ratio (WHR)
 CRP relation to, 1543, 1544
- Waist-to-hip ratio (WHR) (*Continued*)
 CV risk and, *see* Waist-to-hip ratio, CV risk and
 diet effects on, *see* Waist-to-hip ratio, diet effects on
 FAs and, *see* Waist-to-hip ratio, FAs and
 GHR effects on, 53
 in HIV infection with lipodystrophy, 622, 1346, 1347, 1351
 in NIDDM, *see* Waist-to-hip ratio of NIDDM subjects
 in non-obese subjects, *see* Waist-to-hip ratio of non-obese subjects
 of obese subjects, *see* Waist-to-hip ratio of obese subjects
 of older subjects, insulin action and, 853
 plasma ghrelin and, 1461
 of PM women, CETP and LCAT activities and, 286
 PPAR γ ₂ Pro12Ala polymorphism effects on, 779
 as risk for NIDDM, 888, 1213
 and sex hormone relation to AT, insulin, and risk for MI in men, 785
- Waist-to-hip ratio (WHR), CV risk and
 for CHD, 1532
 ethnicity and, 1296
 and prediction of, with plasma cortisol measurement, 525
- Waist-to-hip ratio (WHR), diet effects on
trans FA intake effects on, 695, 696
 of high-CHO and/or high-MUFA diet, apo E polymorphism and, 1457
 and malnourishment in first year of life, 1006-1008
 margarine-enriched phytosterol diet effects, 1374
- Waist-to-hip ratio (WHR) of NIDDM subjects
 in Chinese subjects, 1449, 1450
trans FA intake effects on, 695, 696
 and FFA metabolism regulation by NPY gene Leu7Pro polymorphism, 644
 of NIDDM first-degree relatives of NIDDM subjects, 1580
 PP lipemia after fat ingestion and, 1039
- Waist-to-hip ratio (WHR) of non-obese subjects
 high-fat and high-CHO diet effects on cardiac autonomic nervous system activity in obese women, 1428
 with PAI-1-associated insulin resistance, 227
- Waist-to-hip ratio (WHR) of obese subjects
 with central obesity, 1001
 effects of weight loss on, 138
 with hypercholesterolemia, and disturbed cholesterol synthesis effects on monocytes, 2
 of obese men, energy intake restriction and 16-week exercise effects on, 109, 112
 of obese women, *see* Waist-to-hip ratio of obese women
- Waist-to-hip ratio (WHR) of obese women
 high-fat and high-CHO diet effects on cardiac autonomic nervous system activity, in obese women, 1428
 PP apo A-IV distribution between apo B- and non-apo B-containing Lps and, 1538-1540
- Weight, *see* Body weight; Non-obese subjects; Obesity; Organ weight; Weight gain; Weight loss by obese subjects
- Weight gain
 effects of short-term rosiglitazone on, in obesity with insulin resistance, 220
 hyperinsulinemia, insulinogenic diet and, 840
- Weight loss by obese subjects
 effects of, in PM obese women, 599-604
 massive, by severely obese subjects, counterregulatory responses to insulin-mediated hypoglycemia after, 900-907
 by obese exercising men, effects of, on postprandial lipemia and LDL receptor binding, 136-141
- WHR, *see* Waist-to-hip ratio
- WinSAAM, 1153-1166

- WinSAAM, 1153-1166 (*Continued*)
 computations of, 1154-1155
 fitting models to data for, 1156-1165
 present and future directions with, 1165
 simulation of biological systems and experimental protocols with, 1155-1156
 structure and language of, 1153-1154
 uses of, 1155
- Withdrawal of insulin in DM, and ischemic heart failure prevention with exercise, 791-797
- Women
 bald in, DHT and testosterone production rate in, 927-929
 exercising, *see* Women, exercising
 with gynoid adiposity and swelling syndrome, lymphatic function in, 805-809
 non-obese, *see* Non-obese women
 older, IGF-1 effects on glucose kinetics or insulin sensitivity in, 1182-1190; *see also* Older subjects
 PCOS, *see* Polycystic ovary syndrome
 postmenopausal; *see entries beginning with terms:* Postmenopausal women
see also Pregnancy; Sex; Women, obese; *and specific conditions*
- Women, exercising
 adrenocortical responses to submaximal exercise by PM women, race and, 1643-1647
see also Exercise
- Women, obese
 cardiovascular disease risk factors in, *see* Cardiovascular disease, risk for, in obese women
 effects of high-fat and/or high-CHO diet on cardiac autonomic nervous system activity in, compared, 1426-1432
 effects of weight loss on, 599-604
 fasting and daylong TGs in PM, 1045
 2-keto[1-¹³C]isocaproate breath test assessment of mitochondrial response to calorie-restricted diet in, 463-467
 with NIDDM, *see* Women, obese NIDDM
 PM, *see* Women, PM obese
 PP apo A-IV distribution between apo B- and non-apo B-containing Lps in, 1537-1541
- Women, obese (*Continued*)
 race of morbidly obese, SM FA oxidation and, 735-738
see also Obesity
- Women, obese NIDDM
 fasting and daylong TGs in PM, 1045
 Thai, abdominal AT and, 1444-1447
- Women, PM obese
 effects of weight loss on, 599-604
 with and without NIDDM, fasting and daylong TGs and, 1045
- Wortmannin, effects of, on insulin secretion, 1395
- Xanthinuria type II, point mutation of molybdenum cofactor sulfurase gene in 1501-1504
- Young adult(s)
 interaction effects of serine447Stop polymorphism of LPL gene and C-514T polymorphism of hepatic lipase gene on serum TGs in, 1337-1342
 obese, glucose and insulin responses to 16 weeks of exercise by, 1175-1181
- Young adulthood, NIDDM parents and risk of insulin resistance syndrome in offspring from childhood to, 443-453
- Young men
 CRPs in, associated with serum leptin, QTc interval, and HDL-C, 1113-1116
 effects of margarine-enriched phytosterols on blood lipids, platelet function, and fibrinogen level in, 1373-1378
 exercising, serum level of IGF-1, IGFBP-1 and -3 in, glucose disposal and, 821-826
- Young subjects
 IDDM, autoantibodies to ICA512/IA-2 and GAD as IDDM markers and their relationship to residual beta-cell function and glycemic control in, 25-29
 smokeless nicotine effects on HTN, glucose tolerance, or insulin sensitivity in, 67-72
see also Young adult(s); Young adulthood; Young men
- Zinc (Zn), antidiabetic effects of AA and, in STZ-DM, 7-12